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Abstract 
OBJECTIVES: Primary end-point was to assess the cost-effectiveness of lumbar 
laminectomy versus X-stop insertion in patients with neurogenic claudication secondary 
to LSS. Secondary end-points were to compare quality of life, clinical outcomes, 
radiological parameters and complications within two groups. This is a pilot study to 
produce predictive models and allow sample size calculation.   
 
DESIGN: Multicentre randomised trial with two interventional arms, namely the 
lumbar laminectomy(LL) and X-stop(XS) groups.  
METHODS: Patients were recruited from two neurosurgical centres after fulfilling 
eligibility criteria and followed up for 1 year. Self-reported general quality of life and 
disease-specific questionnaires were used. The assessments were performed at 
discharge, 6 weeks, 6 and 12 months. Also, radiological parameters were analysed.  
RESULTS: In this pilot study 26 patients were identified of which 6 were excluded and 
20 were randomised with 10 in lumbar laminectomy  and 10 in X-stop(XS) group from 
June 2008 to January 2010.  LL group incured lower costs than the XS group but 
showed no significant between-group differences in utility values (QALYs). We found 
that LL was perhaps more cost-effective than the XS but with uncertainty, suggesting 
the need for a larger trial. There were no significant differences between the two groups 
in quality of life, clinical outcomes or success rates but within group improvements 
were found. Importantly, 6 out of 10 patients (60%) from XS group crossed over to LL 
group. 
Sample size calculation with the original data showed the need for 25 patients in each 
arm to detect clinical significance in future clinical trial. 
 
CONCLUSION: Our results suggest that LL is possibly cheaper and more cost-
effective than XS over a 1-year period, in National Health Service. No significant 
differences in quality of life and clinical outcomes between the two procedures were 
detected although this is only a pilot study with a small sample size.  
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1. INTRODUCTION 
1.1. Definition: - Lumbar stenosis is defined as the reduction in the diameter of 
the spinal canal, lateral nerve canals, or neural foramina, associated with a 
complex of clinical signs and symptoms comprising back pain and stress 
related symptoms (pain, paraesthesia) in the legs (claudication).  
 
 
                    
      A)                                                         B) 
Figure 1.1: MR images T2 –weighted sequences of lumbar spine showing the stenotic 
segment at the L4/5 level (white arrow): A) Sagittal view; B) Axial view. 
 
1.2. Epidemiology: - The annual incidence of degenerative lumbar spinal 
stenosis (LSS) is reported to be 5 cases per 100,000 individuals. This is 4-fold 
higher than the incidence of cervical spinal stenosis.(1) 
LSS has become the most common indication for lumbar spine surgery, in part 
because of the increasing quality and availability of radiological imaging.(2)  
The increasing frequency of LSS surgery seems to reflect the elevated demand 
for mobility and flexibility in the aging population. (3)(4)(5)   
 
 
 
1.3. Cost burden: - Loss of productivity at work represents the majority of the 
costs associated with LSS, the economic burden of which is estimated to 
exceed US$100 billion. (6).  
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1.4. Historical perspective: - Sachs and Fraenkel, 1900 (7) and Baily and 
Casamajor, 1911 (8) are the first to describe lumbar spinal changes leading to 
spinal stenosis and nerve root compression with supporting evidence provided 
by Elsberg (9) and Kennedy (10) describing that  thick laminae, hypertrophied 
articular facets, and thickened ligamentum flavum lead to spinal stenosis and 
nerve root compression.  
Neurogenic claudication, as a classical symptom of LSS, was a term coined by 
Dejerine (1911) (11) and defined by von Gelderen (1948) (12) and, later, 
Verbiest (1954). (13) Van Gelderen (1948) described LSS as localized, bony 
discoligamentous narrowing of the spinal canal that is associated with a 
complex of clinical signs and symptoms comprising back pain and stress 
related symptoms in the legs.(12)  This description is still used today. 
Schlesinger and Taveras (14) were the first to emphasize that the dimension of 
the spinal canal was more important than the size of the disc protrusion in the 
production of symptoms in patients with herniated discs and concomitant 
multiple root and cauda equina compression. 
Verbiest (13) (15)  (15) was the first to define the pathomorphologic changes 
specifically the encroachment of the canal by hypertrophied articular processes, 
and called attention to the characteristic clinical manifestations of the condition 
including neurogenic claudication. 
The progressive pathologic changes that occur in the three joint complex of the 
disc anteriorly and the zygoapophyseal joints posteriorly as well as the natural 
history of the condition were described initially by Kirkaldy-Willis (1983). (16) 
(17)(18)  
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1.5.  PATHOPHYSIOLOGY  
There are two postulated mechanisms of degenerative lumbar spinal stenosis: 
the molecular mechanism and the mechanistic mechanism. 
1.5.1. The molecular mechanism: The putative substance responsible for bone 
degeneration and osteophyte formation remains elusive. Bone 
Morphogenetic Proteins (BMPs) are multipotent proteins that regulate the 
growth, differentiation, and programmed death (apoptosis). They are 
abundantly present in cartilage and bone. BMPs and their receptors are 
greatly expressed during maturation of the intervertebral disc and seem to be 
related to chondrogenesis within the disc. As the disc degenerates, BMPs 
and its receptors migrate from the hyaline cartilage of the vertebral endplate 
to fibrous cells within the annulus and to the calcified cartilage at the site of 
the enthesis and thus may be related to the formation of osteophytes. It also 
is suggested that the BMPs, by mediating an effect on cellular apoptosis, 
contribute to the degenerative process because it has been clearly shown that 
apoptosis plays a pivotal role in disc degeneration.(19)   
The LSS is caused by remodeling and overgrowth of bone with osteophyte 
formation. It is thought that the degenerative process initiates or accelerates 
the bony overgrowth affecting the three joint complexes, which comprises 
the two zygoapophyseal joints and the adjoining disc. (18)  Commonly, the 
degenerative process starts in the disc and affects the articular processes 
secondarily. Loss of tissue (e.g.from articular cartilage chafing due to 
friction), synovitis, or loss of disc height results in relative ligamentous 
laxity and accelerated joint degeneration. Interestingly, the remodeling of the 
bone can be considered either as a reaction to the excessive joint motion or a 
physiologic attempt for local arthrodesis, leading to end of result of 
decreased segmental mobility. However, decreased mobility in one segment 
generates abnormal stress forces on adjacent spinal segments, causing them 
to degenerate at an accelerated rate. 
The association between the degenerative process and mobility arises from 
the fact that the two lower motion segments (L3-L4, L4-L5), which are the 
most mobile in lumbar region, are most commonly affected by degenerative 
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stenosis. The L5-S1 has a relatively large L5 transverse processes with 
strong ligamentous attachments to the iliac crest.  
Bone morphogenetic proteins (BMPs) are the cytokines of the TGF- 
superfamily that have been implicated in the process of disc 
degeneration.(20) (21)  
1.5.2. The mechanistic mechanism: Numerous factors can contribute to the 
development of spinal stenosis.  These can act synergistically to exacerbate 
the condition. Degeneration of the vertebral disc often causes a protrusion, 
which leads to ventral narrowing of the spinal canal.  As the disc 
degenerates, the height of the intervertebral space is further reduced, which 
causes the recess and the intervertebral foramina to narrow, exerting strain 
on the facet joints causing their hypertrophy.(22)  
In addition, as a result of the reduced height of the affected spinal segment, 
the ligamentum flavum forms creases, which exert pressure on the spinal 
dura from the dorsal side. Loosened ligaments concomitantly propagate 
hypertrophic changes and osteophytes, creating the characteristic trefoil-
shaped narrowing of the central canal. (23)(24) (22) (25) (26) (27) (28) (29) 
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1.6. PATHOLOGICAL ANATOMY 
 
Degenerative lumbar spinal stenosis is a spectrum of the following conditions: 
central canal stenosis, lateral spinal stenosis and intervertebral foraminal canal 
stenosis. 
 
 
Central stenosis is caused by hypertrophy of the facet joints, ligamentum 
flavum, disc protrusion, spondylolisthesis, or by a combination of these. (30) 
(31)    
Hyperextension of the lumbar spine increases the extent of compression because 
of the effect of additional narrowing of the spinal canal. By contrast, 
hyperflexion results in widening of the spinal canal. It is shown that LSS is 
frequently exacerbated further by vertical load. (32)   
Indeed, epidural pressure is elevated while standing or walking, and lowered 
when sitting and in flexion.(33)(34) Experimental animal models have been 
developed to investigate the underlying pathophysiology of LSS in more detail 
(35) and to test pharmacological interventional strategies. (36) In one such 
experimental model for spinal canal stenosis, a piece of silicon is placed under 
the lamina at L4 level in young adult rats. Thus this model would perhaps be 
more relevant to acute cord compression rather than chronic conditions. 
Furthermore, biomechanics of quadripedal rats is different from those of bipedal 
patients. 
 
Stenosis at multiple levels is more common than strictly segmental stenosis. 
In approximately 40% of cases, central stenosis is caused by soft tissue 
hypertrophy. On computed tomography (CT) scans, midsagittal lumbar canal 
diameters less than 10 mm represent absolute stenosis and midsagittal lumbar 
canal diameters less than 13 mm represent relative stenosis.(37)  
 
LSS can also be subdivided into relative and absolute according to the anterior–
posterior diameter of the spinal canal.  Relative LSS (10–12 mm diameter in 
spinal canal; physiological value is 22–25 mm) is usually asymptomatic, 
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whereas absolute LSS (spinal canal <10 mm in diameter) is often symptomatic 
and is associated with absence of free subarachnoid space.  
The most common symptom associated with LSS is neurogenic claudication, 
which comprises limping or cramping lumbar pain that radiates into the legs 
primarily during walking. Degenerative LSS can ultimately lead to the 
compression of individual nerve roots, the meninges, the intraspinal vessels, 
and, in exceptional cases, the cauda equina (Figure 2). (38)  
Nerve root compression triggers localized inflammation, which affects the nerve 
root’s excitatory state. (39)  
 
Lateral spinal stenosis is a common cause of lumbar radiculopathy. The 
nerve root canal has been divided into three anatomic zones: the entrance zone, 
the midzone, and exit zone.(40)  
 
The entrance zone is the subarticular zone medial to the pedicle and is 
synonymous with the lateral recess. Its borders consist laterally of the pedicle, 
posteriorly of the superior articular facet, anteriorly of the posterolateral surface 
of the vertebral body caudally and the disc rostrally, and medially by the thecal 
sac. The root sleeve containing cerebrospinal fluid covers the nerve root at the 
entrance zone. Lateral to the entrance zone the nerve root sleeve coalesces with 
the nerve root and is devoid of cerebrospinal fluid. The minimal height of a 
normal lateral recess is 5 mm; a height of 3 to 4 mm is suggestive of lateral 
recess stenosis and a height of 2 mm is considered pathologic.(41)  
 
The majority of cases of lateral recess stenosis are produced by posterolateral 
disc protrusion or hypertrophy of the superior articular process also referred to 
as lateral recess syndrome.  
 
The midzone is the part of the canal beneath the pars interarticularis and just 
inferior to the pedicle where the nerve root takes an oblique downward course 
from the lateral recess to the foramen. Anteriorly, the midzone is bordered by 
the posterior aspect of the vertebral body, posteriorly by the pars interarticularis 
and medially by the opening to the spinal canal. Computed tomography scans 
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accurately show the pars interarticularis and its relationship to the underlying 
nerve root.(42)    
A T1- weighted parasagittal magnetic resonance imaging (MRI) scan defines the 
pars as a high signal intensity bone marrow surrounded by the lower signal of 
the cortical bone. The bone marrow signal remains continuous from the superior 
to the inferior articular process. An interruption of this signal is indicative of a 
pars defect.(43)(44)  
The most common causes of midzone nerve root compression include a pars 
defect or pedicular compression. A pars defect such as in isthmic 
spondylolisthesis with fibrocartilaginous tissue overgrowth can cause nerve root 
entrapment. More common in patients with rotational deformities or 
spondylolisthesis is kinking of the nerve root situated inferomedially to the 
pedicle by one pedicle that is lower than the other because of a rotation 
deformity or asymmetric disc collapse.  
 
The exit zone corresponds to the intervertebral foramen. It is bordered superiorly 
and inferiorly by the pedicles of adjacent vertebrae, posteriorly by the pars 
interarticularis and ligamentum flavum, and anteriorly by the posteroinferior and 
posterosuperior aspects of the adjacent vertebral bodies and intervening disc.  
The foramen is shaped like an inverted teardrop; its normal height varies from 
10 to 23 mm and its width at the upper foramen varies from 8 to 10 mm. A 
foraminal height of less than 15 mm and a disc height of less than 4 mm are 
associated with nerve root compression 80% of the time. The ventral and dorsal 
nerve roots occupy 23% to 30% of the foramen and lie anterior to the dorsal root 
ganglion. The dorsal root ganglion usually is located in the superior lateral 
aspect of the foramen directly below the pedicle in 90% of lumbar levels.(45)  
Parasagittal T1-weighted MR images readily define the integrity of the foramen. 
The nerve root proper has a low signal and is surrounded by the higher intensity 
signal of fat. Obliteration of the fat pad often is indicative of foraminal stenosis. 
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1.7. Natural course of the disease 
LSS is a degenerative condition that develops slowly over time, with neurological 
deficits being usually only subtle. It is usually diagnosed in patients over the age of 
50 years. There are, however, no prospective long-term studies that document the 
natural symptomatic changes over time.(46) This makes the initiation and choice of 
a specific therapy difficult, as such decisions ideally require an estimate of the 
natural course of the condition. (4) .  
The Spine Patient Outcomes Research Trial (SPORT) reported that there was no 
worsening of symptoms over 2 years in most patients in the conservatively treated 
control group. (47) Another study reported an increase in the severity of symptoms 
in ~20% of the untreated cases, (46)  whereas a further trial focusing on pain 
development over almost 5 years found that the clinical symptoms of 70% patients 
reached a plateau, 15% experienced pain exacerbation and 15% spontaneously 
improved. (22) (48)   
 
 
1.8. Clinical Features 
 
Onset: - Usually manifests in patients in the sixth or seventh decade of life. The 
congenital form of spinal stenosis or canal and lateral recess stenosis usually 
manifest in patients in the third or fourth decade of life. 
 
Gender: - LSS has a slight preponderance in women.  
 
Levels affected:- Degenerative spinal stenosis most commonly affects the L3-L4, 
and L4-L5 segments to cause cauda equina compression. 
 
Clinical features: - Some patients with stenosis primarily compressing a nerve root 
have symptoms of a radiculopathy but most experience a combined mixed 
symptomatology.   
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- Pain: - Radicular pain is localized better, may be claudicant and neurogenic, and 
can be associated with weakness in specific well-localized muscles or dermatomal 
sensory changes. One or several nerve roots may be involved, occasionally 
segmentally separated, and sometimes both lower limbs are affected. 
Lower extremity pain is present in approximately 80% of patients and back pain is 
present in approximately 65% of patients.  Pain is often poorly localized and 
frequently associated with paresthesias.  
 
-Other symptoms: - Patients describe their symptoms as a discomfort ranging from a 
rubberlike feeling, leg weakness to actual pain in the back, buttocks, thighs, and 
legs.  
 
- Spread of symptoms: - Symptoms may ascend from the distal lower extremities to 
the buttock, or alternatively descend the lower extremity.  
 
-Localisation of symptoms: - There is generally a bilateral distribution but can be 
also be unilateral. Symptoms may not be symmetric and may affect the entire limb 
or parts thereof. The back pain is localized to the lumbar spine and can radiate 
towards the gluteal region, groin and legs. In cases of lateral recess stenosis or 
foraminal stenosis, isolated radiculopathy can occur.  
- Relationship between symptoms and level of activity (Neurogenic claudication):- 
Neurogenic claudication is the most specific symptom of LSS (4) although it is 
nearly always accompanied by further symptoms mainly pain but also paraesthesias. 
This is considered a pathognomonic aspect of lumbar stenosis as a relationship 
between symptoms and function. Symptoms are likely to manifest on prolonged 
standing or walking and decrease when the individual stops the provoking activity 
and rests. As the disorder progresses however, the individual’s time of activity 
before symptoms manifest shortens. Because of the clinical similarity to 
claudication caused by vascular insufficiency of the lower extremities, the lumbar 
stenosis pain syndrome has been termed pseudoclaudication or neurogenic 
claudication.(49)(50)  
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There are three prevailing theories that explain neurogenic claudication: the 
ischemic theory, the mechanical compression theory and the theory of stagnant 
anoxia.  
 
The ischemic theory: This theory postulates that as metabolic demands increase 
during activity such as walking, this increased demand cannot be met because of 
an insufficient blood flow secondary to segmental compression. A relative nerve 
root ischemia ensues and may lead to pain, sensory loss, and a motor deficit.(51)  
In support of the vascular insufficiency theory is the fact that the intrafascicular 
microvascular matrix is predisposed to decrease in diameter and flow as a result 
of stretch and vessel angulation caused by bone overgrowth and stenosis. Under 
normal conditions, nerves are tolerant of traction because the intrafascicular 
arterial branches have compensating coils that can elongate on traction. In 
stenosis, acute angulation and tethering of the neural elements restrict the 
intrafascicular micromovement associated with traction, which results in 
narrowing of the blood vessels and diminished blood flow.(52)  
Conversely, compressive radiculopathy can cause autonomic impairment 
resulting in impairment of circulation in the legs. (53)  
 
The mechanical compression theory: The fact that many patients with 
claudication attributable to cauda equina dysfunction have symptoms 
commensurate with posture rather than activity, has advanced the mechanical 
compression theory. In many such patients, assuming a lordotic posture is 
sufficient to provoke symptoms that are alleviated by flexion.(54)  
 
The theory of stagnant anoxia: This theory may reconcile the vascular and 
mechanical-compressive hypotheses and explain the appearance of symptoms in 
static and dynamic conditions. In this hypothesis, the mechanical compression 
by bone and soft tissues may compress the neural elements, the draining veins 
that exit the canal with the spinal roots or cause cerebrospinal fluid entrapment, 
thus resulting in interference with venous return.(55)  
This dynamic entrapment of cerebrospinal fluid and ensuing increase in fluid 
pressure occurs distal to the site of narrowing or compression within a segment 
constricted rostrally and caudally by a two level stenosis. This increase in 
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cerebrospinal fluid pressure may impede with the radicular venous return to 
culminate in relative hypoxia, or cause a reduction in the metabolic exchange 
and nutritional supply to the roots. 
 
- Relationship between symptoms and posture: - Often, patients with spinal stenosis 
assume a characteristic posture either standing erect or in a flexed forward position. The 
stooped posture occurrence is attributed to two changes to spinal column at the affected 
levels. In flexion, the vertebral canal lengthens and the spinal roots stretch. In extension, 
the canal shortens and the roots undergo an increase in their total volume. In addition, 
increase in spinal lordosis by trunk extension increases the bulging of the ligamentum 
flavum and intervertebral discs into the spinal canal and thereby compromises the size 
of the canal additionally. The onset of symptoms in the lower limbs after prolonged 
standing and their improvement on sitting, lying with the legs flexed, flexing at the 
waist, or squatting all are presumably attributable to the same mechanism. 
 
-Autonomic dysfunction: - Autonomic-sphincter dysfunction manifesting as recurrent 
urinary tract infections associated with an atonic bladder, incontinence, and more rarely, 
episodes of urinary retention are not infrequent and occur in approximately 10% of 
patients mainly with advanced stages of spinal stenosis. Other and rarer autonomic 
symptoms have been described, and in general autonomic dysfunction responds 
favorably to decompression.(56)  
In addition, as previously mentioned, compressive radiculopathy can cause autonomic 
dysregulation and impaired circulation in the legs.(21)  
 
- Neurological signs:- A paucity of neurologic findings on physical examination, often 
despite a history of severe disability, is typical for patients with spinal stenosis. 
Furthermore, characteristic for the condition is the development of neurologic signs 
when the patient becomes symptomatic after a period of activity (walking) that 
provokes the symptoms. The most common findings are of deep tendon reflex changes, 
sensory loss, and muscle weakness. Straight leg raising rarely is positive, but flattening 
of the lumbar lordosis and a decrease in lumbar extension are common findings. 
Lasegue testing (a passive leg flexing test) often remains negative in patients with LSS 
and is frequently accompanied by a feeling of ‘heavy legs’, a characteristic sign of LSS. 
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Diagnosis of LSS is hampered by a number of frequent comorbidities such as peripheral 
neuropathies, which can themselves be relevant differential diagnoses.  
 
-Depression:- Approximately 20% of patients with LSS exhibit symptoms of depression 
and 25% are dissatisfied with their life before surgery, a similar pattern to that seen in 
patients with other chronic disorders. (57)(58)  
Evaluation of mood and contentment in patients is important, as both can markedly 
differ between patients with LSS and healthy controls, and can influence diagnostic and 
therapeutic decisions. Patient reported symptoms—even those that are transient in 
nature should be considered seriously in the diagnostic workup, especially during initial 
consultations. 
 
 
- Grading of LSS based on symptoms: 
Three grades of LSS have been described. (59).  
• Grade I (neurogenic claudication): - characterized by a reduced walking distance 
(caused by pain) and sensory-motor deficits that at rest might be unremarkable, 
but can deteriorate while walking. However, not all patients with LSS exhibit 
symptoms consistent with neurogenic claudication, which is why other 
classifications of LSS exist.  
• Grade II (Neurogenic paresis):- refers to already persistent sensitivity deficits, 
loss of reflexes and neurogenic paresis.  
• Grade III is reached if persistent, progressing paresis is present, accompanied by 
partial regression of pain.  
 
-Correlation of clinical symptoms to radiological findings: - The scarcity of neurologic 
findings is in marked contrast to the profound changes seen on myelography, CT scans 
and MRI scans. The history rather than the objective clinical findings and imaging 
studies are the decisive factor in establishing the diagnosis.  
 
- Correlation of clinical symptoms to neurophysiological findings: - Of the ancillary 
laboratory studies that may be helpful in the diagnosis, except for imaging studies, is the 
neurophysiologic investigation. The results of electromyography will be abnormal in the 
majority of patients. Electromyography is considered more sensitive than the neurologic 
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examination. Abnormalities seen on electromyography consist of denervation in 
muscles innervated by lumbosacral nerve roots. Findings often are bilateral and are 
located in the paraspinal area. 
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1.9.  Differential diagnosis 
The differential diagnosis of spinal stenosis includes disc herniation and 
neoplasia that can be ruled out by imaging studies. More perplexing is the 
differentiation between neurogenic claudication attributable to cauda equina 
compression and claudication attributable to peripheral vascular disease. There 
often is an overlap in the two conditions. Vascular Neurogenic claudication 
causes pain that is more cramp-like, there is absence of one or more peripheral 
pulses, and often there are trophic changes in the extremities. Worsening 
neurologic symptoms and signs after ambulation or with an increase in the 
lordotic posture of the spine and/or relief of symptoms with a change in posture 
alone while exercise continues suggests neurogenic claudication (Table 1.1.). 
Walking-induced symptoms of neurogenic claudication often disappear when 
the patient sits or are relieved after a few minutes of rest. In vascular 
claudication, lower extremity symptoms often decrease or disappear even simply 
on standing or walking. 
Osteoarthrosis of the hips may mimic spinal stenosis because of similar gait 
disturbance and buttock and proximal thigh pain. 
Careful examination of the hips is recommended and occasionally radiographs 
of the hips are warranted. Gait disturbance and bladder incontinence are 
prominent symptoms of normal pressure hydrocephalus, a condition affecting 
patients in the same age range as those patients who are affected with spinal 
stenosis. Pain is not a feature of normal pressure hydrocephalus, the gait is 
characteristically shuffling and cognitive dysfunction is common. A non-
contrast CT scan or MRI scan of the brain readily rules out this condition. 
In contrast to the situation in LSS, hyposensibility resulting from peripheral 
neuropathies usually exhibits a bilateral distal stocking-shaped pattern, 
irrespective of posture, rest or physical stress. Iliosacral joint disorder 
occasionally mimics LSS, with low back pain radiating to the buttocks and the 
thighs when standing and walking. 
Unlike LSS, iliosacral joint pain is characterized by tenderness of the joint. 
Sphincter involvement is very rare in LSS, as the sacral nerves are relatively 
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protected from compression owing to their central position within the cauda 
equina. (46) 
In patients exhibiting vesicorectal voiding and upper motor neuron signs (for 
example, Babinski’s reflex and hyperreflexia), cervical or thoracic myelopathy 
needs to be ruled out. Neuroradiological assessment when performing 
radiological assessment of LSS, some inherent problems with imaging of the 
lumbar spinal canal need to be considered. 
 
DIFFERENTIAL DIAGNOSIS: 
■ Neurogenic claudication or vascular claudication 
■ Radiculopathies or polyneuropathies 
■ Intraspinal synovial cyst 
■ Disc prolapse 
■ Tethered cord or spina bifida 
■ Coxarthrosis or arthrosis of the iliosacral joint 
■ Abdominal aortic aneurysm 
■ Neoplasia (for example, tumor, spinal roots, meninges, bones or filiae) 
■ Inflammatory conditions (for example, spondylodiscitis,  
arachnoiditis) 
■ Dissociative syndromes 
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TABLE 1.1. Comparison of Vascular and Neurogenic Claudication (63) 
Signs and Symptoms   Vascular   Neurogenic 
 
Claudication     Fixed    Variable 
distance 
Type of pain     Cramps, tightness  Dull ache, 
numbness 
Relief at cessation    Immediate   Lingers for a 
of activity few minutes 
Back pain     Rare    Occasional 
Pain relief     Standing   Flexion and 
sitting 
Posture     Uncommon   Common 
provocation 
Walk up hill     Pain    No pain 
Bicycle riding    Pain    No pain 
Pulses                 Absent   Normal 
Trophic changes    Likely    Absent 
Muscle atrophy    Rare    Occasional 
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1.10. CLASSIFICATION OF LSS 
 
Lumbar spinal stenosis may be classified by either its aetiology or location. The 
classification of lumbar stenosis is important because of the implications of the 
underlying aetiology of the condition and when forming a therapeutic strategy, 
specifically directing surgical approaches.(60)  
 
1.10.1. Aetiological classification 
 
According to Arnoldi et al,(61) aetiological classification comprises two major 
groups: primary (congenital or developmental stenosis) and acquired stenosis. 
Primary stenosis is caused by congenital narrowing of the spinal canal. (23)(24) 
(62) 
Congenital stenosis is divided additionally into idiopathic and achondroplastic 
aetiologies. Acquired (secondary) stenosis can result from a wide range of 
conditions, most often chronic degeneration, which leads to a destabilized 
vertebral body. Acquired stenosis is subclassified into degenerative, combined 
congenital and degenerative, spondylotic and spondylolisthetic, iatrogenic 
posttraumatic, and metabolic (Table 1.2.). Other causes of secondary stenosis 
include rheumatoid diseases, osteomyelitis, trauma, tumours, and, in rare cases, 
Cushing disease or iatrogenic cortisone application.(62)   
 
1.10.2. Anatomical classification 
Anatomical classification incorporates central canal stenosis, lateral recess 
stenosis and neural foraminal stenosis (Table 1.2.).  
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TABLE 1. 2. Classification of Spinal Stenosis (63) 
Aetiological classification 
Congenital (primary or developmental stenosis) 
Idiopathic 
Achondroplastic 
Acquired stenosis – much more common 
Degenerative 
Congenital or degenerative 
Spondylotic or spondylolisthetic 
Iatrogenic (postlaminectomy, postfusion) 
Posttraumatic 
            Metabolic (Pagets disease) 
Anatomical classification 
Central canal stenosis 
Lateral recess stenosis 
            Neural foraminal stenosis 
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1.11. INVESTIGATIONS 
1.11.1. Imaging  
There are a few inherent problems with imaging of the lumbar spinal canal 
that need to be considered.  
First, degenerative changes in the lumbar spine are very common in the 
asymptomatic population, especially in patients over 60 years of age, 20% 
will reveal signs of LSS.(64). This confounds imaging of symptomatic 
patients. 
Second, it has been shown that imaging often tends to exaggerate 
pronounced degenerative changes and effects on the spinal canal.(62)(65)  
Imaging tends to be used most frequently in patients with medium to severe 
symptoms of LSS. (66)   
The purpose of imaging is to assess the extent of LSS, to rule out other 
differential diagnoses, and to point out the pathological anatomy of LSS for 
the purpose of preoperative planning.(62)(67)  
In LSS, imaging studies include: 
1.11.1.1. Plain radiographs of lumbar spine:- Routine use of plain radiographs 
when  evaluating patients with LSS has been questioned.(62)(68)(69)  
Conventional radiographs might be of use, albeit in a limited fashion, in 
assessing the contribution of bony degeneration to LSS and the alignment of 
the vertebral bodies in lateral and coronal planes. It can also potentially be 
used to rule out traumatic changes or other findings (e.g. Paget disease, 
spondylolisthesis or scoliosis) as possible differential diagnoses.(62)(70) The 
sensitivity and specificity of plain radiographs concerning the contribution of 
bony changes to central spinal stenosis were reported to amount to 66% and 
98% respectively of those of CT. The need of additional lateral radiographs 
in flexion and extension to rule out segmental instability is not routinely 
required, as segmental instability can be detected on routine lateral 
radiographs in a reasonably accurate manner.(62)(71) It is shown that no 
additional benefits were conferred from these additional views (62)(70) 
Interestingly, even in patients for whom segmental instability was expected, 
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the diagnostic purpose of lateral radiographs in flexion and extension views, 
is not definitively determined.(62)(72)  
 
1.11.1.2. Magnetic resonance imaging (MRI) of lumbar spine: - MRI is the 
preferred imaging modality for the radiological assessment of LSS. (73).  
This technique provides superior soft tissue contrast compared with other 
imaging modalities, has multiplanar imaging capabilities and does not 
produce ionizing radiation. MRI is contraindicated in patients with 
pacemakers, certain other types of metal implants or claustrophobia.  
MRI of patients with LSS usually comprises T1 weighted and T2 weighted 
images (sagittal and axial). A fat-suppressed T2 weighted sequence can be 
added, as such images seem to allow more accurate detection of associated 
degenerative bone marrow changes. With T2 sequences and with signal 
intensity of cerebrospinal fluid, images of the thecal sac, the intrathecal and 
intraforaminal nerve roots, and the spinal cord can be obtained 
noninvasively. MRI can also visualise the bony and discoligamentous 
structures contributing to LSS, similar to the computed tomography imaging. 
Interestingly, some studies have produced conflicting results concerning the 
clinical usefulness of the information gained by MRI.(62)(74)(75) 
It has been implied that changes observed by means of MRI add little 
clinically useful information to clinical assessment alone in relation to 
prognosis and predicting the outcome of surgery. (74)(76)  
Contrast-enhanced MRIs are only required if previous surgery was done and 
fibrous scar need to be excluded. (77)(78).  
Other studies have suggested that contrast-enhanced MRI in LSS patients 
with neurogenic claudication can help in viewing the enhancement of 
compressed nerve roots which can be visualized in some patients. 
(79)(80)(81) 
This enhancement is thought to reflect either obstructed peri-radicular veins, 
indicating venous stasis, or breakdown of the blood–nerve barrier, a sign of 
chronic compressive radiculitis. 
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1.11.1.3. Computed tomography (CT):  -CT of lumbar spine is helpful to 
visualize the bony and discoligamentous anatomy.  It has also an additional 
purpose of ruling out any compression fractures and assessing previous 
surgery or instrumentation.   It can be performed rapidly and allows 
differentiation between spinal canal compression caused by discs, ligaments 
and bony structures.  
A limitation of CT is that intrathecal nerve roots and the spinal cord cannot 
be visualized, because these structures have similar densities to the 
cerebrospinal fluid.  
 
1.11.1.4. CT myelogram: - At present, this is the only accurate imaging technique 
for patients with spinal metallic implants, which can cause artefacts on MRI 
and CT. It  is an invasive procedure that requires intrathecal administration 
of iodinated contrast agent.  Consequently is associated with side effects 
such as post-lumbar puncture headaches, anaphylaxis and spinal infections. 
Like other imaging techniques, conventional myelography frequently reveals 
abnormalities that were not suspected clinically.(65) 
However, there are studies that have shown that the diagnostic and 
predictive values of conventional myelography, CT myelography and MRI 
are not markedly different.(82)   
 
1.11.2. Correlation of clinical features with radiological findings 
It has been shown that the radiological degree of LSS, both before and after 
surgery, does not necessarily correlate with the degree of the clinical signs 
and symptoms. (47)(64)(82)(83)(84)   
As previously mentioned, it has been shown that imaging often tends to 
exaggerate pronounced degenerative changes and effects on the spinal canal. 
(65).  
Thus, radiologically diagnosed LSS usually identifies involvement of more 
segments than is suspected clinically (66)  
The aim of imaging is to assess radiologically the extent of LSS, to rule out 
differential diagnoses, to relate stenotic symptoms to osseous and 
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discoligamentous structures, and to identify the exact location of LSS for 
preoperative planning.(67)  
 
 
1.11.3. Additional diagnostics 
1.11.3.1. Pain injections: - Selective pain injections can be useful to estimate the 
contribution of different pain components to the symptoms of the LSS.  
 
1.11.3.2. Nerve conduction studies: 
Given the low practical importance of classical electromyography and 
nerve conduction studies in diagnosing LSS, an electrophysiological 
examination is only recommended to exclude other disorders, especially 
if the distribution of pain and numbness is unusual (for example, 
suspicion of peripheral polyneuropathy or myopathy, which might both 
occur concomitantly with LSS). (83)(84) 
 
1.11.3.3. Walking treadmill test:  
Walking on a treadmill is an appropriate provocation test for the 
assessment of extent of LSS, although this technique is not yet common 
in daily practice. (83)(84). 
 
1.11.3.4. Routine laboratory tests: 
This tests can be used to detect comorbidities, such as diabetes or 
diabetic polyneuropathy (by detection of glucose and Hba1c), and 
infections such as spondylodiscitis (by measurement of C - reactive 
protein). (62)  
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1.12. TREATMENT 
Decision-making regarding treatment of LSS is a complex issue considering the 
progressive nature and the heterogeneity of the condition. Treatment strategies 
have mostly focused on pain and physical function as primary end points.(47) 
Because of the lack of therapeutic recommendations and the large number of 
distinct therapies, the selection of an appropriate procedure is difficult.(13)  
The need for prospective, randomized studies comparing the various therapies 
are required.(48)(6)  
The treatment for LSS can be: conservative (nonoperative) and operative. 
The standard operative treatment for lumbar stenosis includes decompressive 
laminectomy and/or foraminotomy at appropriate levels. As most patients are 
elderly, they can have multiple medical comorbidities including cardiac, 
pulmonary, or renal disease. For this reason, less invasive surgical treatments 
have been sought, including minimally invasive approaches and interspinous 
spacers. More recently, preservation technologies, such as the X-stop device, 
Wallis Normalization System, or Device for Intervertebral Assisted Motion 
(DIAM), have been developed and used. 
 
1.12.1. CONSERVATIVE MANAGEMENT:  
1.12.1.1. Overview 
Typical nonoperative management of lumbar stenosis includes: 
- physical therapy,  
- nonsteroidal anti-inflammatory drugs,  
- braces, or  
- epidural steroid injections. 
The effectiveness of conservative therapy in treating LSS has been reported to 
have high success rates.(85)(86)(87)  In one study there was 70%  clinical 
improvement compared to baseline when non-surgical treatment by 
physiotherapy was applied. This study included 57 patients with LSS and follow 
up over 3 years. Limitations of this study were small sample size, with 25% of 
these patients who did not have MRI lumbar spine. Those with radiologically 
confirmed LSS had various levels of lumbar spine affected. Also three patients 
with previous lumbar surgery were included in the study.(85) 
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However, none of the studies has provided a full support for a single 
conservative treatments. (4)(88) 
In the absence of clear evidence-based guidelines, it has been suggested that a  
multidisciplinary approach should be given preference over a single 
therapy.(88)(89)    
The main objectives of physiotherapy are flexion, distraction, neural 
mobilization, relief of the affected segments and improvements in paravertebral 
muscle tone with stabilizing exercises. (85) 
There is a consensus between clinicians that bed rest is not recommended in the 
therapy of chronic and acute pain.(88) 
The pharmacological component of conservative therapy aims to relieve painful 
nerve root pathologies. Drugs used to treat LSS include NSAIDs, other 
peripheral analgesics, steroids, muscle relaxants, opioids, antidepressants and, in 
very severe cases, neuroleptics.  
Evidence-based facts mainly suggest short-term efficacy of administration of 
NSAIDs, muscle relaxants, steroids, antidepressants and opioids. (4)(89)  
Likewise, the evidence for the efficacy of therapeutic injections for LSS has not 
been confirmed. (90)(91) 
 
1.12.1.2. Evidence of outcomes of conservative vs surgical management 
Numerous studies have been performed to compare nonoperative and operative 
approaches to the spondylotic spine. 
There are RCTs that assessed surgical versus conservative approaches. In one 
trial, 44 patients with mild-to-moderate leg pain were randomized to receive 
conservative treatment (i.e., back braces, physical therapy, and exercise 
programs) or lumbar laminectomy. Both treatment groups showed significant 
clinical improvement after 1 year of treatment. However, only the surgery group 
continued to show improvement after 2 years.(92)  
In the second trial, patients with moderate pain were randomized to undergo 
surgery or receive conservative therapy again (i.e., bracing and physical 
therapy).(65) 
 Patients with more severe pain underwent surgery, and patients with milder 
symptoms received conservative therapy. Within 3 to 27 months of starting the 
study, 10 out of the 18 (56%) conservatively treated patients with moderate 
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symptoms crossed over to the surgery group. Among patients with moderate 
symptoms, a greater proportion of surgery patients had a decrease in symptoms. 
These data further suggest that surgery may be more beneficial than 
conservative therapy in patients with moderate to more severe symptoms.(93)  
The randomized controlled trial (94) looked at operative versus nonoperative 
treatment for lumbar spinal stenosis. This Finnish study aimed to assess the 
efficacy of decompressive surgery in comparison with conservative treatments 
such as nonsteroidal anti inflammatories and routine physical therapy. A total of 
94 patients were randomized, 50 to the operative arm and 44 to the conservative 
treatment arm. The operative arm received a decompressive laminectomy at the 
stenotic levels and in 10 of these patients, an instrumented fusion was performed 
with pedicle screws. 
In the same study (94), there was an improvement in the functional disability 
score and pain scores for both groups. However, the surgical arm was found to 
benefit more with regard to back and leg pain, and overall disability. This study 
confirmed that there is a place for conservative management of lumbar spinal 
stenosis; however, surgery seems to be more effective, especially during the first 
year. Outcomes remained favourable at 2 years, however. longer follow-up is 
needed in these patient arms to get a better feel for long-term differences 
between the nonoperative and operative arms. 
The Maine Lumbar Spine Study was a prospective, observational cohort study, 
with  a subgroup of patients with moderate neurogenic claudication. The follow 
up for this study was over an 8 to 10-year interval. 56 underwent surgery, and 41 
were treated with conservative management to include bed rest, physical 
therapy, exercise, braces, traction, transcutaneous electrical nerve stimulation, 
spinal manipulation, narcotic analgesics, or epidural steroids.(95)  
After 8 to 10 years, of the 62% of patients who chose to forego surgical 
intervention had no worsening of their symptoms. Thus, the remainder, or 38%, 
of these patients actually crossed-over to the surgical arm. The authors 
concluded that, with time, it was likely symptoms of lumbar spinal stenosis 
would remain stable for many patients who had surgery. Unfortunately, the same 
study found diminished benefits (despite initially better baseline symptoms) in 
those patients who elected to wait before crossing over to the surgical 
side.(95)(96)(97)  
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Notably although, at 10 years, patients who had been treated surgically reported 
less leg pain and greater improvement in functional status than the nonoperative 
patients.  
Another study known as the Spine Patient Outcome Research Trial (SPORT) 
reported 2-year outcomes of patients with spinal stenosis with regard to 
operative versus conservative therapies.(98) This study looked at 289 patients as 
a randomized cohort and 365 patients as an observational cohort. These patients 
had 12 weeks of symptomatic spinal stenosis without spondylolisthesis. Surgical 
treatment consisted of decompression with only 6% receiving instrumented 
fusion. The nonsurgical treatment consisted of medical therapy including steroid 
injections. 
This study found that surgery was superior to nonsurgical therapy in improving 
patients’ symptoms and improving function. However, results were affected by 
significant lack of adherence to treatment assignments by randomization.  
 
1.12.1.3. Epidural steroid injections 
The mechanism of action of epidural injections is thought to consist of neural 
blockade altering or stopping nociceptive input, reflex mechanisms of the 
afferent limb, self-sustaining activity of the neuron pools and neuroaxis, and the 
pattern of central neuronal activities.(97)  It has been demonstrated that all 
lumbar epidural steroid injections provided short-term relief but limited long-
term relief.(97)  
One randomized placebo-controlled trial studied the effects of epidural steroid 
injections and a local anaesthetic on neurogenic claudication.(99)  
This study suggested that the local anaesthetic mepivacaine would reduce 
symptoms while increasing walking distance in the short-term. However, these 
effects last for no more than 1 month. Epidural steroids seemed to offer no 
additional benefit to the effects of the anaesthetic block, however. In patients 
with more severe symptoms who have failed conservative management, surgery 
was thought to be more beneficial. 
Caudal epidural steroid injections are commonly used to help reduce radicular 
pain in lumbar spinal stenosis. In a study, the therapeutic benefit of 
fluoroscopically guided caudal epidural steroid injections was evaluated in the 
treatment of bilateral radicular pain from symptomatic lumbar spinal stenosis. 
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This prospective cohort study was performed on 34 patients with bilateral 
radicular pain from lumbar spinal stenosis who received epidural injections as 
they did not improve with other therapy. Patients were injected once, and then 
again at 6 weeks, 6 months, and 12 months after the injections. 65% of patients 
at 6 weeks, 62% at 6 months, and 54% at 12 months had a successful outcome, 
reporting at least a 50% reduction between pre-injection and post-injection 
visual analogue scores. Fifty-nine percent of patients had an improved walking 
tolerance at 6 weeks, 56% at 6 months, and 51% at 12 months.(100)  
Another retrospective study,(101) looked at the duration and amount of pain 
relief, change in functional status, patient satisfaction, and surgical rate. The 
researchers found that 39% of patients reported less than 2 months of pain relief, 
32% more than 2 months, and 29% reported no relief from the injections. 
Twenty percent subsequently had surgery. They concluded that epidural steroid 
injections are a reasonable treatment for lumbar spine stenosis, providing for 
some pain relief and some sustained improvement in function as well. 
 
1.12.1.4. Physiotherapy 
In a RCT 58 patients with LSS were randomized to one of two 6-week physical 
therapy programs. One program included manual physical therapy, body weight 
supported treadmill walking, and exercise, whereas the other included lumbar 
flexion exercises, a treadmill walking program, and subtherapeutic ultrasound. 
A greater proportion of patients in the manual physical therapy, exercise, and 
walking group reported recovery at 6 weeks compared with the flexion exercise 
and walking group. At 1 year, 62% and 41% of the manual therapy, exercise, 
and walking group and the flexion exercise and walking group, respectively, still 
met the threshold for recovery. Thus, it seems that patients with lumbar spinal 
stenosis can benefit from physical therapy.(102)  
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1.12.2. OPERATIVE MANAGEMENT 
Patients with established diagnosis of LSS from clinical history, physical 
examination and radiological assessment, would usually have conservative 
treatment applied for 3–6 months. If severe symptoms persist and functional 
impairment develops, surgery is the recommended option, unless there are 
contraindications or patients are unwilling to undergo the operation. Some 
patients may have unrealistic expectations of what can be achieved with surgical 
procedures. (103) 
The aim of the procedures in LSS is to decompress the entrapped neural 
elements, without disrupting the stability of the segment. Such decompression 
surgery usually leads to spontaneous relief of pain in the legs, and, to a lesser 
degree, of low back pain. (95) 
The speed and extent of recovery is, however, unpredictable, even if pressure on 
nerve roots, dura and blood vessels is sufficiently eliminated. Decompressive 
surgical procedures include laminectomy and hemilaminectomy, 
hemilaminotomy, fenestration, foraminotomy and the implantation of 
interspinous distraction devices.(91)(104)(105)  
 
1.12.2.1. Lumbar laminectomy 
Lumbar laminectomy is a common operation and involves removal of the lamina 
of the symptomatic stenosed spinal levels.  
Early treatment is important for a successful outcome in those who are deemed 
surgical candidates. Surgical decompression of the neural structures usually 
treats the symptoms effectively and patients often can resume some active lives 
compared to preoperative states.(106)   
 
Importantly, patient selection is key.(107) The history, physical examination, 
and appropriate imaging studies provide enough information to make the correct 
diagnosis. Some patients may require further studies, such as somatosensory 
evoked potentials, electromyography, vascular tests, including an ankle brachial 
index, or lumbosacral plexus imaging, to confirm the diagnosis. 
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The selection of more severe cases of LSS for surgery and less severe cases for 
conservative treatment, has potentially introduced a major selection bias in all 
retrospective and prospective non-randomised trials. This has made difficult the 
decision-making process in choice between conservative therapy and 
surgery.(108)  
Cochrane reviews of surgical treatments for spinal stenosis concluded that there 
is still insufficient evidence to support surgery over nonsurgical 
treatments.(4)(109)  
A pair-matched study demonstrated no statistically significant difference in 
clinical outcome between surgically decompressed and conservatively treated 
patients after a 4year follow-up period. (110)  
In a further study 5–10 years after treatment there was  no longer a significant 
difference between the two groups with regard to back pain and patient 
satisfaction with their condition, although differences in leg pain and functional 
status were still detectable. (108)  
Two prospective trials indicated that surgical decompression is superior to 
conservative therapy. (47)(111) However, the differences in pain relief and 
improvement in functional status narrowed during the 2 year follow-up period 
(47). 
Aside from the short period to follow-up, other limitations of the study were the 
use of only one type of operation and the high rate of crossover from surgery to 
conservative therapy and vice versa. Moreover, a later meta-analysis was unable 
to provide evidence for the effectiveness of surgery in patients with LSS. (89)   
So far, only a few prognostic signs, such as young age, (112) short preoperative 
duration of claudication (the absence of sphincter dysfunction and atrophy), 
symptom relief with lumbar flexion and a limited number or absence of 
comorbidities (for example, peripheral vascular disease and cardio-vascular 
disorders), predict a favourable outcome after surgery.(113)(114)(115)  
In addition, in the case of concomitant degenerative spondylolisthesis, the 
clinical results are better after surgery than after conservative therapy. (116). 
The extent of radiological findings are generally of little help for the 
identification of a surgery indication. 
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1.12.2.1.1. Success rate: - Success rates for decompression surgery in cases 
of LSS range from 40–90% in the literature and depend on a wide variety 
of factors such as type of decompression, duration of follow-up, age of 
patients and comorbidities. (60) (113) (117) (118) (119) (120) (121)  
 
1.12.2.1.2. Complication rate:- The complication rates for decompression 
surgery (during and after the surgical procedure) range from 14% (116) 
to 35% or more.(122) (123)  
 
1.12.2.2. Interspinous spacers 
New techniques for the treatment of lumbar stenosis include motion preservation 
devices known as interspinous distracters (Figure 1.2). Examples of such 
devices include the X-stop device, the Wallis System, the DIAM, and the Coflex 
system. As the name implies, the mechanism by which these devises work, is by 
providing distraction between the spinous processes hence providing extra space 
to the neural foramina and lateral recesses. 
The X-stop interspinous distraction device has shown to be an attractive 
alternative to conventional surgical procedures in the treatment of symptomatic 
degenerative lumbar spinal stenosis.  
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1.12.2.2.1. Biomechanics  
The understanding of biomechanics of interspinous distracters is important to 
understand their therapeutic role in treatment of LSS. 
In vitro studies in cadaveric spinal column specimens have shown that IPDs have 
following biomechanical effects: 
• IPDs do not change: 
- the ROM in flexion, extension, lateral rotation and axial rotation. 
- the intradiscal pressure in flexion, lateral rotation and axial rotation. 
• IPDs reduce: 
- the intradiscal pressure in extension 
(124) 
There is cadaveric evidence that X-stop reduces flexion-extension range at the 
instrumented level with no effect on axial rotation and lateral bending ranges of 
motion. The range of motion in flexion–extension, axial rotation, and lateral 
bending at the adjacent segments was not significantly affected by the implant.(125)  
Another study has shown that in extension, the implant significantly increased the 
spinal canal area by 18% (231–273 mm2), foraminal area by 25% (106–133 mm2), 
and the foraminal width by 41% (3.4 – 4.8 mm).(126) 
In addition, another study has shown that the pressures at the adjacent discs were not 
significantly affected by the interspinous implant insertion.(127)  
These findings could explain the proposed mechanism of beneficial effect of the X-
stop device. 
  
1.13. Clinical outcomes 
Numerous studies have shown the superiority of operative treatment compared to 
conservative treatment for LSS patients. 
The first RCT comparing the clinical efficacy of X-stop versus conservative 
treatment showed the success rate of 52% for X-stop patients and 10% for 
conservatively managed patients at 6 weeks. At 6 months, the success rates were 52 
and 9%, respectively, and at 1 year, 59 and 12%. The results of this prospective 
study indicate that the X-STOP offers a significant improvement over non-operative 
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therapies at 1 year with a success rate comparable to published reports for 
decompressive laminectomy, but with considerably lower morbidity.(128) 
Using the ODI and a clinical exam as the outcome measures, the authors did not 
find a significant difference in subjective disability or functional status between the 
two groups.(129) (130) 
At 2 years follow up of the same study, the X-stop patients improved by 45.4% over 
the mean baseline Symptom Severity score compared with 7.4% in the control 
group; the mean improvement in the Physical Function domain was 44.3% in the X-
stop group and  0.4% in the control group. In the X-stop group, 73.1% patients were 
satisfied with their treatment compared with 35.9% of control patients. The X-stop 
provides a conservative yet effective treatment for patients suffering from lumbar 
spinal stenosis. In the continuum of treatment options, the X-stop offers an attractive 
alternative to both conservative care and decompressive surgery such as lumbar 
laminectomy.(131) 
Same study, followed up 18 patients who have had X-stop and suggested that X-
stop success is stable as measured by ODI.  ODI showed that the success rate in the 
X-stop interspinous process decompression group was 78% at an average of 4.2 
years postoperatively. The results suggest that intermediate–term outcomes of X-
stop surgery are stable over time as measured by the ODI. 
Limitations of the study are a high rate of loss to follow up, small sample size and 
no indication that statistical testing was performed considering that there were no 
patients in conservative treatment to be compared with. (132) 
The significant clinical outcomes of the X-stop were also shown by other studies. 
(133)  
In a similar manner, two major RCTs showed that lumbar laminectomy 
demonstrated significantly improved outcomes compared to conservative 
treatment.(98) (111) 
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1.14. Quality of life 
At the 6-week, 6-month, and 1-year post-treatment follow-up time points, the X-
stop group scored significantly better than the non-operative group in every 
domain. In addition, at each time point, the mean scores in each category for the 
X-stop group were significantly better than the respective pre-treatment scores, 
whereas in the non-operative group, none of the mean scores was significantly 
better.(128) 
It has been suggested that SF-36 domain scores are valid for measuring 
morbidity and surgical outcomes in common spinal disorders. (134) 
It was shown that the EQ-5D is useful for estimating health state values and for 
monitoring outcome of patients undergoing low-back surgery. Hence, this 
instrument would provide valid data for cost– utility analyses in lower back 
surgery.(135) 
Another study showed an improvement in EQ5D postoperatively following 
lumbar laminectomy operation.(136) 
The long-term follow-up showed that patients operated on for LS continue to 
improve their QoL pattern even between the 4th and the 8th year after surgery. 
Specifically improvements were observed in Physical Function, Bodily Pain, 
Mental Health and the Physical Composite Score with respect to the first follow- 
up. Conversely, Vitality worsened during this follow up.(137) 
 
1.15. Radiological parameters  
The biomechanical effect of X-stop on the vertebral spine has been used to 
explain the beneficial effect of the implant. It has been shown that X-stop 
significantly increases the foraminal height, foraminal width, foraminal cross-
sectional area, intervertebral angle and decrease in anterior disc height and 
posterior disc height.(138) 
The widening effect on spinal canal area and neural foramina was confirmed in 
another study.(139) (140) 
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1.16. Costs associated with operations 
There are two studies supporting the use of X-stop over lumbar laminectomy on 
the grounds of higher cost-effectiveness.(141) (142)  
Although both studies were RCTs both studies only chose a subgroup of 
laminectomy patients and as such introducing some selection bias.  
 
 
1.17. Economical evaluation of health  
Excellent description of health economic evaluation is given in book by Morris 
et al, 2007. (143) 
In view of current financial climate and limited budgets, understanding the 
health economics is becoming increasingly important concerning the decision-
making in provision of care. 
Two main factors underpin the economic analysis: 
- resources are limited, and 
- potential uses of those resources are unbounded. 
 
1.17.1. Cost-benefit analysis(CBA) 
CBA is the analysis of decision regarding whether to do or not to do something, 
which depends on weighing its costs and benefits.  
 
1.17.2. Cost-effectiveness analysis (CEA) 
The special case of CBA is the cost-effectiveness analysis (CEA), which seeks to 
answer the question of which among the two or more alternatives provides the 
most output for a given cost, or the lowest cost for a given output. To compare 
alternatives, cost –effectiveness ratio (CER) is used, which is calculated as a 
cost per unit of output or effect. 
The health measure used to calculate CER is gains in quality adjusted life years 
(QALYs). QALY is a composite measure of gains in life expectancy and health-
related quality of life. 
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1.17.3. Cost-effectiveness ratio (CER) 
Let us assume that Ca and Cb are the costs of the standard treatment a and its 
best alternative b respectively. Also, let us assume that Ea and Eb are the effects 
health measures of the standard treatment a and its best alternative b. Then the 
CER is calculated as follows: 
 
CER = 
)(
)(
EbEa
CbCa
−
−  
or 
CER = 
E
C
∆
∆ ,   
where,     
Incremental cost = ΔC = Ca – Cb;  Incremental effect = ΔE = Ea –Eb 
 
1.17.4. The Cost-Effectiveness Plane 
The cost-effectiveness plane is a useful way of showing the decision rules that 
apply to the CER. (144)  
In the diagram (Figure 1.3) the vertical axis represents the difference 
Incremental cost ΔC diagram while the horizontal axis shows the Incremental 
effect ΔE of an activity compared to some alternative.  These lines divide all 
possible cost and effect combinations into four quadrants.  The CER in north-
west quadrant indicate that costs are higher and effects are lower.  Therefore, the 
activity is said to be dominated by its alternative and should not be used. On the 
other side, to the south-east, costs are lower and the effects are greater, so the 
activity dominates its alternative and should be used. In the other two quadrants, 
either greater effectiveness is gained at a higher cost (north-east quadrant), or a 
reduction in costs is achieved at the expense of lower effects (south-west 
quadrant). In these two quadrants, whether or not the activity should be 
undertaken on the efficiency grounds depends on the trade-off between costs and 
effects. 
The slope of a line from the origin represents the CER of an activity.  
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1.17.5. The Incremental Cost-Effectiveness Ratio (ICER) 
The ICER refers to comparing the activity with another alternative i.e. ‘another 
way of doing something’. There is one precondition which requires that the 
alternative is cost-effective itself otherwise the results may be misleading (e.g. 
non-cost effective alternative which when used in comparison with the 
alternative spuriously seems to be cost-effective).  
 
1.17.6. Measurement of health outcomes 
There are two types of questionnaires used: disease-specific and general 
questionnaires used to get the health outcome measures. Disease-specific 
questionnaires, as the name suggests, attempts to address functional status of the 
patient regarding the particular disease. The general questionnaires measures 
health outcomes by its impact on quality of life (QOL) or health-related QOL 
(HRQOL). 
The HRQOL is defined as: 
 
CER, higher costs 
with higher effects 
CER, lower costs 
with loer effects 
Dominated 
activity 
Activity 
dominates 
(-
) I
nc
re
m
en
ta
l c
os
t (
+)
 
(-) Incremental effect (+) 
Figure 1.2: The cost-effectiveness  plane 
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‘The value assigned to duration of life as modified by the impairments, 
functional status, perceptions and social opportunities that are 
influenced by disease, injury, treatment or policy.’(145) 
 
Questionnaires which measure the HRQOL indicators  are called instruments. 
The people who are completing the questionnaires are called respondents. 
 
1.17.7. Criteria’s for health outcome questionnaires 
The principal criteria for a good health outcome questionnaire are: 
- reliability –produces consistent measurements 
- validity – measures what is supposed to measure 
- responsiveness – it means how sensitive the results from the 
health outcome instrument are to changes in health. If people who 
have a serious illness have the same HRQOL scores as healthy 
people, we might suspect that the instrument is not very sensitive.  
- feasibility – how acceptable is instrument to the respondents i.e. 
relevance or length issues. 
 
 
1.17.8. Types of health outcome measures 
There are two types of health outcome questionnaires: 
1. Generic health state instruments – (such as EQ5D and SF36) intended to 
be independent of particular health conditions and interventions and 
therefore applicable in all circumstances. These measures are intended to 
be all-encompassing measure that tells you all you need to know in every 
circumstance, and sometimes a common minimum data set collection is 
collected for various facets of health (e.g. pain, dysfunction, mobility, 
washing, dressing etc). 
2. Disease-specific (or treatment- or domain-specific) health 
questionnaires – (such as Zurich Claudication Questionnaires) intended 
only for a specific illness (or treatment- or domain-specific health state).   
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1.17.9. Measurement of health gain 
The health gain is calculated as a difference with and without the intervention.   
This health is regarded as the product of the level of health and the length of 
time experienced (Figure 1.4.). 
 
 
 
Figure 1.3: Measuring the health gain (area shown by the diagonal shading) from 
intervention. (143) 
 
The most common measure used is quality-adjusted life years (QALYs). 
QALYs are calculated similarly as the example above, by multiplying the 
amount of time in a particular health state by the quality of life during that time, 
then summing up over all time periods. 
 
1.17.10. Thresholds in cost effectiveness analysis 
What represents society’s willingness to pay for a unit of health improvement?  
In the UK, the threshold value of CER proposed by NICE is considered as 
£30000/QALY. 
 
It has been stated that: 
Onset of illness 
Time 
H
RQ
O
L 
1 
0 
Intervention 
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‘NICE would be unlikely to reject a technology with a ratio in the range of 
£5000 - £15000/QALY solely on the ground of cost-ineffectiveness but would 
need special reasons for accepting technologies with ratios over £2500 -
£35000/QALY as cost effective.’(146) 
 
The so-called cost-effectiveness acceptability curve showing the probability that 
the standard treatment is more cost effective for various maximum acceptability 
ceiling ratios (thresholds).(147)  
 
 
1.17.11. Cost-effectiveness versus Clinical evidence in decision making 
So the question arises of where do we stand when we have the cost-effectiveness 
evidence and clinical evidence regarding the standard treatment and its 
alternative.  
Cost-effectiveness evidence seems to explain decisions to recommend for or 
against a therapy, whereas clinical evidence considers the decisions to 
recommend restricted or unrestricted use.(148) 
 
2. BACKGROUND TO THE STUDY 
Lumbar spinal stenosis (LSS) is a common and debilitating condition, which 
consumes large amounts of healthcare resources. It occurs in 13-14% of patients 
who consult a specialist with back-pain, and in the US costs tens of billions of 
dollars in health-care.(125) 
 
Degenerative changes in the facet joints and ligamentum flavum cause 
narrowing of the spinal canal and compression of lumbar nerve roots. This 
results in neurogenic claudication: a debilitating pain or heaviness in the legs 
that is aggravated by walking, thereby limiting mobility. There have been an 
increasing number of treatments for LSS over the years, including 
physiotherapy, lumbar laminectomy, lumbar foraminotomy and devices for 
interspinous distraction. Lumbar laminectomy and interspinous distraction are 
both effective methods for treatment of LSS but there is little published 
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regarding the cost effectiveness of these treatments and quality of life for 
patients.  
Lumbar laminectomy is a relatively safe operation, but it is thought that it results 
in longer operative time, more immediate post-operative back-pain, longer 
hospital stay, and greater complications compared to the insertion of the X-stop 
device. However, the cost of the X-stop device itself has to be weighed against 
the advantages. This constitutes the basis for this study. 
The all Titanium X-stop device was first implanted nearly 15 years ago as part 
of a series of developments of the evolving product.  The current Titanium 
versions gained CE mark approval in 2002 and the Titanium plus PEEK upgrade 
(XSTOPPK®) shortly after that.  In the USA, a multicentre randomised controlled 
trial (RCT) was conducted comparing X-stop surgery to conservative therapy in 
a population of patients with Lumbar Spinal Stenosis (135)  The RCT results 
were submitted to the FDA in a full PMA application, and FDA approval to 
market the XSTOP® was granted in November 2005. 
The current biomechanical model suggests that placement of the XSTOPPK® 
implant in the anterior column will result in load sharing and thus reduced strain 
on degenerative lumbar discs with concordant pain relief. 
This prospective, randomised, multi-centre study seeks to show that X-stop 
device despite the extra cost of the implant itself, is more cost effective.  This 
presumed cost effectiveness is linked to presumed shorter operative times, lower 
risk of dural damage associated with surgical decompression techniques and the 
associated costs of treating this problem, shorter hospital stays, potential use of 
local anaesthesia for the procedure and faster rehabilitation.  We have 
undertaken the task of prospectively and in a randomised fashion, to compare 
the cost effectiveness, clinical outcomes and safety of X-stop versus surgical 
decompression in the treatment of symptomatic lumbar spinal stenosis. 
Effectiveness of the different treatments will be assessed using general quality of 
life questionnaires and disease-specific questionnaires. 
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2.1. Primary end-point 
Primary end-point of our study is to assess the cost-effectiveness of lumbar 
laminectomy versus X-stop device insertion.  
  
2.2. Secondary-end points 
Secondary end-points to the study are comparing between and within each 
treatment group the following:  
• Quality of life as measured by: 
- EQ5D and VAS 
- SF36 and separately for each domain. 
• Costs  
• Clinical outcomes: 
- Quebeck Back Pain Disability Score  
- Oswestry Disability Index, 
- Zurich Claudication Questionnaire 
• Assessing predictive factors for: 
- Quality of life,  
- Costs 
- Clinical outcomes 
 
Ten predictive factors considered are: ASA score, age, smoking status, 
gender, duration of symptoms, actual levels operated, number of levels 
operated, BMI, procedure (Lumbar laminectomy versus X-stop), and Cobb 
angle. 
• Correlation between general quality of life and disease-specific 
questionnaires as applied to lumbar stenosis patients. The aim here is to 
work out if there is a significant valid convergence for the use of EQ5D and 
SF36 in lumbar spinal stenosis patients.  
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• Assessment of radiological changes associated with each intervention. 
- at the same level 
- if there is any evidence of accelerated degeneration 
 
Radiological parameters analysed are: - spinal canal area, foraminal area, 
fact joint size, anterior disc height, posterior disc height, Cobb angle, 
intervertebral angles. Also, the upper and lower adjacent vertebral levels to 
the operated level(s) were assessed for changes in: -spinal canal area, 
foraminal areas, facet size, ligamentum flavum, disc heights. 
• Complications 
 
• Reoperation rates. 
 
• Sample size calculations –as derived from this pilot study  
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3. METHODS 
 
3.1. Study design 
The purpose of this thesis is to inform a larger UK based prospective, 
randomised multi-centre study, by providing pilot data of sample size, feasibility 
and outcome.  The Ethics approval was obtained from the National Research 
Ethics Committee UK and the study is registered with International Standard 
Randomised Controlled Trial (ISRCTN88702314).  
Recruitment was done from two UK neurosurgical centres. Patients are initially 
assessed against our inclusion and exclusion criteria (see below). After reading 
Patient Information Sheet eligible patients were recruited into the study after 
giving written informed consent and they were subsequently subject to the 
routine surgical and post-operative care at each participating centre.  
Assessments have been carried out similar to the routine practice with strict 
appointments at the following time periods: preoperatively; intraoperatively and 
postoperatively at discharge, 6 weeks, 6, 12, 24 months.   
This thesis constitutes the analysis of the first 12 months following the 
randomisation and operation. 
 
3.2. Primary Objective 
The primary objective of this clinical investigation is to provide pilot data of 
whether there is a difference in cost of implanting XSTOP® PK compared to 
conventional surgical decompression, initially at 2 weeks post-op and up to 12 
months.   
 
3.3. Secondary Objectives 
The secondary objectives are to compare quality of life measures between the 
two groups (EQ5D, SF-36), clinical efficacy (QBPDS, Oswestry disability 
index, Zurich Claudication Questionnaire), radiological parameters and 
complications. 
67 
 
 
3.4. Patient Selection 
3.4.1. Randomisation and Blinding 
In order to ensure similar numbers of treatment allocation between the two 
groups, balanced block randomisation was done of size ten with 1:1 treatment 
allocation ratio in each block. The random allocation was obtained via computer 
random number generator. An independent person not involved in the study did 
the random number assignment and preparation of identically looking 
envelopes.  After eligibility had been confirmed, patients were randomly 
assigned by selection of the concealed lowest numbered treatment envelope 
from each block batch.  
 
Randomisation envelopes were opened on the day prior to surgery, to facilitate 
theatre planning, and the appropriate procedure completed.   
 
3.4.2. Target Population 
Patients with at least 6 months unsuccessful conservative treatment for Lumbar 
Spinal Stenosis with Neurogenic Claudication with/without lower back pain 
(LBP) were considered for inclusion in this study.  There should be no evidence 
of psychiatric disease or ongoing litigation, and all patients should be considered 
suitable for posterior or postero-lateral lumbar spine surgery for the treatment of 
their condition. 
Patients who fulfil the following inclusion and exclusion criteria were 
considered eligible to be entered into this investigation. 
 
3.4.3. Inclusion Criteria 
Patients were admitted in the study if they met all of the following inclusion 
criteria: 
a) is a male or non pregnant female patients 
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b) is aged between 18-80 years (inclusive) 
c) has a BMI <35 kg/m2 
d) has chronic leg pain with or without back pain of greater than 6 months 
duration, partially or completely relieved by adopting flexed posture and 
who are suitable candidates for posterior lumbar surgery 
e) has completed at least 6 months of conservative treatment without obtaining 
adequate symptomatic relief 
f) has degenerative changes at 1 or 2 adjacent levels between L1-S1 confirmed 
by X-Ray, CT or MRI scan with one or more of the following: 
o lumbar spinal stenosis with Neurogenic claudication  
o decrease in disc height > 50% 
o annular thickening 
o degenerative Spondylolisthesis ≤ Meyerding Grade 1 
o thickening of ligamentum flavum 
g) is physically and mentally willing and able to comply with the postoperative 
scheduled clinical and radiographic evaluations. 
 
3.4.4. Exclusion Criteria 
A patient will not be admitted into the study if he/she meets any of the following 
exclusion criteria: 
a) fixed motor deficit 
b) is skeletally immature 
c) has undergone previous lumbar spinal surgery  
d) has obvious signs of psychologicali or worker compensation or litigation 
claimsii
f) has active infection or metastatic disease 
 elements to their condition 
e) is unwilling or unable to give consent or adhere to the follow-up 
programme 
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g) has non-degenerative spondylolisthesis 
h) has degenerative spondylolisthesis > Meyerding Grade 1 
i) has a known allergy to implant materials 
j) has severe osteoporosis or rheumatoid arthritis 
k) cauda equina syndrome 
l)  acute disc extrusion or sequestered fragments  
 
3.5. Hypothesis 
The null hypothesis is stated as: 
“There is no difference in cost effectiveness of the X-stop device compared to 
that of conventional decompressive surgery.” 
The null hypothesis will be rejected if the mean cost of treatment in the X-stop 
group is significantly different to the decompressive surgery group.  Two-way 
analysis of variance will be performed to determine any statistically significant 
difference between the mean costs of treatment in the X-stop and decompression 
groups (p=0.05). 
3.6. Sample size calculation 
The sample size calculation is done by statistician and is based on a comparison of 
short-term costs between the randomised groups using a standard 2 sample t-test 
approach.  Katz et al 1997 estimate mean hospital cost for lumbar laminectomy at 
£6639, with a standard deviation £1879.(149) 
The consideration was made to detect at least a 20% difference in costs between 
the laminectomy and X-stop groups. In calculating sample size, an assumption of 
normality is considered acceptable since similar costs were noted to be 
symmetrically distributed by Katz et al. To detect at least a 20% difference with a 
5% significance level and 90% power requires 43 patients per group. This number 
also allows 80% power to detect at least a 20% difference in the SF36 physical 
functioning scale at a 5% significance level (assuming mean after laminectomy of 
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72, standard deviation 22.8). The study by Katz et al suggests a dropout rate of up 
to 27% over a 2-year follow-up. To allow for this in the analysis of long-term 
outcomes we have inflated the sample size accordingly, requiring a minimum of 
55 patients per group.  
For clinical efficacy, 40 patients per group would allow us to detect at least a 20% 
difference in the SF36 physical functioning scale at a 5% significance level, 80% 
power. This calculation has used estimates from a previous study which reported 
mean (sd) for SF36 physical functioning score after laminectomy of 72 (22.8). 
(150)  The method is based on a 2 sample t-test which requires assumptions of 
Normality and equal variance.  The study by Katz et al, 1997 suggests a dropout 
rate of up to 27% over a 2-year follow-up.  
 
3.7. Operative techniques 
3.7.1. Lumbar laminectomy 
Under general anaesthetic patients were positioned in the prone position in a theatre 
table which was adjusted to flex their spine.  After the operative level(s) were 
confirmed through fluoroscopy, a mid-sagittal incision was made over the spinous 
processes of the stenotic level(s) and the musculature was elevated to the level of 
laminae and facets. Then laminae were removed over the stenotic segment. Skin 
closure was made. 
 
3.7.2. X-stop device insertion 
Under general anaesthetic patients were positioned in the prone position in a theatre 
table which was adjusted to flex their spine.  After the operative level(s) were 
confirmed through fluoroscopy, a  mid-sagittal incision was made over the spinous 
processes of the stenotic level(s) and the musculature was elevated to the level of 
laminae and facets. Occasionally, hypertrophied facets that blocked entry to the 
anterior interspinous space were partially trimmed to enable anterior placement of 
the implant. A curved dilator was inserted in the anterior margin of the interspinous 
space to pierce the interspinous ligament. A sizing distractor was then inserted to 
determine the appropriate implant size. The X-STOP was then secured to the 
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insertion instrument and inserted into the interspinous space.An attempt was made 
to place the implant as close to the posterior aspect of the lamina as possible. An 
adjustable wing was fastened to the implant and positioned as close to the midline as 
possible.The incision was closed 
 
 
3.8. Outcome measures 
 
3.8.1. Measuring costs 
Costs were measured in UK Sterling (2010) as a sum of costs incurred for theatre 
time, inhospital stay, implant costs, physiotherapy sessions, outpatient clinic 
appointments attended and imaging.  
 
 
3.8.2. Measuring quality of life 
Quality of life is measured by general outcome measures such as EQ5D and SF36.  
The EQ-5D derives its name from the European Group (EuroQoL) that originally 
created the EQ-5D. (151) It is made up of 5 dimensions: Mobility, Self-Care, Usual 
Activities, Pain/Discomfort, Anxiety/Depression. Each dimension consists of 3 
levels as follows: 
Level 1: indicating no problems 
Level 2: indicating some problems 
Level 3: indicating extreme problems. 
A unique health state is then defined by combining 1 level from each of 5 
dimensions. Each unique health state is then converted to a particular unique score 
between -0.594 (worst then death) and 1(perfect health). There is also EQ5D VAS 
score where patients need to score a value out of 100 in a range 0 (worst imaginable 
health state) and 100 (best imaginable health state). (151) 
 
SF36 is a widely used quality of life questionnaire, developed in USA, which stands 
for Short Form and it is made up of 36 items divided between 8 domains with each 
domain attempting to capture a specific aspect of quality of life. The domains are: 
Bodily pain (BP), Physical function (PF), General health (GH), Role emotional 
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(RE), Vitality (VT), Social functioning (SF), Mental health(MH), Role physical 
(RP). The higher the percentage the better the quality of life for each domain.(152) 
 
3.8.3. Measuring utility values  
QALYs were calculated from two sources and analysed separately. The sources for 
QALY calculations are made from EQ5D score and SF36. The SF-36 scores were 
transformed to Health Utility Index (HUI2) on the basis of equations from Nicholet 
al. (153)  Then, both EQ5D and HUI2 were transformed by linear transformation on 
a rating scale ranging from 0 (“death”) to 1(“full health”). 
Subsequently QALYs were calculated as a sum of products of QALYs gained with 
length of time (at 6 weeks, 6 months and 12 months) for each patient since the 
operation date for both treatment groups separately. 
 
3.8.4. Measuring clinical effectiveness 
 
Cost-effectiveness analysis of both interventions was performed by first measuring 
outcomes in terms of quality-adjusted life years (QALYs) and in terms of the 
incremental cost. 
As explained earlier the ICER is calculated as the difference in costs lumbar 
laminectomy and X-stop groups incurred divided by the difference in QALYs 
accrued between the two treatments being compared. The term dominant is used to 
reflect instances in which one intervention is both less expensive and more effective 
(i.e., offers better quality of life) than the alternative intervention.  
All results are expressed in UK sterling. 
We represented uncertainty (secondary to sampling variation in the cost-
effectiveness ratios) by using the stochastic (bootstrapping) and probabilistic 
techniques (Monte Carlo simulation), to generate the sampling distribution of the 
cost and efficacy (QALYs). This has enabled us to quantify the uncertainty 
surrounding the estimates of costs and effects, presented graphically on the cost-
effectiveness plane. We generated 1000 bootstrap replications of the cost-
effectiveness ratios.(147)  
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3.8.4.1. Sensitivity Analyses 
Sensitivity analyses were performed to determine the consequences of making 
alternative assumptions, for instance, about the definition of treatment success 
regarding the number of affected levels.  
One-way sensitivity analysis was used to test the robustness of the results and to 
determine if the number of levels operated have a substantial effect on the 
results. The results generated by the cost-effectiveness model are considered 
robust because the cost effectiveness ratios fall within a narrow range when key 
model assumptions and parameters are varied. 
 
3.8.4.2. Uncertainty in cost-effectiveness 
For the decision -maker to make a decision regarding the reimbursement of a 
new technology, the emphasis will lie in the probability that the new technology 
is cost-effective compared to the existing alternative. This can be deduced from 
the incremental cost-effectiveness plane when compared  to maximum 
acceptable ceiling ratio represented by the cost-effectiveness acceptability curve 
(CEAC).  The maximum acceptable ceiling ratio represents the values that 
decision makers are willing to pay for the use of particular treatments.  In 
practice, the maximum acceptability ceiling ratios represent the proportion of the 
incremental cost-effect pairs that fall to the south east of a line with slope 
through the origin. The CEAC indicates the probability that an intervention is 
cost-effective compared with the alternative, given the observed data, for a range 
of maximum acceptability ratio values. 
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3.8.5. Measuring clinical outcomes 
Clinical outcomes in this study were measured using the following disease-
specific questionnaires: 
3.8.5.1. Zurich Claudication Questionnaire (ZCQ):- This is an instrument widely 
used in lumbar stenosis patients with excellent reliability, validity and 
responsiveness. (154) (155)  
It consists of three components:  
1. Symptom component (rated on a scale of 1 – 5)  
2. Physical component (rated on scale 1- 4). 
3. Satisfaction component (rated on scale 1-4) 
The maximum score for each component is represented as percentage of 
total score of each component. 
3.8.5.2. Oswestry Disability Index (ODI):-   The Oswestry Disability Index 
(ODI)(156)  have emerged as one of the most commonly recommended 
condition specific outcome measures for spinal disorders.(157) (158)  
It is made up of 10 sections each comprising of 5 questions. The score is 
calculated as the percentage of the total. The higher the score the worse is 
the outcome.(159)  
 
3.8.5.3. Quebeck Back Pain Disability Scale (QBPDS):- This is an additional  
disease –specific test used to encompass more outcome features as the ODI, 
for example, does not include body movements such as bending or pushing. 
QBPDS is thought to be highly sensitive and reliable in lower back pain 
conditions. (160)  
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3.9. Time line 
The following assessments will take place preoperatively and at following 
follow-up periods - 6 weeks, 6 and 12 months:  
• EQ5D (also at discharge),  
• SF36 
• QBPDS 
• Oswestry Disability Index (ODI)  
• Zurich Claudication Questionnaire (ZCQ) (Symptom and Satisfaction 
component also at discharge) 
 
3.10. Radiological data 
The changes between preoperative and postoperative changes were analysed for 
the following radiological features: 
-spinal canal area, foraminal area, facet size, anterior and posterior disc heights, 
inetrvertebral angles, Cobb angle. 
The spinal canal area was calculated as an average of the anterior-posterior 
diameter and transverse diameter of the spinal canal divided by two which gives 
the radius.The formula for the area of the circle was utilised as follows: 
 
Area of circle (mm2)= п x Radius2 =  п x (average diameter/2)2 
where п = 3.1415926535 (pi value) and    
average diameter = (anteriorposterior diameter +transverse diameter)/2 
 
The patients were positioned in such a way in the MRI scanner to preserve the 
angle of cuts and patients were entered in the scanner head first. There were no 
claustrophobic patients in this study which would have required different means 
of positioning (leg first or open MRI scanners) The imaging cuts were 
consistently done parallel to the discs so that a more representative homogenous 
spinal canal area is obtained.  
 
Also, the radiological parameters for the upper and lower adjacent vertebral 
levels to the operated level(s) were analysed such as: -Spinal canal, foraminal 
area, ligamentum flavum thickness, disc heights 
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3.11.  Complication  and  Reoperation rates 
We report on complications encountered and on the reoperation rate for patients 
in both treatment groups. 
 
3.12. Statistical Analysis 
Continuous data with more than two groups were analysed by: 
- two-way ANOVA (with two factors such as Procedure (Lumbar laminectomy 
versus X-stop) and Period (preoperative, discharge, 6-weeks, 6-monhts and 12-
months data)), 
- one-way ANOVA  
- Student’s t-test 2-sample testing 
-Mann Whitney non-parametric testing –for data which were either skewed and 
untransformable, or too few. 
Discrete data were analysed by chi-squared. 
Simple regression was used to assess convergent validity of general outcome 
instruments such as EQ5D and SF36 domains. 
Multivariate linear regression analysis, logistic regression and log-linear 
modelling 
GenStat 10th edition was the statistical software package used to analyse the 
results. 
3.13. Intention to treat analysis 
The participants are counted in the treatment group to which they were allocated 
by randomization, even if they later switch treatments.  
 
3.14. Ethical Considerations 
 
         Ethics Committee Approval 
The Charing Cross Research Ethics Committee (Type 3) has granted favourable 
opinion to proceed with the study (Ref No: 08/H0711/12) will be required prior to 
starting the study because of the randomised design. 
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         Declaration of Helsinki 
This study is conducted in accordance with the relevant articles of the Declaration 
of Helsinki as adopted by the 18th World Medical Assembly in 1964 and as 
revised in Tokyo (1975), Venice (1983), Hong Kong (1989), South Africa (1996) 
and Edinburgh (2000). 
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4. RESULTS 
4.1. Recruitment  
In this study, 26 patients were eligible of which 6 were excluded (Table 4.1) and the 
other 20 were randomised into two groups. From the excluded patients, 2 patients did 
not want any operation and opted for conservative treatment, 2 patients were 
untraceable as changed the address, 1 patient developed a persisting confusion state 
following the operation hence was not able to complete the questionnaires and did not 
undergo post-operative MRI Lumbar spine, and1 patient was found to have lung 
malignancy prior to procedure therefore excluded from the study as per our exclusion 
criteria. From 20 patients randomised in the study 10 patients were randomised to 
Lumbar laminectomy and the other 10 to X-stop groups (Fig 4.1).  
         Table 4.1: Reasons for exclusion 
Reason Number of patients 
Unwilling to be operated   2 
Untraceable-changed address 2 
Confusion  following the X-
stop insertion 
1 
Incidental lung malignancy 
found preoperatively 
1 
Total excluded 6 
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Figure 4.1: Flow chart of recruitment process 
4.2. Demographics  
Baseline demographic data of both treatment groups were comparable and statistically 
non-significant (Tables 4.2 & 4.3). Mean age was 66 in Lumbar laminectomy and 69.8 
in X-stop group. Mean claudication distance in Lumbar laminectomy group was 104 
meters and in X-stop group 218 meters. Mean duration of symptoms was 100 months in 
Lumbar laminectomy group and 50.6 months in X-stop group. Mean VAS score was 7.4 
in Lumbar laminectomy and 7.6 in X-stop group (p=0.830).  Male to Female ratio was 
about 1 in 2 in X-stop group and 1 in 1.5 in Lumbar laminectomy group.  
We found that there were no differences in theatre time (p=0.454) (Figure 4.2A) as well 
as in-hospital stay (p=0.895) (Figure 4.2B) between the two treatment groups (Table 
4.4). 
      
 
18 patients excluded or 
refused 
20 randomised 
10 lumbar laminectomy 
group 
  10 in intention-to-treat 
analysis 
10 X-stop group 
10 in intention-to-treat 
analysis 
38 patients assessed 
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Table 4.2: Baseline demographic data for continuous data: Age, Gender, Claudication 
distance and Duration of symptoms preoperatively. N=10 in each group; Students t-test   
used. 
 
 
 
 
 
                  
 
 
 
 
 
 
 
Table 4.3: Baseline demographic data for discrete data: Gender, Number of levels 
operated,  Actual level(s) operated and Smoking status. N=10 in each group; Chi-
squared test used. 
   
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                Total 
          Procedure      Mean   SE               StDev p-value 
Age (years)         LL                66.00             1.99              6.31          0.322 
                    XS                 69.80          3.13              9.89 
 
BMI(kg/m2)          LL                 31.57            1.63              5.17    0.258 
                    XS                 29.08          1.36              4.31  
 
Claudication    LL               104.00           25.40           80.20     0.285 
 Distance (metres)              XS              218.00            97.60         308.80    
 
Duration of    LL              100.80             27.40           86.80 0.184 
 Symptoms (months)         XS                50.60             23.70          74.80    
 
Visual Analogue Scale LL                  7.40    1.71             0.54  0.830 
XS                 7.20    2.35            0.74 
 
 
 
                                                                    Counts (Percentage)   
Procedure                   LL                XS                        p-value   
  
     Gender   
                   Female 7(54) 6(46) 13(65)  0.639 
                   Male        3(43)                4(57)                7(35) 
 
     
  
    Number of levels operated   
 1 6(43) 8(57)               0.329  
 2 4(67) 2(33)  
 Total 10(50) 10(50)  
  
     
   
   Actual level(s) operated   
 L2/3 1(100) 0(0)                 0.475 
 L3/4 3(60) 2(40)  
 L4/5 3(33) 6(67)  
 L2/3, L3/4 1(100) 0(0)  
 L2/3, L4/5 0(0) 1(100)  
 L34, L4/5 2(67) 1(33)  
 Count 10(50) 10(50)  
   
   Smoking status 
                           Smoker                           4(40)                 3(30)                  0.639 
                          Non-smoker                     6(60)                 7(70) 
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In Lumbar laminectomy majority of patients (33%) were operated at L3/4 and L4/5 
while majority of patient (67%) in X-stop group were operated at L4/5 (Table 3). One-
level operation was performed in 43% of patients in lumbar laminectomy group, and 
57% in X-stop group. Two-level operations were done in 67% of patients in Lumbar 
laminectomy group and 33% in X-stop group (Table 4.3).  
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Table 4.4: Theatre time and inhospital stay. 
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         B) 
Figure 4.2: A) Theatre time and B) Inhospital stay for Lumbar laminectomy and the X-
stop groups. 
 
Procedure     Mean   SE      StDev p-value 
Theatre time (min)   LL           131.70     13.70             43.20 0.454 
                    XS          119.10       9.06            28.66 
 
Inhospital stay    LL                5.70       1.28               4.06 0.895 
 (days)                  XS                6.00       1.84               5.81 
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4.3. Quality of life 
As previously mentioned, quality of life was analysed using the EQ5D and SF36 
outcome measures. 
4.3.1. EQ5D Levels 
In our study log-linear modelling has shown that there is no statistically significant 
interaction between all five 5 dimensions (Mobility, Self care, Usual activities, 
Pain/Discomfort, Anxiety/Depression), treatment group and Period (p>0.05). 
Levels 1, 2, 3 represents worsening dimension (‘1’ best, ‘3’ worst). 
4.3.1.1. Mobility  
There is baseline similar Mobility dimension scores between patient with all of them 
scoring 2 which is ‘I have some problems in walking about’ in both treatment groups 
with an improving trend at different Periods (Table 4.5 and Figure 4.3).  
Table 4.5: Mobility dimension counts for each level of dimension for both treatment 
groups.  
 
   
  
 
 
 
 
 
 
 
 
      Number of patients 
 OPERATION LL XS 
 MOBILITY PERIOD   
 1 12months 1 4 
  6months 2 5 
  6weeks 1 4 
  Discharge 1 3 
  Preoperative 0 0 
 2 12months 9 6 
  6months 8 5 
  6weeks 9 6 
  Discharge 9 7 
  Preoperative 10 10 
 3 12months 0 0 
  6months 0 0 
  6weeks 0 0 
  Discharge 0 0 
  Preoperative 0 0 
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A)                                                 B) 
   
C)                                              D) 
 
  
    E) 
Figure 4.3: Mobility levels at different periods, A)Preoperative; B)Discharge; C) 6 
weeks; D) 6 months; E) 12 months. Horizontal axis indicates levels of Mobility. 
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4.3.1.2. Self-Care 
There was no trend in change in Self-care in Lumbar laminectomy group while there 
was a trend towards worsening in X-stop group. These changes were found to be non-
significant (p>0.05) (Table 4.6 and Figure 4.4). 
 
Table 4.6: Self Care dimension counts for each level of dimension for both treatment 
groups. 
 
    
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
                                                                         Total Counts 
                                         OPERATION                 LL                      XS 
               SELF-CARE PERIOD   
 1 12months 4 5 
  6months 4 4 
  6weeks 6 5 
  Discharge 3 4 
  Preoperative 4 6 
 2 12months 6 4 
  6months 6 5 
  6weeks 4 5 
  Discharge 4 5 
  Preoperative 6 4 
 3 12months 0 1 
  6months 0 1 
  6weeks 0 0 
  Discharge 3 1 
  Preoperative 0 0 
 
86 
 
 
       
A)                                                 B) 
 
    
C)                                                D) 
 
 
E) 
 
Figure 4.4: Self-Care levels at different periods, A)Preoperative; B)Discharge; C) 6 
weeks; D) 6 months; E) 12 months. Horizontal axis indicates levels of Self-Care. 
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4.3.1.3. Usual Activities 
There seems to be some improving trend in Usual Activities in X-stop group with 
somewhat unchanged trend in Lumbar laminectomy group. These changes were found 
to be non-significant (p>0.05) (Table 4.7 and Figure 4.5). 
 
 
Table 4.7: Usual Activities dimension counts for each level of dimension for both 
treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Total Counts 
                                     OPERATION  LL  XS 
USUAL-ACTIVITIES PERIOD 
1 12months  1  3 
6months   1  3 
6weeks   2  4 
Discharge  1  2 
Preoperative  3  3 
2 12months  7  5 
6months   8  3 
6weeks   6  4  
Discharge  6  8 
Preoperative  6  7 
3 12months  2  2 
6months   1  4  
6weeks   2  2 
Discharge  3  0 
Preoperative  1  0 
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A)                                                 B) 
   
C)                                                D) 
 
E) 
 
Figure 4.5: Usual Activities levels at different periods, A)Preoperative; B)Discharge; 
C) 6 weeks; D) 6 months; E) 12 months. Horizontal axis indicates levels of Usual 
Activities. 
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4.3.1.4. Pain/Discomfort 
There seems to be an improving trend in Pain/discomfort levels across Lumbar 
laminectomy and X-stop group. These changes were found to be non-significant 
(p>0.05) (Table 4.8 and Figure 4.6). 
 
 
Table 4.8: Pain/Discomfort dimension counts for each level of dimension for both 
treatment groups. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
   Total Counts  
 OPERATION LL XS 
PAIN_DISCOMFORT PERIOD   
 1 12months 1 1 
  6months 1 1 
  6weeks 1 1 
  Discharge 0 3 
  Preoperative 0 0 
 2 12months 7 6 
  6months 6 6 
  6weeks 8 6 
  Discharge 8 4 
  Preoperative 4 3 
 3 12months 2 3 
  6months 3 3 
  6weeks 1 3 
  Discharge 2 3 
  Preoperative 6 7 
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A)                                                B) 
   
C)                                                D) 
 
E)                                                 
Figure 4.6: Pain/Discomfort levels at different periods, A)Preoperative; B)Discharge; 
C) 6 weeks; D) 6 months; E) 12 months. Horizontal axis indicates levels of 
Pain/Discomfort. 
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4.3.1.5. Anxiety/Depression 
There is an improving trend in Anxiety/Depression which is statistically non-significant 
(p>0.05) (Table 4.9 and Figure 4.7). 
 
Table 4.9: Anxiety/Depression dimension counts for each level of dimension for both 
treatment groups. 
 
 
 
 
 
 
 
 
  Total Counts  
 OPERATION LL XS 
ANXIETY DEPRESSION PERIOD   
 1 12months 6 5 
  6months 5 4 
  6weeks 5 4 
  Discharge 7 5 
  Preoperative 3 2 
 2 12months 3 4 
  6months 4 4 
  6weeks 5 5 
  Discharge 3 4 
  Preoperative 4 6 
 3 12months 1 1 
  6months 1 2 
  6weeks 0 1 
  Discharge 0 1 
  Preoperative 3 2 
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A)                                                  B) 
   
C)                                                 D) 
 
E) 
Figure 4.7: Anxiety/Depression levels at different periods, A)Preoperative; 
B)Discharge; C) 6 weeks; D) 6 months; E) 12 months. Horizontal axis indicates levels 
of Anxiety/Depression. 
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4.3.2. EQ5D scoring and EQ5D VAS 
The quality of life, as measured by EQ5D score, seems to be similar in both treatment 
groups per each period (Table 4.10A and Figure 4.8). However, the Two-way ANOVA 
assessing EQ5D score based on Procedure and Period, showed that there is a significant 
difference in EQ5D score at different periods (p=0.03) but there is no difference 
between the two treatment groups (p=0.965). 
In addition, two-way ANOVA showed that there was no significant difference in EQ5D 
VAS at different periods (p=0.774) but with significant difference between the two 
treatment groups overall (p=0.029).  This difference can be accounted by Lumbar 
laminectomy group starting with a better quality of life in EQ5D VAS scale in 
preoperative period (p=0.044) but in other periods there was no difference between the 
groups (p>0.05) ((Figure 4.9, Table 4.11)). This result is most likely due to natural 
variation in data considering that the trial was randomised with the aim of avoiding 
selection bias. 
 
4.3.2.1. Lumbar laminectomy group 
Further analysis using One-way ANOVA with contrast analysis of EQ5D score between 
preoperative and overall postoperative time period showed that there was a significant 
improvement of quality of life in Lumbar laminectomy (p=0.005, One way contrast 
ANOVA) but not in X-stop group. This improvement in quality of life in Lumbar 
laminectomy group is noted at discharge, 6 months and at 12 months (Table 4.10B). 
 
4.3.2.2. X-stop group 
There is an improving trend in quality of life in X-stop group (Table 4.10C, Figure 4.8, 
Figure 4.9), although this was not statistically significant  across all time periods for 
EQ5D score (p=0.426, One-way ANOVA) and EQ5D VAS (p=0.649, One-way 
ANOVA). We did not detect statistical significance with further analysis, where 
preoperative and overall post-operative groups were compared for EQ5D score 
(p=0.089, One-way contrast ANOVA) and EQ5D VAS (p=0.153, One way contrast 
ANOVA). However, p-value of 0.089 could reflect the small sample size in the study to 
reach statistical significance.  
There is an  improving trend in quality of life, especially between preoperative and 
discharge periods (Figure 4.8) with small p-value of  0.072 (Table 4.10C) supporting 
the fact that our sample size may be too small to detect the differences statistically. 
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Table 4.10: EQ5D score at different periods. A) Between-group differences, B)Within- 
group in lumbar laminectomy (LL), C) Within- group in X-stop (XS). Note that in A) p-
values indicate the strength of evidence between treatment groups in each period, while 
in B) and C) p-values indicate the strength of evidence between preoperative and other 
periods. RED text indicates significant results. 
A) 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
 
 
 
 
C) 
 
 
 
Period              Procedure         Mean        SE     StDev            p-value 
Preoperative      LL                 0.116     0.065        0.205             0.679 
               XS                  0.170    0.111        0.350 
 
6-weeks     LL           0.557     0.094       0.298    0.392 
               XS           0.417     0.128        0.403 
 
6-months    LL          0.390    0.126      0.399              0.802 
               XS           0.342    0.141    0.445 
 
12-months   LL           0.470    0.101         0.320   0.849 
               XS           0.437    0.138         0.437 
 
 Period          Mean   SE  StDev p-value 
EQ5D_LL       12 months       0.470     0.101    0.320 0.009 
            6 months        0.390     0.126    0.399 0.070 
            6 weeks         0.557    0.094   0.298 0.001 
            Discharge       0.370     0.100    0.317 0.048 
            Preoperative    0.116   0.065   0.205 
 
Period          Mean   SE  StDev p-value 
EQ5D_XS       12 months  0.437     0.138   0.437 0.149 
            6 months       0.342     0.141   0.445 0.400 
            6 weeks        0.417     0.128   0.403 0.160 
            Discharge      0.520     0.147   0.464 0.072 
            Preoperative   0.170     0.111   0.350 
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Figure 4.8: EQ5D score at different time points for both treatment groups. Data shown 
as 95% CI of the mean. 
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Figure 4.9: EQ5D VAS at different time points for both treatment groups. Data shown as 
95% CI of the mean. 
 
*p=0.044 
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Table 4.11: EQ5D VAS at different periods. RED text indicates significant results. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
EQ5D VAS 
  
Period              Procedure         Mean        SE        StDev p-value            
Preoperative      LL          67.00     5.73      18.14  0.044 
                       XS          46.50       7.42     23.46 
 
Discharge          LL          66.20     4.86       15.38  0.835 
                          XS           64.20     8.04       25.42 
 
6-weeks LL          67.00     6.33       20.03 0.522 
            XS           58.70    10.9        34.50 
 
6-months  LL          73.50     6.79         21.48 0.146 
            XS          57.50     8.00         25.30 
 
12-months    LL          65.00     8.20       25.93 0.604 
            XS          59.50     6.39       20.20 
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4.3.3.  SF36 Domains 
 
The quality of life as measured by SF36 instrument, which consists of 8 domains, 
showed that there were no significant differences between the two treatment groups for 
any of domains (Table 4.12). However, there are improving trends in Physical 
functioning, Bodily pain and Mental Health in Lumbar laminectomy group (Figure 
4.10).  There are also improving trends in Physical functioning, Role Physical, Bodily 
pain, Role emotional and Mental health in the X-stop group (Figure 4.10).  
Statistically-significant improvements (Table 4.12) compared to the preoperative state 
were reached in the following: 
- X-stop group:     -Physical functioning (p=0.034, Mann Whitney test) at 6 
     weeks 
   -Bodily pain (p=0.028, Mann Whitney test) at 12 months 
- Lumbar laminectomy: - Bodily pain (p=0.017, Mann Whitney test) at 6 weeks
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               Table 4.12: Quality of life (using SF36 scores per domains) for Lumbar laminectomy versus X-stop treatment groups including p-values  
                for each time points. Values are expressed as Median (Interquartile range) 
   PFLL              PFXS              p           RPLL            RPXS         p       BPLL       BPXS     p      GHLL        GHXS          p        VTLL         VTXS     p         SFLL         SFXS      p     RELL         REXS      p       MHLL     MHXS    p 
 
Preoperative     17.5(21.25)    25.0 (27.5)   0.820    25.0 (62.5)  12.5(62)   0.678  22(14)   22(9.5)      1.0    69.5(44)   52.5(43.2)   0.880  57.5(53)  47.5(40)  0.345  68.8(78)  50(44)  0.385  100(75)  16.7(75)  0.162  60(43)  60(31)  0.326 
 
6 weeks          35(37.5)         50(50)          0.226     12.5(81.3)   0(100)     0.910  41(18)  31.5(45)  0.345  59.5(32)      50(48.2)   0.734  66(32.5)  32.5(30)   0.257  62.5(62)  50(37) 0.450   33(100)  16.7(100) 1.0     80(50)  62(29)  0.545 
                              0.212            *0.034                         0.597          0.880                 *0.017    0.678                   0.880           0.970        0.705      1.0               0.910     0.910               0.241      0.940              0.940     0.623 
 
6 months            27.5(43.7)     40(48.7)        1.0          12.5(81)     37(100)   0.427  36(57)  46(54.2)  0.762  55(43.2)     41(45.7)    0.290   50(23.7)  52.5(42)   0.738 62.6(66)  69(78)  0.820  33.5(100)  33(75)  0.910  62(42)  62(38)  0.910   
                               0.150               0.174                 0.734         0.406                 0.406    0.257             0.970          0.364                       0.597     0.406                  0.450        0.650            0.385        0.545            0.940    0.273 
 
12 months         37.5(41.2)    35(63.7)          1.0         12.5(75)    37.5(100)  0.427  41(39)     51(28) 0.791  54.5(42)    42.5(42)     0.650   50(43.7)  52.5(37) 0.650  56.3(69)  56.(87)   1.0   66.7(100)  67(67) 0.596    78(41)  70(28)    0.940 
            0.130             0.241                            0.545          0.545                0.096    *0.028                  0.791         0.734       0.623       0.273                   0.623       0.678              0.571     0.102              0.850    0.082 
 
Indices LL and XS stand for Lumbar laminectomy and X-stop groups respectively. 
PF, Physical Functioning;  
RP, Role Physical;  
BP, Body Pains;  
GH, General Health;  
 VT, Vitality;   
SF, Social Functioning;  
RE, Role Emotional; 
MH, Mental Health 
*, significant p-value <0.05.  Student’s t-test used. 
 
RED text are the p-values of the domains between the two treatment groups corresponding each period (preoperative, 6 weeks, 6 months, 12 months)  
BLUE text are the p-values of the preoperative values of domains and the other corresponding periods (6 weeks, 6 months, 12 months) for each  treatment group. 
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              Figure 4.10: Quality of life domains for Lumbar laminectomy and X-stop for both treatment groups. 
Note: Last two letters of each horizontal axis labels are LL, which stands for Lumbar laminectomy group, and XS stands for the X-stop group. 
First two letters stand as described below: 
PF, Physical Functioning;  
RP, Role Physical;  
BP, Body Pains;  
GH, General Health;  
VT, Vitality;   
SF, Social Functioning;  
RE, Role Emotional; 
MH, Mental Health 
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Two way ANOVA with factorial analysis by Period and Procedure for each of the 
SF36 domains, showed that there were significantly greater Physical functioning 
between Periods (p=0.049) but not between Treatments (p=0.313) (Table 4.13). 
Further analysis by one-way ANOVA by Period for each Treatment for Physical 
functioning showed that there was overall no significant differences in Lumbar 
laminectomy group (p=0.065) and X-stop group (p=0.164).  However, there was a 
significant overall improvement in Physical Functioning when preoperative and 
overall post-operative periods were compared within the X-stop group (p=0.043, 
One-way Contrast ANOVA). 
In other domains no significant differences were found between Treatment groups 
for each Period or between Periods within each Treatment group.(Table 4.13) 
 
Table 4.13: p-values for each domain of the SF36. Two-way factorial ANOVA 
performed on Period and Treatment groups. One-way ANOVA performed for 
each treatment groups. 
 
 
 
 
 
 
 
 
 
 
Two-way ANOVA     One-way ANOVA            
Period  Treatment groups  Lumbar laminectomy  X-stop 
BP  0.115    0.594    0.436   0.206 
PF  0.049    0.313     0.294   0.164 
RP  0.892    0.478    0.979   0.732 
GH  0.805    0.453     0.985   0.761 
VT  0.958    0.493    0.936   0.550 
SF  0.989    0.498    0.883   0.975 
MH  0.603    0.396    0.947   0.223 
RE  0.531    0.446    0.621   0.368 
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4.3.3.1. Bodily pain 
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Figure 4.11: Bodily pains (percentage) across time periods for both treatment 
groups 
 
Table 4.14: Bodily pains (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
 
 
 
  
 
  
 
 
 
 
 
 
 
Operation   Mean     SE       StDev 
Preoperative  
LL               29.40     8.54     27.00 
            XS              24.70     2.52       7.96 
6 weeks  
LL               46.80     5.93     18.75 
          XS              34.40     8.83      27.93 
6 months  
LL              39.30     9.54     30.16 
          XS              44.50     9.74     30.81 
 
12 months  
LL              45.60     8.57     27.09 
            XS              45.40     7.61     24.07 
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4.3.3.2. Physical Functioning 
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Figure 4.12: Physical functioning (percentage) across time periods for both 
treatment groups 
 
Table 4.15: Physical functioning (percentage) descriptive data, SE=Standard 
error; StDev=Standard deviation 
    
 
 
 
 
 
 
 
 
 
       Operation    Mean   SE     StDev 
Preoperative  
LL  20.00    4.77      15.09 
            XS     22.00    4.78      15.13 
6 weeks  
LL      33.00    6.63      20.98 
            XS      49.50    9.38      29.67 
 
6 months  
LL      36.50    7.99     25.28 
            XS      38.50    8.98     28.39 
 
12 months  
LL    37.50     8.47    26.80 
           XS     39.50     9.79    30.95 
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4.3.3.2. Role physical 
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Figure 4.13: Role physical (percentage) across time periods for both treatment 
groups 
 
Table 4.16: Role physical (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
                   Operation   Mean   SE  StDev 
 
Preoperative  
LL          37.5    11.9   37.7 
             XS          32.5     12.9   40.9 
 
6 weeks  
LL          32.5     13.5   42.6 
             XS          32.5     14.9   47.2 
 
6 months  
LL         35.0     13.5   42.8 
             XS         50.0     14.4   45.6 
 
12 months  
LL         30.0     12.2   38.7 
             XS         47.5     15.1   47.8 
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4.3.3.3. General Health  
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Figure 4.14: General health (percentage) across time periods for both treatment 
groups 
 
Table 4.17: Role physical (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
Operation    Mean   SE  StDev 
  
Preoperative  
LL           57.50     8.44   26.69 
             XS          55.30     7.42   23.45 
 
6 weeks  
LL           57.50     7.29   23.05 
             XS           54.80     8.18   25.85 
 
6 months  
LL           54.00     9.67   30.59 
             XS          44.80      8.13   25.72 
 
12 months  
LL           54.50      8.27   26.15 
             XS           51.30     7.23   22.86 
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4.3.3.4. Vitality 
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Figure 4.15: Vitality (percentage) across time periods for both treatment groups 
 
Table 4.18: Vitality (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
Operation   Mean   SE  StDev 
  
Preoperative  
LL     53.30   10.2    32.20 
           XS     39.50   7.97   25.22 
6 weeks  
LL      49.50  6.60   20.88 
        XS      40.50  7.17   22.66 
6 months  
LL      47.50  7.97   25.19 
        XS     50.00   7.85   24.83 
 
12 months  
LL      46.00   8.65   27.37 
        XS      51.00   5.57   17.61 
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Social functioning 
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Figure 4.16: Social functioning (percentage) across time periods for both 
treatment groups 
 
Table 4.19: Social functioning (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operation   Mean   SE  StDev 
 
Preoperative  
LL           63.80      12.30    38.80 
            XS          50.00     11.00    34.90 
 
6 weeks  
LL           63.75        9.58   30.31 
            XS          53.75        9.14   28.90 
 
6 months  
LL           53.80      10.70    33.90 
          XS           56.30      11.70    36.90 
 
12 months  
LL           56.30      11.40    36.00 
            XS          56.30      12.00    37.80 
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4.3.3.5. Role Emotional 
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Figure 4.17: Role emotional (percentage) across time periods for both treatment 
groups 
 
Table 4.20: Role emotional (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
 
 
 
 
 
 
 
 
 
 
 
     Operation   Mean   SE  StDev 
 
Preoperative  
    LL          66.7      14.1         44.4 
               XS          33.3      13.1         41.6 
6 weeks  
   LL          40.0  13.9    43.9 
              XS          36.7      14.4    45.7 
6 months  
   LL          46.7      15.1    47.7 
              XS          43.3      12.2    38.7 
12 months  
   LL          53.3      15.9    50.2 
              XS          63.3      11.6    36.7 
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4.3.3.6. Mental health 
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Figure 4.18: Mental health (percentage) across time periods for both treatment 
groups. 
 
Table 4.21: Mental health (percentage) descriptive data, SE=Standard error; 
StDev=Standard deviation 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Operation   Mean      SE      StDev 
 
Preoperative  
   LL             68.00     7.38     23.32 
                  XS            54.40     6.70     21.18 
 
6 weeks  
   LL             69.60      8.25    26.07 
              XS             61.60     5.63    17.81 
 
6 months  
   LL             63.60     8.79     27.81 
              XS             65.60     6.14    19.43 
 
12 months  
   LL            70.00      9.09     28.74 
                  XS            72.00     5.27     16.65 
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4.4. COST-EFFECTIVENESS RESULTS 
4.4.1. Quality Adjusted Life Years (QALYs) 
The QALYs were calculated and analysed using both QoL instruments: EQ5D 
and SF36. 
 
QALYs(using EQ5D) 
             There were no significant differences in mean QALYs per patient 
             associated with either intervention (p=0.654) (Table 22, Figure 19).  
The mean QALYs gained per patient were 0.072 with 95% CI (-0.261, 
0.405) in Lumbar laminectomy compared to X-stop group. 
 
           QALYs(using SF36) 
There were no significant differences in mean QALYs per patient 
associated with either intervention (p=0.654) (Table 22, Figure 19).  
The mean QALYs gained per patient were 0.024 QALYs with 95% CI (-
0.175, 0.224) in Lumbar laminectomy compared to the X-stop group. 
 
Table 4.22: Summary analysis of QALYs (using EQ5D for both treatment 
groups.  
 
 
 
 
 
 
 
 
 
 
 
Procedure     Mean     SE      StDev      p-value 
QALY_EQ5D      LL          0.638   0.059    0.186            0.654 
                 XS          0.593   0.079    0.250 
 
QALY_SF36        LL          0.499    0.070    0.219           0.800 
                 XS          0.475    0.060   0.203 
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Figure 4.19: QALYs for both treatment groups (using EQ5D and SF36 
instruments).  
 
4.4.2. Costs 
While there is no significant difference in QALYs between the two treatment 
groups, the total cost was significantly greater in X-stop group (p=0.017) (Table 
4.23). 
 
The costs incurred for both procedures were comparable and non-significant for 
each component apart from the additional implant cost for the X-stop (Table 4.23, 
Figure 4.20A), regardless whether they were incurred in theatre, as inhospital 
stay, physiotherapy costs, outpatient clinics or imaging (Figure 4.20A). 
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Figure 4.20: Costs by treatment group (expressed as confidence intervals):   
A) Outlier included;  B) Outlier excluded. 
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Table 4.23: Costs incurred by theatre, implant, inhospital stay, physiotherapy 
inpatient sessions, outpatient clinics and imaging expenditure. The data analysed 
by Students t-test. A) Outlier included;  B) Outlier excluded.  
RED text indicates significant result. 
 
 
 
 
 
 
 
 
 
 
 
A) 
 
 
 
 
 
 
 
 
 
 
 
 
 
B) 
 
 
  Procedure                 Mean         SE          StDev   p-value 
Cost theatre(£)     LL        2415.00          251.00    792.00   0.454 
                    XS   2184.00          166.00    526.00 
 
Cost implant(£)    LL                0.00              0.00         0.00    >0.05 
                    XS        2397.00          266.00     842.00 
 
Cost inhospital(£) LL      1019.00          229.00      725.00    0.895 
                    XS      1073.00          329.00    1039.00 
 
Cost physio(£)      LL           257.00          108.00      342.00       0.829 
                    XS            226.50            85.00      268.70 
 
Cost outpatients(£) LL            841.60            35.10      110.90       0.697 
                    XS            867.90            56.10      177.50 
 
Cost imaging(£)    LL            342.20            92.10      291.10       0.633 
                    XS            415.00          118.00      374.00 
 
Total cost (£)    LL           4874.00          535.00    1693.00  0.017 
                  XS          7162.00          674.00     2133.00 
 
     Procedure  Mean            SE        StDev p-value 
Cost theatre(£)     LL   2415.00      251.00     792.00 0.443 
                    XS      2165.00     185.00      554.00 
 
Cost implant (£)    LL              0.00         0.00          0.00 <0.05 
                              XS     2441.00      294.00     881.00 
 
Cost inhospital(£)   LL    1019.00     229.00     725.00 0.536 
                    XS        814.00     227.00       68.00 
 
Cost physio(£)      LL       257.00     108.00     342.00 0.396 
                    XS            151.00       43.60     130.80 
 
Cost outpatients    LL        841.60      35.10      110.90 0.620 
                       XS          818.20      29.20        87.70 
 
Cost imaging        LL       342.20      92.10      291.10 0.915 
                    XS          328.20      89.80      269.50 
 
Total cost (£)      LL     4874.00    535.00     1693.00 0.030 
                    XS        6718.00    568.00     1703.00 
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However, there was a significantly higher overall cost in X-stop group compared to 
Lumbar laminectomy group (p=0.017) (Figure 4.21A).  Mean incremental cost for 
Lumbar laminectomy group was  -£2288.60, with 95% CI for difference:  (-4105.55, 
-471.65).  
 
This difference in cost seems to arise from the additional cost of the implant since there 
was no significant difference in the cost for other areas of expenditure i.e. theatre costs, 
inhospital stay, physiotherapy sessions, outpatients and imaging (Table 4.23A, Figure 
4.20A). 
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B) 
Figure 4.21: Overall cost for Lumbar laminectomy and the X-stop group. Data shown as 
95% CI of the mean.A) Outlier included, B)Outlier excluded. RED text indicates 
significant results. 
*p=0.017 
*p=0.030 
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4.4.3. Incremental costs  
The incremental cost effectiveness ratio (ICER) per QALY gained of Lumbar 
laminectomy versus X-stop groups were: 
 
- Using EQ5D: ICER =  -£50919.4/QALY (=-£2288.581/0.0449QALY).   
 
- Using SF36: ICER= -£94068.9/QALY (=-£2288.581/0.024QALY).   
We have shown that the base-case effectiveness ratio with mean NHS cost gained 
of    -£2288.581 in Lumbar laminectomy group yields 0.0449QALY (when EQ5D 
used) and 0.024QALY (when SF36 used) compared to the X-stop group. 
Regardless of which one of two quality of life instruments is used to calculated 
QALYs, the base-case ratio in both situations is  located in South East quadrant of 
cost effectiveness planes (Figure 4.22A and Figure 4.24A ) suggesting that 
Lumbar laminectomy is more cost-effective compared to the X-stop intervention. 
This statement makes sense considering that our results have shown that Lumbar 
laminectomy is cheaper and yields greater QALYs compared to the X-stop group. 
However, this does not take into consideration any uncertainty in the estimates of 
costs and effects. Decision makers will be interested to ascertain how sure they 
can be that this is the correct conclusion to make. 
The use of stochastic (bootstrapping) and probabilistic techniques (Monte Carlo 
simulation), for trial analyses and modelling studies respectively, we have 
generated 1000 sample data based on mean cost and efficacy (i.e. QALYs) from 
our study. This enables us to quantify the uncertainty surrounding the estimates of 
costs and effects. This is represented by the scatterplot of the incremental costs 
and QALYs in the cost-effectiveness plane.(161)  
In order to decide if an intervention offers "good" value for money, the ICER 
must be compared to a specified monetary threshold. This threshold represents the 
maximum amount that the decision-maker is willing to pay for health effects 
(maximum acceptable ceiling ratio). The intervention is deemed cost-effective if 
the ICER falls below this threshold and not cost-effective otherwise.(162)  
115 
 
The suggested threshold acceptable ceiling ratio in technology appraisal for use in 
the NHS is about £30,000 per QALY gained as judged by the National Institute 
for Health and Clinical Excellence in England (167) Thus, the interpretation of the 
CELAX study is that, given a maximum acceptable ceiling ratio of £30,000 per 
QALY gained, the probability that Lumbar laminectomy is cost-effective 
compared to X-stop is 0.543 and 0.517 when EQ5D (Figure 4.23A) and SF36 
(Figure 4.25A) used, respectively. 
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4.4.4. Sensitivity Analysis  
One-level operations 
When we compared 1-level Lumbar laminectomy versus X-stop we found again 
that Lumbar laminectomy group dominates:  
ICER =-£25776/QALY (=-£2849.85/0.11QALYs) 
We found that the cost gain in lumbar laminectomy group was -£2849.83 with 
95% CI for difference:  (-£4549.31, -£1150.36) (p=0.017) but with no significant 
difference in QALYs gained between the two groups (p=0.249). 
 
Two-level operations 
When we compared 2-level Lumbar laminectomy versus X-stop we found again 
that Lumbar laminectomy group dominates:  
ICER =-£ -26348.5/QALY (=-£2890.96/0.11QALY). 
There was no significant difference in cost (p=0.105) and QALYs(p=0.247) for 
two-level operations.  
 
Costs with outlier excluded: 
One of the participants who was randomised to the X-stop procedure continued to have 
ongoing pain postoperatively and stayed for 19 days in the hospital. Because of such a 
long inhospital stay this patient was considered as an ‘Outlier’ because of the suspected 
large impact on the costs.  Postoperative MRI Lumbar spine of this patient showed an 
adequate decompression at the symptomatic level and no further stenosis. Patient 
subsequently had removal of X-stop and lumbar laminectomy which failed to improve 
symptoms. Further management included giving patient the option for spinal fusion or 
pain team follow up. Patient chose the latter. In view of the fact that following the X-stop 
procedure this patient had prolonged inhospital stay of 19 days because of ongoing back 
and leg pains but with evidence of satisfactory decompression on postoperative MRI 
Lumbar spine, we have reanalysed the cost and cost-effectiveness data to assess the 
impact on the costs with this Outlier excluded. 
Even after excluding this patient no significant difference in mean inhospital stay was 
found (p=0.536) between two treatments and there was a persistent significance in lower 
cost of lumbar laminectomy compared to the X-stop (p=0.03)(Table 4.23B ). 
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Cost-effectiveness data confirmed again that the base-case estimate was dominant: 
- Using EQ5D: ICER =  -£148785/QALY (=-£1844.60/0.012QALY)  
(Figure 4.22B ) 
 
- Using SF36: ICER= -£784680/QALY (=-£1844.60/0.002QALY)  
(Figure 4.24B):   
again with low probability of the true effect in cost-effectiveness acceptability curve 
(Figure 4.23B and 4.25B ). 
Overall, exclusion of this outlier did not have any effect on the overall conclusions of the 
results. 
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A) 
 
B) 
Figure 4.22: The incremental cost effectiveness planed showing the scattered 
plots of bootstrapped incremental cost-effectiveness ratios of Lumbar 
laminectomy versus X-stop. A)Outlier included,  B)Outlier excluded. 
      Indicates base case estimates 
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A) 
B) 
Figure 4.23. Cost-effectiveness acceptability curves showing the probability 
that Lumbar laminectomy is cost-effective compared with X-stop 
using a range of cost-effectiveness thresholds. A)Outlier included, B)Outlier 
excluded. 
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A) 
 
B) 
Figure 4.24: Scattered plots of bootstrapped incremental cost-effectiveness ratios 
of Lumbar laminectomy versus X-stop. A) Outlier included,  B) Outlier excluded. 
       Indicates base case estimates 
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A) 
 
B) 
Figure 4.25. Cost-effectiveness acceptability curves showing the probability 
that Lumbar laminectomy is cost-effective compared with X-stop 
using a range of cost-effectiveness thresholds. A) Outlier included,  B)Outlier 
excluded. 
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4.5. CLINICAL OUTCOMES 
4.5.1. QBPDS and ODI  
No significant difference (Table 4.24) were found in outcomes between two 
treatment groups for each period, as measured by QBPDS (Figure 4.26 and Table 
4.25) and ODI (Figure 4.27, Table 4.26).  
 
Table 4.24: p-values for clinical outcomes using different disease-specific 
instruments (QBPDS, ODI, ZCQ). Two-way factorial ANOVA performed on 
Period and Treatment groups. One-way ANOVA performed for each treatment 
groups. 
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Figure 4.26: QBPDS confidence intervals for each Period for both treatment 
groups. 
 
 
      Two-way ANOVA                         One-way ANOVA            
           Period  Treatment groups       Lumbar laminectomy X-stop 
QBPDS   0.640  0.385            0.807  0.303 
ODI   0.466  0.203            0.834  0.546 
ZCQ Symptom  0.001  0.760            0.069  0.042 
ZCQ Physical  0.026  0.801            0.046  0.295 
ZCQ Satisfaction  0.355  0.883                         0.279  0.816 
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Table 4.25: QBPDS summary statistics, SE=Standard error of mean, StDev 
=Standard deviation.           
 
 
 
 
 
 
 
 
 
 
 
Procedure         Mean       SE       StDev 
Preoperative   
LL                64.38      6.00        18.98 
                   XS                62.10   3.81        12.06 
 
6 weeks        
LL                58.85    6.00        18.98 
                   XS                51.10    8.71        27.53 
 
6 months      
LL                54.75   8.40        26.55 
                   XS                55.25   8.03        25.40 
 
12 months     
LL                62.45     8.88        28.08 
                   XS                53.85    7.29        23.07 
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Figure 4.27: ODI confidence intervals for each Period for both treatment groups. 
 
Table 4.26: ODI summary statistics, SE=Standard error of mean, StDev 
=Standard deviation.           
      
 
 
 
 
Procedure   Mean      SE       StDev 
Preoperative   
LL      53.11     4.49     14.19 
                 XS     48.67     3.17     10.02 
 
6 weeks       
LL   47.11     7.06     22.34 
                 XS      38.44     7.30     23.10 
 
6 months   
LL      46.00     7.60     24.05 
XS     44.22     7.25     22.94 
 
12 months   
LL      45.55     6.54     20.69 
                XS     37.11     6.53     20.66 
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4.5.2. ZCQ  
Two-way factorial ANOVA showed the following (Table 4.24): 
- ZCQ Symptom component:- We found significant improvements in 
clinical outcomes between periods (p=0.001) but not between treatment 
groups(p=0.760).  
- ZCQ Physical component: - There was a significant difference in clinical 
outcome between periods (p=0.026) but not between treatment groups 
(p=0.801). 
- ZCQ Satisfaction scale:- There was no significant difference between 
periods(p=0.355) or treatment groups (p=0.883). 
 
One –way ANOVA for different Periods in each treatment groups showed the 
following (Table 4.24): 
- ZCQ Symptom component:- There was a significant improvement in X-
stop group over different periods (p=0.042) but not in Lumbar 
laminectomy group (p=0.069). 
- ZCQ Physical component:- There was a significant improvement in 
Lumbar laminectomy group (p=0.046) but not in X-stop group (p=0.295) 
- ZCQ Satisfaction scale:- There was no significant difference in 
satisfaction scale between periods in Lumbar laminectomy (p=0.279) and 
X-stop group (0.816). 
 
We found that there were significantly improved outcomes in ZCQ Symptom 
(Figure 4.28, Table 4.28) and Physical components (Figure 4.30, Table 4.30) 
noted for Lumbar laminectomy (Tables 4.27A) and X-stop groups (Table 4.27B)  
up to 12 months postoperatively when compared with preoperative period for 
each treatment groups (Student’s t-test used). 
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Table 4.27: P-values of the difference between preoperative and other time periods using 
ZCQ Symptom and Physical component. in A) Lumbar laminectomy and B) X-stop 
groups.  
Note: No Satisfaction component done as no preoperative values to compare it with. Also, Physical 
component at discharge not done in this study. RED values indicate significant p-values. 
A) Lumbar laminectomy 
 
 
 
 
 
B) X-stop 
 
 
 
 
However, no significant results in improvement rates were found between two 
treatment groups for ZCQ Symptom component (Table 29, Figure 29) and ZCQ 
Physical component (Table 31, Figure 31) for each time period. 
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Figure 4.28: ZCQ Symptom component confidence intervals for each Period for 
both treatment groups. 
Symptom component    Physical component     
Discharge  0.032  - 
6 weeks   0.007  0.017 
6 months  0.10  0.154 
12 months  0.019  0.019 
Symptom component    Physical component     
Discharge  0.002   - 
6 weeks   0.001   0.001  
6 months  0.029   0.009 
12 months  0.003   0.049 
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Table 4.28: ZCQ Symptom component summary statistics, SE=Standard error of 
mean, StDev =Standard deviation.  Values expressed as percentages.            
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Figure 4.29: ZCQ Symptom component improvement rate confidence intervals 
for each Period for both treatment groups.  
ZCQ Symptoms Imp_dis =Improvement rate at discharge 
ZCQ Symptoms Imp_6 weeks =Improvement rate at 6 weeks 
ZCQ Symptoms Imp_6 months =Improvement rate at 6 months 
ZCQ Symptoms Imp_12 months =Improvement rate at 12 months 
Procedure    Mean   SE  StDev 
Preoperative    
LL   72.14  5.32   16.82 
                XS     71.43  3.91   12.37 
 
Discharge      
LL       51.78  3.96   12.51 
                   XS     48.57 6.28   19.86 
 
6 weeks 
LL           51.43     5.98   18.91 
                   XS          50.72      5.29   16.73 
 
6 months   
LL           60.36      6.01   19.01 
                   XS          61.07      6.77   21.39 
 
12 months    
LL           57.86      6.02   19.03 
                   XS          56.43      5.10   16.13 
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Improvement rate is calculated using the ZCQ Symptom component scores in 
formula: 
 
Improvement rate = (Preop – postop scores)/preoperative scores*100% 
Note that the higher the ZCQ score the worse is the outcome. 
 
Table 4.29: ZCQ Symptom component improvement rate summary statistics, 
SE=Standard error of mean, StDev =Standard deviation. Values expressed as 
percentages.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement rate = (Preop – postop)/preoperative *100% 
 
Procedure    Mean      SE   StDev     p-value 
Discharge       
LL           24.68     7.74   24.47    0.800 
         XS           28.20      11.2    35.5 
 
6 weeks      
LL           29.49     5.64   17.83    0.884 
XS          28.06     7.80   24.65 
  
6 months    
LL           14.85     7.02   22.21    0.991 
XS          14.98     8.48   26.83 
 
12 months   
LL           20.77     4.85   15.34    0.967  
XS          20.40      7.13   22.56 
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Figure 4.30: ZCQ Physical component confidence intervals for each Period for 
both treatment groups. 
 
Table 4.30: ZCQ Physical component summary statistics, SE=Standard error of 
mean, StDev =Standard deviation.   Values expressed as percentages.                
 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure    Mean   SE    StDev 
Preoperative   
LL           66.88     4.17   13.19 
                   XS          63.75     4.04   12.77 
 
6 weeks 
    LL           51.25     3.06    9.68 
                   XS          50.00     6.39   20.20 
 
6 months    
LL           50.63     4.51   14.27 
                   XS          56.88     7.12   22.53 
 
12 months  
LL           55.00     5.50   17.38 
                   XS           49.38     5.85   18.51 
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 Figure 4.31: ZCQ Physical component improvement rate confidence intervals 
for each Period for both treatment groups.  
ZCQ Physical Imp_dis =Improvement rate at discharge 
ZCQ Physical Imp_6 weeks =Improvement rate at 6 weeks 
ZCQ Physical Imp_6 months =Improvement rate at 6 months 
ZCQ Physical Imp_12 months =Improvement rate at 12 months 
 
Improvement rate is calculated using the ZCQ Physical component scores in 
formula: 
 
Improvement rate = (Preop – postop scores)/preoperative scores*100% 
Note that the higher the ZCQ score the worse is the outcome. 
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Table 4.31: ZCQ Physical component improvement rate summary statistics, 
SE=Standard error of mean, StDev =Standard deviation. Values expressed as 
percentages.         
 
 
 
 
 
 
   
 
 
 
 
 
It was not possible to compare the preoperative ZCQ satisfaction scores 
considering the obvious reason that satisfaction scores can only be obtained 
postoperatively. Descriptive summary of Satisfaction components are depicted in 
Table 32 and Figure 32). 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Improvement rate = (Preop – postop)/preoperative *100% 
 
 
Procedure    Mean    SE     StDev   p-value 
6 weeks     
LL           22.30       4.16    13.15   0.973 
               XS          22.61       7.75    24.51 
 
6 months    
LL           22.92       6.44    20.35   0.327 
              XS          12.78       7.73    24.44 
 
12 months   
LL           16.89       7.96    25.18   0.615 
XS          22.69       8.05    25.45 
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Figure 4.32: ZCQ Satisfaction component confidence intervals for each Period 
for both treatment groups. 
 
 
Table 4.32: ZCQ Satisfaction component summary statistics, SE=Standard error 
of mean, StDev =Standard deviation.  Values expressed as percentages.         
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Procedure   Mean  SE    StDev 
Discharge   
LL         43.33     3.69   11.65 
                   XS         47.08     7.45   23.57 
 
6 weeks 
LL         50.83     4.80   15.19 
                   XS         56.67      8.38   26.51 
 
6 months 
LL         58.33      6.63   20.97 
                   XS         56.25      8.01   25.32 
 
12 months 
LL         56.67      7.59   23.99 
                   XS         52.08      8.06   25.48 
 
133 
 
 
4.5.3. Success Rates 
The success rates of both lumbar laminectomy and X-stop groups were equal at 6 
weeks of 50 % each followed by decreasing trend in both groups with 40% in 
Lumbar laminectomy and 30% in X-stop group. At 12 months period success 
rates of Lumbar laminectomy were 30 % while that of the X-stop was 60%. 
However, none of these success rates were significantly different from each other 
as their corresponding relative risks 95% confidence intervals include the 
indifference value of 1 (Table 4.33).  
 
 
Figure 4.33: Success rate of the interventions. Success defined as ZCQ Symptom and 
Physical component more than 0.5 improvement in score and Satisfaction component <2.5. 
 Data presented as percentage of successes                       
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Table 4.33:   Success rate of the interventions.  Success defined as ZCQ Symptom and 
Physical component more than 0.5 improvement in score and Satisfaction component <2.5. 
 Data presented as Counts(Percentage). Relative risks (RR) with 95% confidence 
intervals included.   
 
 
 
 
 
 
 
 
 
 
                        
 Success rate -Counts(Percentages)   
 6 weeks 6 months 12 months 
LL 5(50) 4(40) 3(30) 
XS 5(50) 3(30) 6(60) 
   
 
RR12 months =0.5 with 95% confidence interval is (0.17, 1.46) 
 
RR6 months =1.33 with 95% confidence interval is (0.396, 4.48) 
 
RR6 weeks =1.0 with 95% confidence interval is (0.416, 2.40) 
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4.6. Predictor variables 
Using multivariate regression analysis techniques various proposed variables were 
analysed for the purpose of predictive values for costs, quality of life and clinical 
outcomes in our population group. Stepwise Regression methods were used to 
generate a more simplified model and yet to account for greater variance of data 
to explain the response variables analysed. 
The explanatory variables chosen are the following: 
 - American Society of Anaesthesiology (ASA) score (levels 1 – 5) 
-  Actual level (the actual levels operated e.g. L2/3=2, L3/4=3, or L4/5=4, or L3/4, 
L4/5=34) 
                          The values are the levels of the lumbar spine operated) 
-  Age  
-  BMI (Body Mass Index) 
-  Cobb angle 
-  Duration of symptom (months)  
-  Gender (Male =0; Female = 1) 
-  Levels (Variable ‘Levels’ takes only values 1 which means only one level 
operated and 2  means two levels operated) 
-  Procedure (Lumbar laminectomy = 0; X-stop =1) 
-  Smoking status (Non smoker = 0;  Smoker = 1) 
-  Visual Analogue Scale (VAS) 
Response variables used were: 
- Cost 
- EQ5D Score  
- ODI 
- QBPDS 
- ZCQ Symptom component 
- ZCQ Physical component 
- ZCQ Satisfaction scale 
at 12 months. 
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 Table 4.34: Predictor factors for outcome measures below. ( -) indicates 
NEGATIVE prediction; (+) indicates POSITIVE prediction; (0) indicates no 
prediction. 
 ASA Actual 
level 
Age BMI Duration 
of 
symptoms 
Levels 
(number 
of levels 
operated) 
Smoker VAS 
(pain 
score) 
Cost + + + - - 0 0 - 
EQ5D 0 0 0 0 0 - 0 0 
 
SF36  
BP 0 0 0 0 0 0 0 + 
GH 0 - 0 0 0 0 0 0 
MH 0 0 0 0 0 - - 0 
PF 0 0 0 0 0 - 0 0 
RE 0 - 0 0 0 0 0 0 
RP 0 - 0 0 0 0 0 0 
SF 0 0 0 0 0 0 0 + 
VT 0 0 0 0 0 0 0 0 
 
QBPDS 0 0 0 0 0 + 0 0 
ODI 0 0 0 0 0 0 0 0 
 
ZCQ  
Symptom 
component 
0 0 0 0 0 0 0 - 
Physical 
component 
+ + 0 - 0 0 0 0 
Satisfaction 
component 
0 0 0 0 0 0 0 0 
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4.6.1. Cost 
We found that preoperative higher ASA score, older age, lower BMI, higher 
actual levels operated (e.g. L3/4 is higher level than L4/5), shorter the duration of 
symptoms and lower preoperative VAS score for pain were associated with higher 
costs. 
 
Regression model for Cost is as follows: 
Total Cost (£) = 5757+1793 x ASA +171.6 x Age -359.7 x BMI +156.4 x Actual 
levels -13.29 x Duration of symptoms – 674 x VAS. 
 
4.6.2. Quality of life 
EQ5D score: - It is found that only Levels variable (number of levels operated) 
was associated with worse quality of life as measured by EQ5D score. 
Regression model for EQ5D score is: EQ5D score = 1.168 – 0.561 x Levels. 
 
SF36 domains: 
 
Bodily pain (BP): - VAS score were negatively associated with BP 
score. Regression model is:  BP= -10.8 + 7.88 x VAS. 
 
General Health (GH):- It is found that only ‘Actual levels’ variable was 
associated with worse GH score. This means that the lower the level 
where decompression takes place, the worse the GH domain score. This 
is because the lower levels operated take higher values and that the 
Actual level has negative predictive values (as shown in regression 
equation). Regression model is:   
GH = 63.59 – 0.924 x Actual level. 
 
Mental Health (MH):- It is found that number of levels operated and 
people who smoke have worse MH score. Regression model is:  
          MH = 118.9-26.68 x Levels -15.92 x Smoker 
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Physical Functioning (PF): -Higher the number of levels operated, is 
associated with worse PF score. Regression model is: PF = 79.1 – 30.6 x 
Levels 
 
Role Emotional (RE):- The lower the actual levels are operated the worse 
the Role Emotional score is predicted. Regression model is: RE = 76.3 – 
1.686 x Actual level 
 
Role Physical (RP):- The lower the actual levels are operated the worse 
the Role Physical score is predicted. Regression model is: RE = 58.4 – 
1.99 x Actual level 
 
Social Functioning (SF):- Higher VAS score pain, is associated with 
worse SF score. Regression model is: SF =-11.5 + 9.51 x VAS 
 
Vitality (VT):- No predictor variables were found for VT score. 
 
 
4.6.3. Clinical outcomes 
 
- QBPDS:- Higher the number of levels operated, is associated with higher 
(worse) QBPDS score. Regression model is: QBPDS = 45.92 +1.172 x Levels. 
 
- ODI:- Interestingly no predictors were found for the ODI score. 
 
- ZCQ Symptom component:- Higher the number of levels operated, is 
associated with higher (worse) ZCQ Symptom component score.  
Regression model is:  
 ZCQ Symptom component = 93.4 – 5.1 x VAS 
 
- ZCQ Physical component:- Higher ASA score, lower segmental levels 
operated and higher the BMI have negative predictive values on ZCQ Physical 
component. Regression analysis model is:  
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ZCQ Physical component = 86.7 +17.01 x ASA +1.038X Actual level – 2.806 
x BMI 
 
- ZCQ Satisfaction component:- No variables were found to be significant  
predictors at 12 months. 
 
- Success rates:- Logistic binary regression for Success of treatment (defined as 
at least response ‘somewhat satisfied’ and ZCQ Symptom and Physical 
component improvement of greater than 0.5) then the POSITIVE predictive 
factor to success is:- higher BMI, while the NEGATIVE predictors to success 
are: - higher ASA score, the lower the operated levels and longer the duration 
of symptoms preoperatively. 
Regression analysis model is:  
Logit (p) = -152 - 49 x ASA -3.0 x Actual level +11  x BMI -0.83 x Duration 
of symptoms.  
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4.7. RADIOLOGICAL DATA 
There were no significant differences in baseline radiological features between Lumbar 
laminectomy and X-stop group (Table 4.35). 
 
 
Table 4.35: Radiological preoperative data summary for two treatment groups. 
SE=Standard error of mean, StDev =Standard deviation. Number of patients in 
Lumbar laminectomy group were 9 while in X-stop group were 10.          
                                
 
 
 
 
             Operation   Mean    SE  StDev  p-value 
Spinal canal    LL              89.7                  17.5    52.6     0.121 
 area (mm2)  XS                 54.8                  12.8    40.5 
 
Interspinous distance LL                  5.9      0.8     2.6     0.071 
 (mm)                    XS               3.8      0.7     2.1 
 
Foramen area(mm2)      LL            69.6      9.3   27.9     0.396 
                    XS             58.3       9.0   28.5 
 
Anterior disc height(mm)   LL              9.7       1.3      3.8     0.671 
                    XS               9.0       1.2      3.7 
 
Posterior Disc Height  LL               5.6      0.6     1.9     0.740 
(mm)                   XS               5.3      0.9     2.8 
 
Size of ligamentum   LL              5.2      0.7     2.1     0.745 
 flavum (mm)                XS              4.8      0.8     2.4 
 
Average facet size(mm)  LL             17.8      0.7     2.0     0.184 
                    XS            15.8     1.3      4.0 
 
Size of  posterior disc  LL                 3.7      0.5     1.6     0.720 
 bulge (mm)                 XS               4.1      1.0     3.1 
 
Intervertebral angle   LL               6.0       1.0      3.0     0.149 
 (degree)                  XS               3.9      0.9     2.9 
 
Cobb angle (degree)       LL              12.3      2.7      8.2     0.106 
                    XS               5.6       2.8     8.9 
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4.8. BIOMECHANICAL ANALYSIS 
Further analysis of biomechanical features were done. In view of small number of 
patients who have had preoperative and postoperative MRI Lumbar spine, we 
have used nonparametric statistical tests to analyse the results. 
The analysis was done AT THE OPERATIVE LEVEL and ADJACENT 
LEVELS. 
 
4.8.1. Operative level 
Our analysis showed that: 
4.8.1.1. Spinal canal area:- There was no significant difference in 
the change of the spinal canal area between the two treatment 
groups (p=0.136) (Figure 4.34 and Table 4.36). In addition, there 
were no significant differences between preoperative and 
postoperative spinal canal area in Lumbar laminectomy (p=0.144) 
and X-stop (p=1.0). 
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Figure 4.34: Boxplot of change of preoperative and postoperative spinal canal 
area for two treatment groups. 
 
142 
 
Table 4.36: Preoperative, postoperative and change in spinal canal area(mm2).  
IQR=Interquartile range. 
                           
 
 
 
 
 
 
 
 
 
 
 
    Number of 
     Procedure   patients    Median     IQR p-value 
Preoperative     LL       5        75.5       93.7 - 
                 XS     3        55.7       78.9 
 
Postoperative    LL        5     152.2       51.2 - 
                 XS         3        79.5    135.4 
 
Change in   LL         5        55.0       78.2 0.136 
spinal canal         XS          3        23.8       56.5 
area (mm2) 
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4.8.1.2. Foramen canal area:- There was no significant difference 
in the change of the intervertebral foramen area between the two 
treatment groups (p=0.767) (Figure 4.35 and Table 4.37). Also, 
there were no significant differences between preoperative and 
postoperative intervertebral foramen in Lumbar laminectomy 
(p=1.0) and X-stop (p=1.0). 
Po
st
op
 -
 p
re
op
 fo
ra
m
en
 a
re
a 
(m
m
2)
X-stopLumbar laminectomy
60
50
40
30
20
10
0
-10
-20
Difference of foramen canal area
 
Figure 4.35: Boxplot of change of preoperative and postoperative foramen area 
for two treatment groups. 
 
Table 4.37: Preoperative, postoperative and change in foramen area(mm2). 
IQR=Interquartile range. 
 
          
 
 
 
 
              
 
Number of 
Procedure   patients   Median    IQR  p-value 
Preoperative     LL              5      82.0    61.2 - 
                    XS             3      54.2    76.4 
 
Postoperative     LL              5     76.0   37.5        - 
                    XS              3      68.0    36.1 
 
Change in foramen area (mm2) LL              5       0.9   33.8        0.767 
                   XS              3     -0.9    55.1 
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4.8.1.3. Anterior disc height:- There was no significant difference 
in the change of the anterior disc height between the two treatment 
groups (p=1.0) (Figure 4.36 and Table 4.38). In addition, there 
were no significant differences between preoperative and 
postoperative anterior disc height in Lumbar laminectomy 
(p=0.917) and X-stop (p=1.0). 
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 Figure 4.36: Boxplot of change of preoperative and postoperative anterior disc 
height for two treatment groups. 
 
Table 4.38: Preoperative, postoperative and change in anterior disc height(mm). 
IQR=Interquartile range. 
 
                                 
 
 
 
 
 
 
Number of 
        Procedure   patients       Median     IQR p-value 
Preoperative    LL              5           9.4     4.3 - 
                    XS              3          9.5    1.7 
 
Postoperative    LL              5          9.1    3.7 - 
                    XS             3                      10.2     5.0 
 
Change in anterior  LL              5    0.0    2.3 1.0 
disc height (mm)  XS              3                    -0.9     5.1 
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4.8.1.4. Posterior disc height: - There was no significant difference 
in the change of the posterior disc height between the two 
treatment groups (p=0.551) (Figure 4.37 and Table 4.39). Also, 
there were no significant differences between preoperative and 
postoperative posterior disc height in Lumbar laminectomy 
(p=0.531) and X-stop (p=1.0). 
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Figure 4.37: Boxplot of change of preoperative and postoperative posterior disc 
height for two treatment groups. 
 
Table 4.39: Preoperative, postoperative and change in posterior disc height(mm). 
IQR=Interquartile range. 
                                 
 
 
 
 
 
Number of 
Procedure   patients   Median    IQR p-value 
Preoperative  LL              5     5.7   2.4 - 
                   XS              3     5.0    5.5 
 
Postoperative   LL              5     6.0  4.1 - 
                    XS              3      4.8     4.6 
 
Change in posterior     LL              5     1.0      2.6 0.551 
disc height (mm)                XS              3     0.4   1.5 
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4.8.1.5. Facet joint size: - There was no significant difference in the 
change of the facet joint size between the two treatment groups 
(p=0.551) (Figure 4.38 and Table 4.40). Also, there were no 
significant differences between preoperative and postoperative 
facet joint size in Lumbar laminectomy (p=0.144) and X-stop 
(p=1.0). 
 
P
o
st
o
p
 -
 P
re
o
p
 f
a
ce
t 
si
ze
 (
m
m
)
X-stopLumbar laminectomy
1
0
-1
-2
-3
-4
-5
Difference in facet size 
 
Figure 4.38: Boxplot of change of preoperative and postoperative facet size for 
two treatment groups. 
 
Table 4.40: Preoperative, postoperative and change in facet size(mm). 
IQR=Interquartile range. 
 
 
 
 
 
 
                                Number of 
Procedure   patients   Median    IQR p-value 
Preoperative       LL              5    16.6    2.6 - 
                   XS              3     15.5     5.7 
 
Postoperative    LL              5     13.0     5.4 - 
                    XS            3    13.6    2.3 
 
Change in facet joint size LL              5    -2.6    3.3 0.551 
 (mm)                    XS              3     -2.3     3.8 
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4.8.1.6. Intervertebral angle: - There was no significant difference 
in the change of the facet joint size between the two treatment 
groups (p=0.767) (Figure 4.39 and Table 4.41). Also, there were no 
significant differences between preoperative and postoperative 
intervertebral angle in Lumbar laminectomy (p=0.834) and X-stop 
(p=0.383). 
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Figure 4.39: Boxplot of change of preoperative and postoperative Intervertebral 
angles for two treatment groups. 
 
Table 4.41: Preoperative, postoperative and change in Intervertebral angles 
(degrees). IQR=Interquartile range. 
                                
 
 
 
Number of 
Procedure   patients   Median     IQR p-value 
Preoperative    LL              5      8.2     4.5 - 
                    XS              3     5.4    1.5  
 
Postoperative    LL              5      5.5     4.9 - 
                    XS              3     4.2    3.3 
 
Change in intervertebral  LL              5                 -1.4     4.3 0.767 
angle (degree)                   XS              3                -0.8  2.2 
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4.8.1.7. Posterior disc bulge: -  There was no significant difference 
in the change of the posterior disc bulge between the two treatment 
groups (p=1.0) (Figure 4.40 and Table 4.42). Also, there were no 
significant differences between preoperative and postoperative 
posterior disc bulge in Lumbar laminectomy (p= 1.0) and X-stop 
(p=1.0). 
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Figure 4.40: Boxplot of change of  preoperative and postoperative posterior disc 
bulge for two treatment groups. 
 
Table 4.42: Preoperative, postoperative and change in posterior disc bulge (mm). 
IQR=Interquartile range. 
 
 
 
 
 
 
Number of 
Procedure   patients        Median     IQR p-value 
Preoperative    LL             5          4.1    1.5 - 
                    XS             3          4.0     8.5 
 
Postoperative    LL             5          4.2    1.8 - 
                    XS             3          5.5     5.9 
 
Change in posterior  LL             5          0.3    1.1 1.0 
disc bulge (mm)      XS             3    0.0    4.1 
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4.8.1.8. Cobb angle:- There was no significant difference in the 
change of the Cobb angle between the two treatment groups 
(p=0.881) (Figure 4.41 and Table 4.43). Also, there were no 
significant differences between preoperative and postoperative 
Cobb angle in Lumbar laminectomy (p=0.917) and X-stop (p=1.0). 
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Figure 4.41: Boxplot of change of  preoperative and postoperative Cobb angles 
for two treatment groups. 
 
Table 4.43: Preoperative, postoperative and change in Cobb angles (degrees). 
IQR=Interquartile range. 
Number of 
Procedure   patients       Median     IQR p-value 
Preoperative          LL              5          18.2    19.2 - 
                    XS              3            9.9    22.3 
 
Postoperative        LL              5          13.5    16.9 - 
                    XS              3             9.9    20.2 
 
Change in Cobb angle LL              5      0.0    13.4 0.881
  
 (mm)                   XS              3      0.0      2.1 
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4.8.2. Adjacent Spinal Segment Changes 
 
4.8.2.1. Upper adjacent spinal canal area  
              (above the operated level(s)) 
There was no significant difference in the change of the spinal canal area 
between the two treatment groups (p= 0.551) (Figure 4.42 and Table 4.44). 
Also, there were no significant differences between preoperative and 
postoperative spinal canal area in Lumbar laminectomy (p=0.403) and X-
stop (p=1.0). 
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Figure 4.42: Boxplot of change of  preoperative and postoperative upper adjacent 
spinal canal area for two treatment groups. 
 
Table 4.44: Preoperative, postoperative and change in upper adjacent spinal canal 
area(mm2) for two treatment groups. IQR=Interquartile range. 
 
 
 
 
 
 
 
                            Number of 
Procedure   patients   Median    IQR p-value 
Preoperative    LL        5     175.7   109.8 - 
                    XS        3     162.4      77.7 
 
Postoperative   LL        5     117.8      59.7 - 
                    XS        3     167.6      45.1 
 
Change in upper  LL          5     -37.8   150.9 0.551 
adjacent spinal  XS          3      -19.1      60.4 
canal area(mm2)                          
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4.8.2.2. Upper adjacent intervertebral foraminal area  
(above the operated level(s)) 
There was no significant difference in the change of the foraminal area 
between the two treatment groups (p=0.136) (Figure 4.43 and Table 4.45). 
Also, there were no significant differences between preoperative and 
postoperative foraminal area in Lumbar laminectomy (p=0.676) and X-
stop (p=0.662). 
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Figure 4.43: Boxplot of change of  preoperative and postoperative upper adjacent 
intervertebral foraminal area for two treatment groups. 
 
Table 4.45: Preoperative, postoperative and change in upper adjacent 
intervertebral foraminal area(mm2) for two treatment groups. IQR=Interquartile 
range. 
 
 
 
 
 
 
 
 
 
                           Number of 
Procedure   patients   Median     IQR p-value 
Preoperative      LL              5     67.7    41.5 - 
                XS             3      47.0     37.0 
 
Postoperative    LL              5      48.7    45.9 - 
                XS              3      80.6    69.2 
 
Change in upper adjacent  LL             5     -4.4    28.8 0.136 
intervertebral foramina     XS              3      32.5     33.3 
above (mm2)   
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4.8.2.3. Upper adjacent facet size  
(above the operated level(s)) 
There was no significant difference in the change of the facet size length 
between the two treatment groups (p=0.551) (Figure 4.44 and Table 4.46). 
Also, there were no significant differences between preoperative and 
postoperative facet size length in Lumbar laminectomy (p=0.531) and X-
stop (p=0.383).  
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Figure 4.44: Boxplot of change of preoperative and postoperative upper adjacent 
facet size for two treatment groups. 
 
Table 4.46: Preoperative, postoperative and change in upper adjacent facet 
size(mm) for two treatment groups. IQR=Interquartile range. 
 
 
 
 
 
 
 
 
 
                               Number of 
       Procedure   patients   Median     IQR p-value 
Preoperative   LL      5    14.7    2.9 - 
                    XS          3    15.4    1.0 
 
Postoperative    LL       5    13.7   0.9 - 
                    XS        3    14.2    2.1 
 
Change in upper  LL         5    -0.5    2.1 0.551 
adjacent facet size XS         3    -1.2    1.1 
length (mm)                   
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4.8.2.4. Lower adjacent spinal canal area  
            (Below the operated level(s)) 
There was no significant difference in the change of the spinal canal area 
between the two treatment groups (p=1.0) (Figure 4.45 and Table 4.47). 
Also, there were no significant differences between preoperative and 
postoperative spinal canal area in Lumbar laminectomy (p=0.403) and X-
stop (p=1.0). 
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Figure 45: Boxplot of change of preoperative and postoperative lower adjacent 
spinal canal area for two treatment groups. 
 
Table 4.47: Preoperative, postoperative and change in lower adjacent spinal canal 
area(mm2) for two treatment groups. IQR=Interquartile range. 
 
 
                                Number of 
Procedure   patients   Median    IQR p-value 
Preoperative     LL              5     150.3        66.5 - 
                     XS              3     149.5        59.4 
 
Postoperative     LL              5     152.9        90.8 - 
                     XS             3     163.7     149.3 
 
Change in lower     LL              5        25.5        45.7 1.0 
adjacent spinal    XS              3        14.2        89.9 
canal area(mm2)                   
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4.8.2.5. Lower adjacent intervertebral foramen area  
    (below the operated level(s)) 
There was no significant difference in the change of the foraminal area 
between the two treatment groups (p=0.371) (Figure 4.46 and Table 4.48). 
Also, there were no significant differences between preoperative and 
postoperative foraminal area in Lumbar laminectomy (p=1.0) and X-stop 
(p=0.190). 
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Figure 4.46: Box plot of change of  preoperative and postoperative lower 
adjacent intervertebral foraminal area for two treatment groups. 
 
Table 4.48: Preoperative, postoperative and change in lower adjacent 
intervertebral foraminal area(mm2) for two treatment groups. IQR=Interquartile 
range. 
 
 
 
 
 
 
 
 
                                      Number of 
        Procedure              patients  Median    IQR p-value 
Preoperative       LL              5     73.3    43.1    - 
                  XS              3    66.0    16.8 
   
Postoperative     LL              5     64.5     44.8    - 
                  XS              3    57.6       8.9 
 
Change in lower adjacent    LL              5       5.1    33.5   0.371 
 intervertebral foramen   XS              3   -11.0    23.1 
area(mm2)                  
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4.8.2.6. Lower adjacent facet size  
(below the operated level(s)) 
There was no significant difference in the change of the facet size length 
between the two treatment groups (p=0.551) (Figure 4.47 and Table 4.49). 
Also, there were no significant differences between preoperative and 
postoperative facet size length in Lumbar laminectomy (p=0.754) and X-
stop (p=0.383). 
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Figure 4.47: Boxplot of change of  preoperative and postoperative lower adjacent 
facet size for two treatment groups. 
 
Table 4.49: Preoperative, postoperative and change in lower adjacent facet size 
(mm) for two treatment groups. IQR=Interquartile range. 
 
 
 
 
 
 
 
 
 
 
 
                    Number of 
          Procedure   patients   Median     IQR p-value 
Preoperative   LL             5    16.8       3.4 - 
                   XS             3     18.0       3.7 
 
Postoperative LL             5     16.8       4.7 - 
                   XS             3    19.5       2.4 
  
Change in lower  LL             5        1.0       4.8 0.551 
adjacent facet  XS             3       1.5        1.2 
size length(mm)                  
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4.8.2.7. Upper adjacent ligamentum flavum thickness 
(above the operated level(s)) 
There was no significant difference in the change of the ligamentum 
flavum thickness between the two treatment groups (p=0.551) (Figure 4.48 
and Table 4.50). Also, there were no significant differences between 
preoperative and postoperative facet size length in Lumbar laminectomy 
(p=0.676) and X-stop (p=1.0). 
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Figure 4.48: Boxplot of change of  preoperative and postoperative upper adjacent 
ligamentum flavum thickness for two treatment groups. 
 
Table 4.50: Preoperative, postoperative and change in upper adjacent ligamentum 
flavum thickness(mm) for two treatment groups. IQR=Interquartile range. 
                                Number of 
Procedure   patients   Median     IQR p-value 
Preoperative    LL              5      5.6     4.3 - 
                    XS              3      6.3     4.2 
 
Postoperative  LL              5     4.6   3.7 - 
                    XS              3      5.1     5.6 
 
Change in upper adjacent  LL              5          1.5            3.7 0.551 
 ligamentum flavum         XS              3     0.6        3.2 
thickness(mm) 
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4.8.2.8. Lower adjacent ligamentum flavum thickness 
(above the operated level(s)) 
There was no significant difference in the change of the ligamentum 
flavum thickness between the two treatment groups (p=0.456) (Figure 4.49 
and Table 4.51). Also, there were no significant differences between 
preoperative and postoperative facet size length in Lumbar laminectomy 
(p=0.917) and X-stop (p=1.0). 
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Figure 4.49: Boxplot of change of  preoperative and postoperative lower adjacent 
ligamentum flavum thickness for two treatment groups. 
 
Table 4.51: Preoperative, postoperative and change in lower adjacent ligamentum 
flavum thickness(mm) for two treatment groups. IQR=Interquartile range. 
 
 
 
 
 
 
 
 
 
 
 
                                Number of 
Procedure   patients            Median        IQR  p-value 
Preoperative  LL              5          4.3           1.3  - 
                    XS              3           4.1        10.5 
 
Postoperative   LL              5          3.9           3.0  - 
                    XS              3         4.1     0.0 
 
Change in lower adjacent  LL              5          0.6       2.6  0.456 
 ligamentum flavum         XS              3     0.0  10.5 
thickness(mm) 
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4.8.2.9. Upper adjacent disc height  
(above the operated level(s)) 
We found that there was a significant loss of disc height in the upper 
adjacent spinal (i.e. above the operated level(s)) in Lumbar laminectomy 
group compared to X-stop group (p=0.0369).  This suggests accelerated 
degenerative changes in Lumbar laminectomy group compared to the X-
stop group (Figure 4.50 and Table 4.52). However, there were no 
significant differences between preoperative and postoperative disc height 
in Lumbar laminectomy (p=0.754) and X-stop (p=0.383) separately. 
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Figure 4.50: Boxplot of change of  preoperative and postoperative upper adjacent 
disc height for two treatment groups. 
 
Table 4.52: Preoperative, postoperative and change in upper adjacent disc 
height(mm) for two treatment groups. IQR=Interquartile range. 
 
                                Number of 
       Procedure   patients   Median     IQR p-value 
Preoperative        LL              5        9.4    2.9 - 
                   XS              3         7.6     5.2 
 
Postoperative       LL              5       8.9    4.0 - 
                   XS              3     11.7     7.4 
 
Change in upper   LL              5     -0.6    1.3 0.0369 
disc height(mm)              XS              3       3.4    2.9 
 
 
p=0.0369 
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4.8.2.10. Lower adjacent disc height 
(above the operated level(s)) 
There was no significant difference in the change of the lower adjacent 
disc height between the two treatment groups (p=0.136) (Figure 4.51 and 
Table 4.53). Also, there were no significant differences between 
preoperative and postoperative lower adjacent disc height in Lumbar 
laminectomy (p=1.0) and X-stop (p=0.662). 
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Figure 4.51: Boxplot of change of  preoperative and postoperative lower 
adjacent disc height for two treatment groups. 
 
Table 4.53: Preoperative, postoperative and change in lower adjacent disc 
height(mm) for two treatment groups. IQR=Interquartile range 
 
 
 
 
 
 
 
 
 
                               Number of 
Procedure   patients   Median     IQR p-value 
Preoperative LL              5     11.3     4.2 - 
                   XS              3       6.0   2.4 
 
Postoperative     LL              5     11.6     5.4 - 
                   XS              3     12.1     7.2 
 
Change in lower  LL              5     -0.2    1.6 0.136 
adjacent disc  XS              3        4.6     6.3 
height(mm)                     
 
160 
 
4.9. COMPLICATIONS 
In our study, 6 out of 10 (60% ) patients crossed from the X-stop group to the 
Lumbar laminectomy following the X-stop insertion. This makes it a rather high 
reoperation rate in the X-stop group. 1 out of 6 patients who was reoperated, had 
spinous process fracture while the others showed either no improvement or 
worsening of symptoms. Hence removal of X-stop and revision operation with 
Lumbar laminectomy was performed.         
 
Table 4.54: Number of patients who were reoperated. Note: The only reoperation 
was removal of X-stop device and lumbar laminectomy. 
 
 
 
 
 
 
 
4.10. FOLLOW UP 
We have had no loss to follow up. All patients were followed up to 12 months 
postoperatively.  
 
   Number of patients reoperated (Percentages) 
  
  No Yes Total 
 Procedure   
 LL 10(100) 0(0) 10 
 XS 4(40) 6(60) 10 
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4.11. SAMPLE SIZE CALCULATION 
We have used our pilot study data to guide the sample size in continuation of the 
study   (Table 4.55). 
With Significance level 0.05, with Power 0.80 we calculated that we need total of: 
- 50 participants to detect a significant effect size 10% (less than 2.50 
score) for ZCQ Satisfaction component (25 in each group)  
- 28 participants to detect a significant effect size 10% (0.5 score) for ZCQ 
Symptom component (14 in each group) or 
- 14 participants to detect a significant effect size 12.5% (0.5 score) for 
ZCQ Physical component (7 in each group). 
 
It is suggested that using the larger estimated sample size of 50 participants for 
ZCQ Satisfaction component should suffice for ZCQ Symptom and Physical 
component, which both require smaller sample size (Table 54). 
  
 
Table 4.55: Sample size calculated values to achieve a significant size effect of 
10% (0.5) in ZCQ Symptom, 12.5% (0.5) Physical component and 12.5%(2.5) 
Satisfaction component at 12 months, with significance level 0.05, power 0.80. 
         
 
 
 
 
 
 
 
 
 
 
 
 
 
       Procedure    Mean(%)   StDev    StDev pooled Sample size required 
ZCQ Symptom   LL      72.14   16.82  14.76  28(14  in each group) 
preoperative                   XS      71.43   12.37 
 
ZCQ Physical   LL      66.88   13.19  12.98      14(7  in each group) 
 preoperative                   XS      63.75   12.77 
 
ZCQ Satisfaction  LL         56.67      23.99   24.75  50(25 in each group) 
Scale at 12 months   XS         52.08      25.48 
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Reason for the stated size effects: 
As previously suggested (128), the criteria of success of operations in LSS are the 
difference of greater than 0.5 in ZCQ Symptom and Physical component as well 
as mean score of  less than 2.50 in Satisfaction component. 
The required percentage difference effects that we have used in power 
calculations come from the fact that: 
- Difference in ZCQ Symptom component greater than  0.5 is considered as 
significant. Now, as ZCQ Symptom component scores from 1- 5 the 
conversion between the percentage and score is:  
 
ZCQ Symptom component score =(ZCQ Symptom component percentage x5)/100. 
 
Since the required score difference is 0.5, this converts to Percentage as 
follows: 
Percentage of 0.5 score = 0.5 x 20 = 10% is the required percentage difference effect. 
 
- Similarly, the required difference effect for ZCQ Physical component 
(which scores 1 – 4) is 0.5 and is converted to percentage as follows: 
 
ZCQ Physical  component score =(ZCQ Physical component percentage x4)/100. 
 
Since the required score difference is 0.5, this converts to Percentage as 
follows: 
Percentage of 0.5 score = 0.5 x 25 = 12.5% is the required percentage difference effect. 
 
- The required difference effect for ZCQ Satisfaction component is to get 
score difference of 2.50 which is: 
 
ZCQ Satisfaction component score =(ZCQ Satisfaction component percentage x4)/100. 
 
Therefore,  
Percentage of 2.50 score = 2.5 x 25 = 12.5% is the required percentage difference effect 
of ZCQ Satisfaction component. 
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4.12. CORRELATION BETWEEN GENERAL QUALITY OF LIFE 
AND DISEASE-SPECIFIC OUTCOME MEASURES 
Convergent validity was assessed by computing correlations between the specific 
and generic outcome scores. 
Convergent validity was shown by strong correlations between disease-specific 
scores and quality of life as follows: 
• There is a strong correlation between ZCQ Physical component and EQ5D 
score and  
• There is a strong correlation between ZCQ Symptom component and SF36 
domains: Bodily pain. 
• There is a strong correlation between ZCQ  Physical component and SF36 
domains: 
Physical functioning, Bodily pain, General Health, Vitality and Social 
functioning. 
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Table 4.56: Correlation between quality of life questionnaires (EQ5D and SF36 
domains) and Zurich claudication questionnaires. Pearson correlation coefficient 
(r) used. RED indicates significant results. 
. 
 
 
 
 
     p-value 
    Zurich claudication questionnaire 
           Symptom component  Physical component 
Variables                 r             p-value       r  p-value 
EQ5D  -0.284  0.225  -0.551  0.012 
 
 
 
SF36 
 PF  -0.441  0.052  -0.629  0.003  
 
RP   0.283  0.227  -0.027  0.910 
 
BP  -0.709  <0.001  -0.530  0.016 
 
GH  -0.388  0.091  -0.564  0.010 
 
VT  -0.320  0.170  -0.484  0.031 
 
SF  -0.273  0.245  -0.511  0.021 
 
RE  0.231  0.326  -0.048  0.842 
 
MH  -0.125  0.599  -0.352  0.128  
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Table 4.57: Correlation between quality of life questionnaires (EQ5D and SF36 
domains)  and disease-specific  questionnaires (Oswestry Disability Index score, 
Quebeck Back Pain Disability Scale). Pearson correlation coefficient (r) used. 
RED indicates significant results. 
 
 
     
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Disease-specific questionnaires 
                             ODI    QBPDS 
Variables      r             p-value      r  p-value 
EQ5D  -0.394  0.086  -0.285  0.223 
 
SF36   
 PF  -0.533  0.015  -0.749  <0.001 
  
RP  0.005  0.983  0.218  0.355 
   
BP  -0.623  0.003  -0.629  0.003  
 
GH  -0.497  0.026  -0.475  0.034 
 
VT  -0.485  0.030  -0.520  0.019  
   
SF  -0.361  0.118  -0.512  0.021 
  
RE  -0.269  0.251  -0.096  0.688 
   
MH  -0.244  0.300  -0.423  0.063 
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4.13. SUMMARY OF  FINDINGS 
Quality of life 
- There was no difference in EQ5D dimensions and SF36 domains between 
the two treatment groups. 
- No improvements were detected between the two treatments but there is 
evidence to suggest improvements in quality of life within each treatment 
group over time.  
QALYs 
- There were no significant differences in QALYs gained for either 
intervention 
Costs 
- The costs were significantly higher for the X-stop group. This seems to be 
related to the cost of the implant because no significant differences were 
found between costs associated with theatre time, inhospital stay, 
physiotherapy sessions and neurosurgery outpatient attendances. 
 
Cost-effectiveness 
- The base case estimates have shown that incremental cost effectiveness 
ratio (ICER) is dominant suggesting that Lumbar laminectomy is a better 
value for money but with small probability suggesting the need for a larger 
trial. 
 
Clinical outcomes 
- No improvements in back pain outcomes were found using QBPDS and 
ODI. 
- However, there were significant improvements in ZCQ Symptom 
component and Physical components for each intervention separately but 
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not when compared with each other. This improvement is noted from 6 
weeks and remains until 12 months period for both interventions.  
 
Predictive factors 
- ASA score – is a NEGATIVE predictive factor for Cost and ZCQ 
Symptom component, and POSITIVE predictive factor for ZCQ Physical 
component. 
  
- Actual level operated –the lower the level operated (e.g. L4/5 compared 
to L3/4) a NEGATIVE predictive factor for GH, RE, RP, and POSITIVE 
predictive factor for ZCQ Physical component. 
 
- Age – is a POSITIVE predictive factor for the Cost.   
 
- BMI –is a NEGATIVE predictive factor for Cost and ZCQ Physical 
component. 
 
- Duration of symptoms – is a NEGATIVE predictive factor for Cost. 
 
- Levels (number of levels operated) – is a NEGATIVE predictive factor 
for EQ5D score 
 
- Smoking – is a NEGATIVE predictive factor for Mental Health.  
 
- VAS pain score – is a NEGATIVE predictive factor for Cost, and 
POSITIVE predictive factor for BP and SF. 
 
Other factors such as Gender, Procedure (X-stop or Lumbar laminectomy) and 
Cobb angle did not have a significant predictive value on the outcome 
measures in multivariate regression analysis. 
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Correlation between general quality of life and disease-specific 
questionnaires 
- There is significant evidence to suggest convergent validity of EQ5D score 
and SF36 with ZCQ Symptom and Physical component because of their 
significant correlation. This proves the validity of using the EQ5D and 
SF36 domains in patients with lumbar spinal stenosis. 
- There is significant evidence to suggest convergent validity of SF36 with 
Oswestry Disability Index and Quebeck Back Pain Disability scale. This 
proves the validity of using the SF36 domains is appropriate to use in 
relationship to lower back pains in patients with lumbar spinal stenosis. 
 
Radiological changes associated with each intervention. 
- Operative level:- No difference was found between two treatment groups 
in postoperative changes in spinal canal area, intervertebral foraminal area, 
anterior disc height, posterior disc height, facet size, intervertebral angle, 
Cobb angle. 
 
- Adjacent levels – It was found that the Lumbar laminectomy causes a 
significantly greater loss of upper disc height compared to the X-stop 
group (p= 0.037) which could represent an evidence of greater upper 
vertebral degeneration in Lumbar laminectomy group or simply 
biomechanical widening of upper disc height secondary to the upward 
stress force applied by the X-stop device to the vertebra above. No 
difference was found between two treatment groups in postoperative 
changes in upper and lower adjacent spinal canal area, intervertebral 
foraminal area, facet size and ligamentum flavum thickness. 
  
Complications: 
- Six out of ten patients in XS group had X-stop removed and laminectomy 
performed over the affected stenosed levels.  This constitutes a 60% revision rate 
for the XS group in our study. 
 
 
 
Sample size calculations 
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- From our current results of the pilot study, a future randomised study 
should be powered to recruit 50 participants in each group i.e. 25 
participants in each group (Power 80%, p=0.05). 
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5.  DISCUSSION 
The work for this thesis is generated by a high quality randomised controlled trial 
having as a primary end-point to compare which one, lumbar laminectomy or X-
stop procedures is more cost-effective.  
 
5.1. Demographic data 
The baseline demographics data are comparable (Table 4.2 and 4.3) between the 
two treatment groups. 
 
5.2. Quality of life 
It was shown that the EQ-5D is useful tool for estimating health state values and 
for monitoring outcome of patients undergoing low-back surgery. Hence, this 
instrument is useful in providing valid data for cost– utility analyses in lower back 
surgery.(135) 
The assessment of quality of life between lumbar laminectomy and X-stop in 
lumbar spinal stenosis has not been previously done by using the EQ5D 
instrument. One study have shown that there was an improvement in EQ5D 
postoperatively following lumbar laminectomy operation.(136)  
This is in keeping with our findings of improvement of quality of life in Lumbar 
laminectomy group.  Improving trends in quality of life were also noted within the 
X-stop group in our study but this failed to reach significance due to small sample 
size.  
In order to capture further quality of life data we have also used SF36 instrument. 
It has been suggested that SF-36 domain scores are valid for measuring morbidity 
and surgical outcomes in common spinal disorders including lumbar spinal 
stenosis patients.(134) A randomised controlled trial showed an improvement in 
quality of life by using SF36 domains in the X-stop group compared to 
conservative treatment group at  6-week, 6-month, and 1-year post-treatment 
follow-up time points.(128) In the same study, the X-stop group scored 
significantly better than the conservative group in every domain. In addition,it 
was found that even within the X-stop group alone there were significant 
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postoperative improvements in the mean scores in each category than the 
respective preoperative scores. Same study found no significant improvement in 
the conservative group.(128)  
Another study showed that mean General Health (GH), Role Emotional, and 
Mental Component scores continued improving at 2 years in the X-stop 
group.(150)    
Similarly, a long-term follow-up study showed that patients operated on for 
lumbar stenosis continue to improve their quality of life pattern even between the 
4th and the 8th year after surgery. Specific improvements were observed in 
Physical Function, Bodily Pain, Mental Health and the Physical Function scores 
with respect to the first follow- up. However, Vitality worsened during this follow 
up.(137)  
But how does quality of life compares between lumbar laminectomy and X-stop 
treated patients for LSS? 
To our knowledge, no previous studies have directly compared Lumbar 
laminectomy and X-stop in a randomised fashion. One study previously has 
pooled results from various studies and found no difference in quality of life 
between X-stop and Lumbar laminectomy over 2-year period.(163) We also found 
that there was no difference between the two treatment groups in all domains of 
SF36 within 1-year. When assessed separately the X-stop group showed 
significant improvements in Physical functioning at 6 weeks and Bodily pain at 12 
months. Lumbar laminectomy group alone showed an improvement only in 
Bodily pain at 6 weeks. It may be that the differences in quality of life between 
the two treatment groups may appear after a follow up longer than 1 year so a 
longer and larger sample size is required. 
 
5.3. Cost-effectiveness  
No differences in utility values (QALYs) were found between the two treatment 
groups. However, the costs were significantly higher in the X-stop group. This 
seems to be related to the cost of the implant because no significant differences 
were found for costs associated with time in theatre, inhospital stay, 
physiotherapy sessions and neurosurgery outpatient attendances between the two 
treatment groups.  
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In order to increase external validity and make the results more generalisable the 
operations were performed as per routine NHS lists. That is, either consultants or 
their senior neurosurgical registrars performed the XS or LL. Perhaps if only 
consultants performed both procedures then the timing of surgery would be 
shorter and costs may be saved. However this shortening of intraoperative time 
would apply to both procedures. 
Similarly previous studies found no significant difference in QALYs between X-
stop and Lumbar laminectomy when data were pooled from literature search.(163) 
However, this study found that there was a lower cost associated with X-stop 
treatment compared to lumbar laminectomy.  
There is a study supporting the use of the X-stop over lumbar laminectomy on the 
grounds of higher cost-effectiveness. In this study, patients were randomly 
allocated to X-stop and conservative treatment. Cost data from patients who failed 
conservative treatment and went into lumbar laminectomy were used, the process 
that would have introduced selection bias as a result of choosing a poorer 
performing cohort of one of the treatment arms.(141)  
We differ in our results where we found that the costs were significantly lower in 
Lumbar laminectomy group. The results of costs and QALYs led to calculating a 
dominant  base-case estimate, that is, incremental cost effectiveness ratio 
suggesting that Lumbar laminectomy is dominant i.e. ‘better value for money’ 
compared to the X-stop intervention.  
The uncertainty regarding the maximum acceptability values showed that for the 
suggested NHS ceiling of about £30000 per QALY there is a 0.544(for EQ5D-
derived utilities) and 0.512(for SF36-derived utilities) probability that Lumbar 
laminectomy is more cost-effective than X-stop. This finding somehow weakens 
the statement of dominance of lumbar laminectomy when current threshold value 
is suggested. This suggests that there are strong grounds to continue with current 
study to increase the number of participants and re-analyse the cost data. 
 
5.4.  Clinical outcomes 
There are a number of disease-specific questionnaires utilised in assessment of 
spinal disorders. By using more than one questionnaire for QoL and clinical 
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outcomes, we have attempted to capture as much subtle variations between the 
two treatment groups.  
There is evidence to suggest that both X-stop and Lumbar laminectomy 
procedures are superior to conservative treatments.  
The RCTs such as The Finnish Lumbar Spinal Research Group (94) and The 
SPORT study(98) showed that lumbar laminectomy was superior to conservative 
treatment in patients with lumbar spinal stenosis.  
Our data suggest that QBPDS and ODI did not show any improvement between- 
and within-treatment groups, while significant improvements were observed in 
ZCQ Symptom and Physical component when mean preoperative and 
postoperative scores were assessed within each treatment group. These 
improvements remain until 12 weeks postoperatively for each treatment group 
separately.  Our finding regarding the X-stop group alone, are in keeping with 
previous study where improvements in X-stop group compared to conservative 
treatment were significant.(128) We found no improvements in clinical outcomes 
between and within treatment groups over 1-year when QBPDS and ODI 
instruments were used. Previous RCT study found a significant improvement in 
X-stop group compared to conservative treatment over 2 years.(131) Same study,  
at 4-year follow-up, showed an improvement in clinical outcome (132) where 
ODI was used as an outcome instrument. Limitations of this study are a high rate 
of loss to follow up ending up with a small sample size and no indication that 
statistical testing was performed. Also, no control group was present in the 4-year 
follow up. 
A prospective observational study was performed to assess the clinical outcome of 
patients with symptomatic lumbar spinal stenosis before and at periodic intervals 
after the X-stop was implanted. Forty consecutive patients were enrolled and 
surgically treated with this device, which was implanted at the level of stenosis, 
either at 1 or 2 levels in each patient. Patients were clinically evaluated at the 
preoperative, 3-month, 6-month, and 1-year stage with questionnaires (Zurich 
Claudication Questionnaire, Oswestry Disability Index, and SF-36). By 12 
months, over half  (54%) of the patients with implanted X-stop devices reported 
clinically significant improvement in their symptoms, 33% reported clinically 
significant improvement in ZCQ Physical function, and 71% expressed 
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satisfaction with the procedure. The mean ODI score showed maximal 
improvement at the 3-month visit (preoperative: 48%; range, 24%– 62%; 3 
months: 35%; range, 4%–64%) with very little change subsequently.   
Regarding quality of life, the mean Physical function, Bodily pain, and Physical 
cumulative scores of the SF-36 showed maximal increase in the first 3 months 
after surgery. The Role physical score continued to improve up to the 1-year 
postoperatively.(133) Limitations of this study were small sample size, high rate 
of loss to follow up and no p-values or confidence intervals of the outcome 
measures given to indicate the strength of evidence. 
The success rates in our study showed an apparent 60% success rate of the X-stop 
group at 12 months period.  However this should take into consideration that this 
was an intention-to-treat analysis with a 60% cross-over from the X-stop to 
lumbar laminectomy group.  
 
5.5. Predictive factors 
Studies of factors associated with outcome generally have been small, 
retrospective, and limited in the number and types of potential predictor variables 
analyzed.(113) 
A systematic review has shown that depression, cardiovascular comorbidity, 
disorder influencing walking ability, and scoliosis predicted poorer subjective 
outcome. Better walking ability, self-rated health, higher income, less overall 
comorbidity, and pronounced central stenosis predicted better subjective outcome. 
Male gender and younger age predicted were associated with better postoperative 
walking ability. The predictive value may be outcome specific, therefore the use 
of all relevant outcome measures is recommended when studying predictors of 
LSS.(164) 
On the contrary to this systematic review, we found no predictive value with 
gender or degree of scoliosis, for any of quality of life or disease specific 
outcomes. However, in our study, younger age was associated with lower costs 
regardless of which intervention was performed.  
Another study suggests that longer duration of symptoms (over 33 months) is 
associated with functional outcome (as measured by the ODI). Limitations are that 
the predictor effect of duration of symptoms was only noted in subgroup 
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analysis.(165) In our study, multivariate analysis showed that preoperative 
duration of symptoms was negatively associated with costs. That is, the longer the 
duration of symptoms preoperatively was associated with lower the costs over 1 
year, and did not show significant predictive value for other outcome measures. It 
is difficult to explain why longer duration of symptoms preoperatively may lead 
to lower costs. This negative relationship between duration of symptoms and cost 
persisted even when we excluded one patient with shorter duration of symptoms 
whose X-stop was removed and had persistence of symptoms requiring additional 
imaging, physiotherapy sessions and hence much larger costs compared to other 
participants. This unexpected result may be a due to small sample size. 
A better understanding of prognostic factors could enable patients and surgeons to 
develop better expectations concerning the operative outcomes. 
 
5.6. Correlation between general quality of life and disease-specific 
questionnaires 
Predictive validity of general quality of life questionnaires can be demonstrated 
by correlations between pre- and post-operative scores for specific and generic 
instruments. One study found that Physical Function, Bodily Pain, and Mental 
Health domains were all significantly correlated with clinical responsiveness such 
as VAS pain score. This suggested that SF-36 domain scores is considered valid 
for measuring morbidity and surgical outcomes in common spinal disorders.(134) 
In our study, we found that there is significant evidence to suggest convergent 
validity of EQ5D score and SF36 with ZCQ Symptom and Physical component 
because of their significant correlation. We also found significant evidence to 
suggest convergent validity of SF36 with Oswestry Disability Index and Quebeck 
Back Pain Disability scale. These findings prove the validity of using the EQ5D 
score and SF36 domains appropriate to use in relationship to lower back pains in 
patients with lumbar spinal stenosis. 
 
5.7. Radiological changes associated with each intervention 
It has been shown that degenerative changes in the lumbar spine are very common 
in the asymptomatic population, especially in patients over 60 years of age, 20% 
will reveal signs of LSS.(64) 
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Therefore, only the clinical correlation to radiological findings is important to be 
evaluated. 
Previous studies have shown that after implantation of the interspinous device 
there was a significant increase (P<0.0001) of the foraminal height, foraminal 
width, foraminal cross-sectional area, intervertebral angle and decrease in anterior 
disc height and posterior disc height.(138)  
Another study showed that in 12 patients with 17 distracted levels, the area of the 
dural sac at these levels increased from 77.8 to 93.4 mm2 after surgery in the 
standing position (P = 0.006), with increase in the exit foramens, but no change in 
lumbar posture. This study shows that the X-stop device increases the cross-
sectional area of the dural sac and exit foramens without changes in posture.(139)  
 
In our study, no difference was found between two treatment groups in 
postoperative changes in spinal canal area, intervertebral foraminal area, anterior 
disc height, posterior disc height, facet size, intervertebral angle and Cobb angle 
at the operated level. 
However, we found that the Lumbar laminectomy causes a significantly greater 
loss of upper disc height compared to the X-stop group (p= 0.037) as an evidence 
of greater upper vertebral degeneration in Lumbar laminectomy group or simply 
biomechanical widening of upper disc height secondary to the upward stress force 
applied by the X-stop device to the vertebra above. Also our results suggests that 
there is a decrease in lower adjacent intervertebral foramen area following the X-
stop insertion in the XS group only (Table 4.48). However, this result was 
insignificant  which could be due to a too small sample size. 
No difference was found between two treatment groups in postoperative changes 
in upper and lower adjacent spinal canal area, intervertebral foraminal area, facet 
size and ligamentum flavum thickness.  
 
5.8. Complications 
Turner et al in 1992 showed the following complication rates for lumbar 
decompressive surgery: perioperative mortality (0.32%), dural tears (5.91%), deep 
infection (1.08%), superficial infection (2.3%) and DVT (2.78%).(106)  
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On the other side, the reported complications of the X-stop are: malpositioned 
implant(1%), implant dislodgement/migration (1%), spinous process fracture 
(1%) and increased pain at implant level  (1%). (131)  
Another study reported 5.7% device dislodgment and 5.7% of spinous process 
fractures.(166)  In our study we had two dural tears in Lumbar laminectomy group 
and two spinous process fractures in the X-stop groups. This makes for the 
complication rates of 20% in both treatment groups.  
 
5.9. Reoperation  
In our study, there were 60% revision operations of removal of X-stop with 
concomitant lumbar laminectomy. No lumbar laminectomy patients were 
reoperated. The reported reoperation rate in another RCT for the X-stop patients 
was 6%.(131)  
 
5.10. Sample size calculations 
Initial sample size calculation was done based on the data from another study 
(149) and found that we needed  55 patients in each group, taking into 
consideration the losses to follow up in that study. In Katz study the required 
effect difference in cost was chosen at 20% and the loss to follow up was 27%. 
Prior to commencement of our study, Katz study was the only one with available 
cost parameters that we could use for the purpose of power calculation. The 
limitation of Katz study was that evaluation of costs were made between Lumbar 
laminectomy with and without arthrodesis where no X-stop device was used. 
Therefore the sample size calculation was only used as a crude guide to estimate 
the sample size required for our study. The limitation of initial power calculation 
was ameliorated using our original data from our pilot study to calculate a more 
appropriate sample size.Other recruitment problems that we encountered included 
difficulty to find patients who fulfil all eligibility criteria, and some patients 
decided not to opt for the operation  None of the eligible patients preferred one 
surgical treatment over the other one.  
 Our study suggests that there may be some difference in cost with lumbar 
laminectomy being perhaps cheaper than X-stop.  However, in our study, no 
between group differences were found with respect to clinical outcomes, which is 
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likely to be due to small sample size. For the cost-effectiveness study to be valid, 
it is required that the study is powered to detect clinical outcome differences 
between the two procedures too. The success of clinical outcome in lumbar spinal 
stenosis patients, as previously mentioned, is based on criteria of improvement in 
mean ZCQ Symptom and Physical component scores greater that 0.5 and ZCQ 
Satisfaction score less than 2.5.(128) Using our original data we found that in 
order to detect the required differences in clinical outcomes, our study should be 
powered to recruit 50 participants in each group i.e. 25 participants in each group.  
 
6. LIMITATIONS OF THE STUDY 
This study analysis is made from a small number of participants. Hence, the data 
is useful as it constitutes the framework for further research.  
 
Blinding 
The study is not blinded and due to nature of the interventions, this would be 
difficult to achieve, because both patients and surgeons often wish to know which 
procedure has been performed. This means that potentially observer bias may 
have been introduced.  
 
Cross-over 
Large cross-over from the X-stop group into the Lumbar laminectomy (60%) 
makes the intention-to-treat analysis cumbersome. This large cross-over suggests 
further that either X-stop device is not as effective as previously thought or this 
result was obtained as surgeons of various operative skills operated on different 
patients, introducing some heterogeneity in success rate. The small sample size in 
our study does not allow us to come to firm conclusions, but that a larger study is 
required.  In the 6 patients who crossed over, the quality of life measures 
improved after laminectomy in 2 patients.  
Use of statistical tests 
The consequence of our small sample size is the higher likelihood of generating 
false negative results when statistical tests are used. For example, preoperative 
mean spinal canal area in LL group was almost double compared to that of the XS 
group (89.7% vs 54.8%, LL vs XS respectively). Also, preoperative mean Cobb 
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angle was over twice greater than the XS group (12.60 vs 5.60, LL vs XS 
respectively). However, in both cases no statistical significance was found. 
 
Multiple comparisons  
A number of statistical comparisons were made of different parameters between 
the LL and XS groups, and between preoperative time period in one side and 
postoperatively at 6 weeks, 6 months and 12 months. Application of Bonferroni 
correction could have been applied for multiple comparisons which would have 
reduced some of the significance results found. 
 
Outcome measures 
The study could have been improved by using more objective neurological scales 
such as: scales available to assess the gait speed (e.g., time walked test), sensory 
function (e.g. vibration sensation threshold), weakness (e.g. MRC power scale, 
maximal hip flexion using a dynamometer) or sphincter function.  
Previous studies have shown an increase latency of tibial F-wave in LSS patients 
when electromyography studies are used (83)(84). EMG studies could be used in 
future studies to distinguish patients that will do better with LL or XS. However 
the limitation of EMG would arise in patients with concomitant diseases 
predisposing to polyneuropathy e.g. diabetes. 
The need for additional lateral radiographs in flexion and extension to rule out 
segmental instability is not routinely required, as segmental instability can be 
detected on routine lateral radiographs in a reasonably accurate manner.(62)(71) It 
is shown that no additional benefits were conferred from these additional views 
(62)(70).  However those studies were not done for the purpose of comparing XS 
versus LL patients. Therefore various radiological parameters (e.g. interspinous 
process distance changes) can be measured in flexion-extension views and the 
predictive effects analysed. So dynamic flexion-extension plain X-rays of lumbar 
region done preoperatively could prove useful as predictors of which patients will 
do better with which surgical procedure i.e. XS or LL. 
 
Success rate  
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As discussed earlier the success rates may be related to the fact that more than 
half of the cases had LL after the X-stop procedure. 
No intra-observer reproducibility was calculated for this study which we shall 
perform in a bigger study. 
 
More centres could be included to increase the external validity of the study and 
reduce the time to finish the study. 
ASA score has been used as a co-morbid level but we could have improved the 
study by using more sophisticated instruments such as Cumulative Illness Rating 
Scale.(168)  
 
7. CONCLUSION 
Finally, our study showed that there is some evidence that lumbar laminectomy is 
more cost-effective than X-stop although this is a only a preliminary study with a 
1-year follow-up.  We found evidence that there are within-group but not 
between-group improvements in outcome between lumbar laminectomy and X-
stop groups. The lack of finding between-group differences may be attributed to 
small sample size. We suggest a formal trial with 25 patients in each group to 
conclusively determine which treatment is better and more cost-effective. 
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10.2.  Consent form 
Centre Number:                         Version 1.1  
06/03/2008 
Study Number: 08/H0711/12 
Patient Identification Number for this trial: 
 
10.1.CONSENT FORM 
Cost Effectiveness & Quality of Life after Treatment of Lumbar Spinal Stenosis with the 
XSTOPPK® IPD Device or Laminectomy: A Prospective Randomised trial   
(Protocol Number – 07/X01) 
 
Name of the Investigator:                     Please initial box 
 
1. I confirm that I have read and understand the patient information sheet dated 05/03/2008   
        (version 1.3) for the above study and have had the opportunity to  ask questions.  
 
2. I confirm that I had sufficient time to consider whether  I want to be included in the study.  
       
3. I understand that my participation is voluntary and that I am free to withdraw       
at any time, without giving any reason, without my medical care or legal rights 
being affected. 
 
4. I understand that sections of any of my medical notes may be looked at by        
 responsible individuals from UCLH, Kyphon Europe or from regulatory  
 authorities where it is relevant to my taking part in research.                                 
 I give permission for these individuals to have access to my records. 
 
5. I agree to take part in the above study 
 
_____________________ ________________ ______________ 
Name of Patient Date Signature 
 
_________________________ ________________ ______________         
Name of Person taking consent Date Signature 
(if different from researcher) 
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_________________________ ________________ ______________ 
Researcher  Date Signature 
(to be contacted if there are any problems) 
 
Comments or concerns during the study:  
If you have any comments or concerns you may discuss these with the Investigator / Researcher. If you wish to go further 
and complain about any aspect of the way you have been approached or treated during the course of the study, you 
should write or get in touch with the Complaints Manager, UCL Hospitals.  Please quote the UCLH project number at the 
top this consent form. 
When completed, 1 form for the patient; 1 to be kept as part of the study documentation for the 
trial master/investigator site file; 1 original to be kept with the hospital medical notes. 
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10.3..Patient Information Sheet                                                                                                    
Version: 1.3 
Date:   02/05/2008 
Project ID:  08/H0711/12 
 
1. Study title 
Cost Effectiveness & Quality of Life after Treatment of Lumbar Spinal Stenosis with the 
XSTOPPK® IPD Device or Laminectomy: A Prospective Randomised trial 
 
2. Invitation paragraph 
You are being invited to take part in a research study. Before you decide, it is important 
for you to understand why the research is being done and what it will involve. Please 
take time to read the following information carefully and discuss it with others if you 
wish. Ask us if there is anything that is not clear or if you would like more information. 
Take time to decide whether or not you wish to take part.  
 
3. What is the purpose of the study? 
One of the main causes of lower back pain is due to age-related changes in the joints 
and ligaments of the back causing narrowing of the spinal canal where all the nerves 
travel, and compression of nerve roots. This condition is called Lumbar Spinal Stenosis 
(where “Lumbar” means lower back and “Stenosis” means narrowing). This results in a 
debilitating pain or heaviness in the legs that is aggravated by walking, thereby limiting 
mobility. Both the conventional operation of lumbar laminectomy and the use of the 
newer XSTOP-device are been shown to be effective methods for treatment. However 
little is known regarding the costs and how patients function in every day activities after 
they underwent one of these 2 procedures. 
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The purpose of this study is to document the total costs for the operative procedures, 
the degree of back-pain after the operations, the length of hospital stay and 
complication rate on short and long term basis, after having undergone either a lumbar 
laminectomy or the implantation of the XSTOP device. Also the quality of life before and 
after the 2 procedures will be evaluated by completing specific questionnaires.  
The data collected from your X-rays and the study forms completed by your surgeon’s 
staff will be analyzed to determine if there is a significant difference between these two 
treatments.  
The additional cost of the XSTOP device itself has to be weighed against any advantages 
to quality of life.  
 
4. Why have I been chosen? 
You are being invited to participate in this study because you suffer from Lumbar Spinal 
Stenosis at one or two levels in your back, and have tried to obtain symptomatic relief 
with previous non-surgical treatment methods, but without success.     
 
 
5. Do I have to take part? 
It is up to you to decide whether or not to take part. If you decide to take part you will 
be given this information sheet and be asked to sign a consent form. If you decide to 
take part you are still free to withdraw at any time and without giving a reason. A 
decision to withdraw at any time, or a decision not to take part, will not affect the 
standard of care you receive. You may choose to have one treatment rather than the 
other, but if this is the case, you will not be included in the study. If significant new 
findings develop during the course of the study that may affect your health or 
willingness to participate, you will be informed. 
  
6. What is involved in the study?  
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a. What will happen to me if I take part? 
If you agree to take part, you would be asked to follow all the instructions given to you 
by the doctors, nurses and other health personnel as per routine practice in that 
hospital. You would be asked to visit the hospital 6 times during the 2 year follow-up 
period. 
At your initial visit, the doctor would review your medical history including the nature of 
your back pain to make sure that your participation meets the study requirements. If 
you agree, are eligible to participate and have signed the Informed Consent Form, your 
doctor will enrol you into the study. Randomisation envelopes will be opened by your 
doctor on the day prior to surgery. This means that you only then will be assigned to 
either the Laminectomy-treatment group or the XSTOP-device treatment group. Until 
those randomisation envelopes are opened, neither your doctor nor you will know to 
which group you will be assigned.  
If you wish to withdraw from the study you have the right to do so at any time, in which 
case your treatment will not be affected in any way. 
 
b.What will I be required to do? 
 
b1. Pre-operative assessments: 
The following information would be discussed and recorded for both treatment groups 
pre-operative: 
• Your initials, date of birth, weight and height 
• Your diagnosis and relevant medical history 
• Diagnostic measures including:  
• CT (=Computerised Tomography) scan of your spine:  - the CT-machine takes a 
lot of picture of your spine from different angles. The CT scan of your spine will 
only be done during this study if you do not have previous CT images, CT images 
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taken long time ago or the surgeon believes that the existing CT images are 
unsatisfactory and need repeating. 
AND/OR:  
• MRI(=Magnetic Resonance Image) scan of your spine: - the MRI-machine 
produces high quality images of the spinal cord and the surrounding nerves, 
discs and ligaments. 
• CT Myelogram (this investigation will be performed only if unable to get an MRI 
of your spine because of any existing contraindications e.g. pacemaker). - this 
procedure is the same as for getting a CT of your spine (described above) with 
an additional procedure of receiving an injection of a small amount of liquid 
contrast through a small catheter placed in your spinal canal to enhance the 
picture. 
 
All the above investigations and documentation is part of routine clinical practice, 
whether you are part of this study or not. The following questionnaires are for patients 
who agree to take part in this study: 
 
• Your doctor will go over the Inclusion and Exclusion criteria with you to see if 
you qualify to participate in this study. 
• You will be asked to rate your average back pain level over the past week on a 
scale of 0-10 (VAS). 
• You will be asked to complete the following 5 questionnaires about your 
activity level and quality of life:  
- QuebecBack Pain Disability Scale(QBPDS) - -to assess your quality of life 
- EQ5D – to assess your general health and well being 
- SF36 - to assess your general health and well being 
- Oswestry Disability Index (ODI) – to assess pain disability due to Lumbar Spinal 
                                                               Stenosis 
- Zurich Claudication Questionnaire (ZCQ) – to check pain disability due to Lumbar 
                                                                                   Spinal Stenosis 
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The total time to fill in all the questionnaires should be on average 10-20 minutes. If 
you would like, a member of the medical team will be available to read and explain the 
questionnaires to you.  
 
b2.  Treatment Procedure: 
The following information would be reported at time of the operation as per routine 
clinical practice: 
• Assigned operation 
• Amount of blood loss  
• Duration of procedure  
• All procedures performed will be documented 
• Implant information (if assigned to the XSTOP-group) e.g. size of the implant 
used 
• Intra-operative complications if any 
 
b3. Follow-up assessments on the following visits: 7 days, 6 weeks, 6 months, 12 and 
24 months: 
The following information would be reported at the above mentioned time-points: 
• The length of your hospital stay  
• X-rays: will be performed as per hospital standard practice. 
 
The following questionnaires (same as in Section 6(b1)) are for patients who agree to 
take part in this study: 
• You will be asked to rate your average back pain level over the past week on a 
scale of 0-10 on Visual Analogue Scale(VAS). 
• You will again be asked to complete the following 5 questionnaires about your 
activity level and quality of life:  
- EQ5D  
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- QBPDS 
- SF 36  
- Oswestry Disability Index (ODI)  
- Zurich Claudication Questionnaire (ZCQ) 
 
7. Which are the procedures that are being examined? 
A. LUMBAR LAMINECTOMY Treatment group  
Lumbar laminectomy is a relatively safe operation where some bone and soft tissues 
(ligaments) are removed to free up space in the spinal canal and foramina (the opening 
where the nerve roots exit the spine). This way the pressure on the spinal cord and 
nerve roots decreases and will result in symptom relief.  
Procedure: 
The patient lies in face-down position under general anaesthesia. An incision is made 
and the spine is dissected to the level where the decompression will be performed.  
Decompression of the spinal cord and nerve(s) will be done by removing some parts of 
the bone of the spine causing the compression.  As a result the pressure on the nerve 
roots decreases which will result in relief of symptoms.  
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B. XSTOP Implant Treatment group:  
The XSTOP is a metal implant (see Fig 10.1) that fits between the two bony processes of 
the spine and away from the spinal cord and nerves. 
 
 
Fig 10.1: The image of the XSTOP 
 
This is a minimally invasive surgical procedure, during which the device is generally 
implanted under local anaesthesia (with you awake) or general anaesthesia (with you 
asleep under general anaesthetic) and by a minimal open approach to your back at no 
more than 2 disc levels. The beneficial effect of the XSTOP implant is based on the fact 
that it will widen the spinal canal hence free up space for the compressed spinal cord 
and nerves to decompress. 
 
 Procedure:  
The patient is positioned on the side, or face down. An incision is made and the XSTOP 
implant is placed in the created space between the bony processes of the spine. If 
applicable, a second XSTOP will be placed in a similar manner at a neighbouring level. 
This way the spinal canal and the openings where the nerves exit the spine are widened. 
This pressure-reduction should result in pain relief.  
 
Top View Side View 
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8. What are known risks of the study or the side effects of any treatment received? 
   General Surgical Risk assessment: 
There are two categories of risk factors to consider here, namely that associated with 
general spinal surgery and also that associated with any specific surgical procedures 
linked to the instrumentation (surgical tools used for performing the procedure) being 
used.  
 
 
General risks include anaesthetic-related problems, circulatory problems, a collapsed 
lung, pneumonia, blood clots, intra-operative damage to blood vessels, soft tissue, or 
nerves or an allergic reaction to blood products or medications such as antibiotics and 
anaesthetic agents. In very rare instances, heart attack or death may occur.  
Specific risks to XSTOP are very rare and include migration of the implant (1%), 
malpositioning of the implant (1%), migration of the implant (1% ),  fracture of a part of 
the,  bony process(1%),  increased pain at implant level (1% ). 
 
Some specific risks to Lumbar Laminectomy again are rare and include the Spinal fluid 
leak, infection, recurrence of symptoms.   
Although these complications are extremely rare, they may require additional surgery, 
extend the duration of surgery or extend the duration of the hospital stay. Damage to 
the spinal cord, usually limited to Spinal fluid leak, can occur rarely during surgery, 
especially where fine dissection of bone is required for decompression.  
 
  Pregnancy (relevant to female patient participants): 
There is exposure to radiation from standard X-rays taken to diagnose and follow-up 
your spinal stenosis and the status after surgery. There is also radiation exposure during 
surgery from the CT-scan described above. The radiation from X-rays and the CT-scan 
used during the surgery may be harmful to an unborn child.  
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Women who could become pregnant must use an effective contraceptive during the 
course of this study. Thus, if you are a woman who could become pregnant, you must 
have a pregnancy test done prior to your enrolment into the study. If your test is 
positive, these study tests will be cancelled, and you will not be eligible for enrolment 
into this study. Also breastfeeding will exclude you from participation. Any woman who 
finds that she has become pregnant while taking part in the study should immediately 
tell her doctor. 
 
   Risk study-participation: 
Participation in the study per se, does not introduce any additional risk for you, because 
the study will follow normal routine practice used in your hospital for both procedures, 
in term of surgical technique, radiographic review and follow-up visits. Most hospitals 
already collect some form of outcome data, so the only additional inconvenience for you 
will be the need to complete 5 questionnaires instead of one.    
 
9. What are the possible benefits of taking part? 
    General Surgical Benefit assessment: 
Both operations have been shown to be effective in the treatment of lumbar spinal 
stenosis. The degree of benefit expected will be discussed with you by your surgeon, 
since this depends on other factors also. 
 
The benefits of spinal surgery include the potential to dramatically improve a patient’s 
quality of life by enabling them to become more active and take a more constructive 
part in society. This is achieved by the removal of the cause of their pain and through 
rehabilitation reduces their dependence on the medical system for long term medical 
treatment. Obviously the level of improvement is linked to the other pre-existing 
medical conditions. 
 
208 
 
 
   Benefit study-participation: 
The only benefit for you from participation in the study is linked to the data collection 
and regular review, which could identify any potential problems earlier. You will also 
have an additional point of contact with regard to your condition. That contact would be 
the research fellow who is a neurosurgeon in training especially employed for this study 
who will be contactable at any time (this depends on the site involved). 
 
10. Payment for participation 
You will not be paid for participation in this study. 
 
 
11. Costs for participation 
No costs for study participation will be passed on to you. 
 
12. Confidentiality 
Your privacy and all personal health information will remain confidential and will not be 
released without your written permission to the extent permitted by law. You are giving 
permission to you doctor to enter data regarding your treatment and physical status 
into a database. The information gathered will not include your name. Your data will be 
identified by an assigned identification number and your initials. The anonymous 
database information may be analyzed to identify trends that may be used in scientific 
publications or presentations. Any publication of data will not identify you in any way. 
The custodian of the data will be UCLH Foundation Trust, and Mr. David Choi 
(Consultant Neurosurgeon and the Chief Investigator for this study) will be responsible 
for the security of the data. The data will not be stored for longer than 10 years.  
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By signing this consent form, you give permission for the release of the information 
gathered from your participation in the study to the funding Company (Kyphon), for 
possible publication by Mr. Choi and / or other doctors participating in this study. Your 
medical records may also be reviewed by representatives of the funding company 
(Kyphon), by the Institutional Review Board / Ethics Committee and by representatives 
of the FDA or other regulatory representatives for the purpose of verifying medical 
information relating to this study. In addition, your doctors and other study staff at the 
hospital may review your medical records to collect the appropriate data for the study. 
The data collected in this study may be submitted to the FDA, published in medical 
journals, and/or presented at physician meetings. The privacy and confidentiality of your 
individual records will be strictly maintained as per Data Protection Act. 
Data may be transmitted outside the European Union. 
Your general practitioner will be informed if you decide to take part in the study. We will 
not inform your GP if you do not want us to do so. 
 
 
 
13. What happens if something goes wrong? 
In case you have any concern or complaint about any aspect of this clinical trial, you 
should ask to speak with the project’s Chief Investigator, Mr. Choi (Tel. 020-7837-3611, 
Extension 3395 - Mr. Choi’s secretary) who will do his best to answer your questions.  
If you are harmed by taking part in this research project, there are no special 
compensation arrangements. If you are harmed due to someone’s negligence then you 
may have grounds for a legal action but you may have to pay for it. Regardless of this, if 
you wish to complain, or have any concerns about any aspect of the way you have been 
approached or treated during the course of this study, the normal National Health 
Service complaints mechanisms will be available to you. Details are to be obtained from 
the hospital. 
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14. Who is organising and funding the research? 
This is a multicentre, non-commercial study which will run at the National Hospital for 
Neurology and Neurosurgery (London), St Georges Hospital (London) and the Leeds 
General Infirmary (Leeds). This study is funded by the Kyphon Europe. 
 
  
15. Withdrawal form the project 
Your participation in the trial is entirely voluntary. You are free to decline, to enter or to 
withdraw form the study any time without having to give a reason. If you choose not to 
enter the trial, or to withdraw once entered, this will in no way affect your future 
medical care.  
All information regarding your medical records will be treated as strictly confidential and 
will only be used for medical purposes. Your medical records may be inspected by 
competent authorities and properly authorised persons, but if any information is 
released this will be done in a coded form so that confidentiality is strictly maintained. 
Participation in this study will in no way affect your legal rights.    
 
16. Who has reviewed the study? 
The study was reviewed and approved by the Internal Review Panel at the National 
Hospital for Neurology and Neurosurgery, London as well as the Charing Cross Research 
Ethics Committee. 
 
17. Contacts for further information 
If you have any further questions about the study, the investigators within your hospital 
would be delighted to answer them for you.  
 
The investigators for various sites are:  
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The National Hospital for Neurology and Neurosurgery 
Chief Investigator - Mr David Choi  MBChB,  MA, PhD FRCS  FRCS(SN) 
                                Consultant Neurosurgeon and Spinal Surgeon 
                                Victor Horsley Department of Neurosurgery 
                            
                            
                                      
Research Fellow  - Mr Besnik Nurboja  BSc MBBS IMRCS 
                               Victor Horsley Department of Neurosurgery 
                             
                             
                             
                             
St Georges Healthcare NHS Trust  
 
Principal Investigator     - Mr Francis Johnston MBBS FRCS FRCS(SN) 
                                          Consultant Neurosurgeon and Spinal Surgeon 
                                    
                                    
                                    
If you wish to seek independent advice or assistance you may contact the Patient Advice 
and Liason Service (PALS) at the hospital where you were treated. 
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10.4. GP Information Sheet 
Version 1.0 
30 January 2007 
 
Cost Effectiveness & Quality of Life after Treatment of Lumbar Spinal Stenosis with the 
XSTOPPK® IPD Device or Surgical Decompression: A Prospective Randomised trial   
(Protocol Number – 07/X01) 
 
Dear Dr, 
 
Your patient …………………………..  
D.O.B……………………………… …… 
address………………………………… 
 
has agreed to take part in the above study. 
 
 
Background to the study 
 
Lumbar spinal stenosis (LSS) is a common and debilitating condition which consumes 
large amounts of healthcare resource. It occurs in 13-14% of patients who consult a 
specialist with back-pain, and is a considerable drain on NHS resources. 
 
Degenerative changes in the facet joints and ligamentum flavum cause narrowing of the 
spinal canal and compression of nerve roots. This results in a debilitating pain or 
heaviness in the legs that is aggravated by walking, thereby limiting mobililty. There 
have been an increasing number of treatments for LSS over the years, including 
physiotherapy, conventional surgery (eg. lumbar laminectomy) and implantation of 
devices called interspinous distractors. Lumbar laminectomy and interspinous 
distraction are both effective methods for treatment of LSS but there is little known 
about the relative cost effectiveness of these treatments and quality of life for patients 
after treatment.  
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Both the conventional operation of lumbar laminectomy and the newer XSTOP device 
are relatively safe operations and have both been shown to be effective treatments. 
However, we need to establish whether there is a difference in the operative times, 
degree of back-pain after the operations, length of hospital stay, or complication rate 
between the procedures. The additional cost of the XSTOP device itself has to be 
weighed against any advantages to quality of life. This constitutes the basis for this 
study, which is sponsored by St Francis Medical Technologies Inc/ Kyphon. 
 
 
 
 
What will be involved? 
 
Your patient has symptomatic LSS and has agreed to take part in the study. They will be 
randomly allocated to have either the conventional lumbar laminectomy (and 
equivalent surgeries), or the insertion of the XSTOP device.  
 
Aftercare and follow-up arrangements will be the same, regardless of the treatment 
they receive. They will be reviewed in the out-patient clinic for 2 years following surgery. 
 
 
What are the benefits to taking part? 
 
Both operations have been shown to be effective in the treatment of lumbar spinal 
stenosis. The degree of benefit expected will be discussed individually, since this also 
depends on individual symptoms and patient factors. 
 
 
Further questions? 
 
If you have any further questions about the study, we would be delighted to answer 
them for you. Please contact Mr David Choi via the National Hospital for Neurology and 
Neurosurgery.  
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This study has been reviewed by the Research Ethics Committee. 
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10.4.CASE REPORT FORMS 
Version 1.0 
Date: 10/04/2008 
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COST EFFECTIVENESS OF LUMBAR LAMINECTOMY VS XSTOP 
 
CASE REPORT FORM (CRF 1) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                         
 
PATIENT SELECTION 
Inclusion Criteria 
     is a male or non pregnant female patients 
     is aged between 18-80 years (inclusive) 
    has a BMI <35 kg/m2 
     has a preoperative ODI>30 points and a ZCQ-Physical Function Domain > 2 
     has chronic leg pain with or without back pain of greater than 6 months duration 
improved by flexion, and who are suitable candidates for posterior lumbar surgery 
     has completed at least 6 months of conservative treatment without obtaining 
adequate symptomatic relief 
    has degenerative changes at 1 or 2 adjacent levels between L1-S1 confirmed by X-
Ray, CT or MRI scan with one or more of the following: 
     is physically and mentally willing and able to comply with the postoperative 
scheduled clinical and radiographic evaluations. 
     none of the above 
Exclusion Criteria 
fixed motor deficit 
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is skeletally immature 
has undergone previous lumbar spinal surgery which could affect the trial 
outcome (e.g., disc replacement) 
has obvious signs of psychologicaliii
is unwilling or unable to give consent or adhere to the follow-up programme 
 or worker compensation or litigation 
claims elements to their condition 
has active infection or metastatic disease 
has non-degenerative spondylolisthesis 
has degenerative spondylolisthesis ≥ Meyerding Grade 2 
has a known allergy to implant materials 
has severe osteoporosis or rheumatoid arthritis 
cauda equina syndrome 
            none of the above 
 
ELIGIBLE/ NON-ELIGIBLE   (please circle one) 
 
 
 
220 
 
COST EFFECTIVENESS OF LUMBAR LAMINECTOMY VS XSTOP 
 
CASE REPORT FORM (CRF 2) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                         
 
EPIDEMIOLOGICAL/DEMOGRAPHIC  DATA 
 
DOB:  ____ /____ / _______ 
AGE:   
GENDER:                           Male                                  Female 
ETHNICITY:    Afro-Carribean                             White (British) 
 
                             Asian                                              White (Other) 
 
                             Middle Eastern 
 
                             Oriental 
 
 
JOB:   _________________________________________________________ 
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OTHER MH: ________________________________________________ 
_____________________________________________________________________ 
_____________________________________________________________________ 
 
 
EPIDURAL INJECTION:       YES                                         NO   
                                    
                                If YES:        Date(s)__________________________ 
 
MEDICATION: 
 
 
 
ASA SCORE:     I                     II                  III                  IV V 
(circle one) 
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COST EFFECTIVENESS OF LUMBAR LAMINECTOMY VS XSTOP 
 
 
 
CASE REPORT FORM (CRF 3) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                         
CLINICAL FEATURES (pre-operatively) 
 Leg Buttock Back Dermatome 
/Myotome 
Yes No Yes No Yes No  
Pain        
Duration (months)        
 
Paraesthesia        
Duration (months)        
 
Weakness        
Duration (months)        
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COST EFFECTIVENESS OF LUMBAR LAMINECTOMY VS XSTOP 
 
 
CASE REPORT FORM (CRF 4) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                    
 
 
PREOPERATIVE IMAGING 
( l  i k if d ) 
 CT Lumbar  Date:   ___/___/__ 
 
MRI Lumbar  
Date:   ___/___/__ 
 
CT Myelogram  
Date:   ___/___/__ 
 
please tick 
L1/2 
L3/4 
L4/5 
 
………………………………………....
............................................
............................................
.............. 
Lumbar Spinal Stenosis confirmed 
X rays                   
(AP  Fl /E ) 
 
Date:   ___/___/__ 
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CASE REPORT FORM (CRF 5) 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                        
PERIOPERATIVE OUTCOME 
 
LSS surgery date  ___/___/__ 
Lumbar  
laminectomy? 
XSTOP? 
Intraoperative  complications 
Please state the complications 
Early (<48hrs) complications 
 
Theatre time:         ____    Number of surgeons  __________ 
 
Surgeons time     ____   Anaesthetist time _____________ 
 
Blood loss:        _____      Blood transfusion: _____(no. of units) 
Number of  levels   __________ 
 
 Number of implants  _______         
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CASE REPORT FORM (CRF 6) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                        
DISCHARGE OUTCOME 
 
Discharged?               Yes                                            No 
Date of Discharge:   ____/ ___/____   Inpatient stay (no.of days)_______ 
Total analgesia:   NSAIDS  ___________ 
                            Opioids   
- p.o.______________ 
- i.m.  
  
 Total physiotherapy episodes:    ________________________ 
Post-op X rays                  Yes                                             No 
(AP, Flex/Ext) 
VAS (back)    1      2      3       4     5      6     7    8     9     10 
VAS (leg)  1      2      3       4     5      6     7    8     9     10 
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CASE REPORT FORM (CRF 7) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID……………………………………… 
 
PATIENT ASSESSMENT:     6 weeks   6 months    12months    24 months  
  (circle one) 
CLINICAL FEATURES (post-operatively) 
 
 Leg Buttock Back Dermatome 
/Myotome Yes No Yes No Yes No 
*Pain        
Duration        
 
Paraesthesia        
Duration        
 
Weakness        
Duration        
* If you tick response Yes for Pain please include the VAS score. 
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CASE REPORT FORM (CRF 8) 
(see 5 subforms) 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                         
 PATIENT ASSESSMENT:    Preop  Discharge (EQ5D, ZCQ Symptoms component)    6 
weeks   6 months    12months    24 months  
  (circle one) 
OUTCOME QUESTIONNAIRES 
 
 
 
 
 
 
 
 
 
 
 
 
OUTCOME QUESTIONNAIRE SCORES    &  IMAGING                                                                                  
QBPDS(see CRF 7 -1)  ____________         
EQ5D      (see CRF 7 -2) 
- Mobility __   Self-care__   Usual activities__  Pain/Discomfort__  
Anxiety/Depression___  
- Total score:   
 
    - Health state: __________                                                                                         
ODI   (see CRF 7-3) 
    ______%  (10 parts, each part score 0 – 5,  final score(%) = total score/50 x 100%)                                                                                        
ZCQ      Symptom Severity ___    Physical Function____    Satisfaction scale____                                                                                          
SF36  ( see CRF 7- 5)        PF__     RP__    BP__  GH___  VT__  SF__  RE___   MH___         
X rays                       Yes                                             No 
(AP, Flex/Ext)                                                              
X rays Satisfactory:Yes 
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CASE REPORT FORM (CRF 8-1) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………                         
 
 PATIENT ASSESSMENT:    PREOP    6 weeks   6 months    12months    24 months  
  (circle one) 
10.6.The Quebec Back Pain Disability Scale 
This questionnaire is about the way your back pain is affecting your daily life.  People with back 
problems may find it difficult to perform some of their daily activities.  We would like to know if you 
find it difficult to perform any of the activities listed below, because of your back.  For each activity 
there is a scale from 0 to 10  
(0, not difficult at all;  5, moderately difficult;  10, extremely difficult). 
Please choose one response option for each activity (please do not skip any activity) and circle the 
corresponding number. 
 
Today, do you find it difficult to perform the following activities because of your back? 
1. Get out of bed ………………………0   1   2   3   4   5   6   7   8   9    10                            
2. Sleep for at least 6 hours ……………0   1   2   3   4   5   6   7   8   9    10 
3. Turn over in bed …………………….0   1   2   3   4   5   6   7   8   9    10 
4. Travel 1 hour in a car………………..0   1   2   3   4   5   6   7   8   9    10 
5. Stand up for 20-30 minutes………….0   1   2   3   4   5   6   7   8   9    10 
6. Sit in a chair for several hours………0   1   2   3   4   5   6   7   8   9    10 
7. Climb one flight of stairs……………0   1   2   3   4   5   6   7   8   9    10 
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8. Walk a few blocks (300-400 m)……. 0   1   2   3   4   5   6   7   8   9    10 
9. Walk several miles…………………..0   1   2   3   4   5   6   7   8   9    10 
10. Reach up to high shelves…………….0   1   2   3   4   5   6   7   8   9    10 
11. Throw a ball…………………………0   1   2   3   4   5   6   7   8   9    10 
12. Run two blocks………………………0   1   2   3   4   5   6   7   8   9    10 
13. Take food out of the refrigerator…….0   1   2   3   4   5   6   7   8   9    10 
14. Make your bed……………………….0   1   2   3   4   5   6   7   8   9    10 
15. Put on socks (pantyhouse)…………... 0   1   2   3   4   5   6   7   8   9    10 
16. Bend over a sink for 10 minutes……..0   1   2   3   4   5   6   7   8   9    10 
17. Move a table…………………………0   1   2   3   4   5   6   7   8   9    10 
18. Pull or push heavy doors…………….0   1   2   3   4   5   6   7   8   9    10 
19. Carry two bags of groceries…………0   1   2   3   4   5   6   7   8   9    10 
20. Lift 40 lbs (heavy suitcase)…………. 0   1   2   3   4   5   6   7   8   9    10 
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CASE REPORT FORM (CRF 8-3) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID……………………………………… 
 
PATIENT ASSESSMENT:    PREOP   6 weeks   6 months    12months    24 months  
  (circle one) 
10.7.OSWESTRY DISABILITY INDEX 
(Fairbank JCT, Pynsent PB. The Oswestry Disability Index. Spine 
2000;25:2940–53.) 
 
Please Read:  This questionnaire is designed to enable us to understand how much your low back has affected 
your ability to manage everyday activities.  Please answer each Section by circling the ONE CHOICE that most 
applies to you.  We realize that you may feel that more than one statement may relate to you, but please just 
circle the one choice which closely describes your problem right now. 
 
SECTION 1—Pain Intensity 
A. I can tolerate the pain I have without having to use painkillers 
B. The pain is bad but I can manage without painkillers. 
C. Painkillers give complete relief from pain 
D. Painkillers give moderate relief from pain 
E. Painkillers give very little relief from pain 
F. Painkillers have no effect on the pain and I do not use them 
 
SECTION 2—Personal Care 
A. I can look after myself normally without causing extra pain. 
B. I can look after myself normally but it causes extra pain. 
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C. It is painful to look after myself and I am slow and careful 
D. I need some help but manage most of my personal care 
E. I need help every day in most aspects of self-care. 
F. I do not get dressed. I wash with difficulty and stay in bed 
 
SECTION 3 –Lifting 
A. I can lift heavy weights without extra pain 
B. I can lift heavy weights but it gives extra pain 
C. I can’t lift heavy objects from off the floor but off the table is OK. 
D. I can’t lift heavy objects but light to medium ones are OK. 
E. I can only lift very light weights 
F. I cannot lift or carry anything at all.  
 
SECTION 4 – Walking 
A. Pain does not prevent me from walking any distance. 
B. Pain prevents me from walking more than one mile. 
C. Pain prevents me from walking more than one-half of mile. 
D. Pain prevents me from walking more than one-quarter of mile. 
E. I can only walk while using a cane or on crutches 
F. I am in bed most of the time and have to crawl to the toilet. 
 
SECTION 5 – Sitting 
A. I can sit in any chair as long as I like without pain 
B. I can only sit in my favourite chair as long as I like. 
C. Pain prevents me from sitting more than one hour 
D. Pain prevents me from sitting more than ½ hour 
E. Pain prevents me from sitting more than ten minutes. 
F. Pain prevents me from sitting at all. 
 
SECTION 6 – Standing 
A. I can stand as long as I want without extra pain. 
B. I can stand as long as I want but it gives extra pain 
C. Pain prevents me from standing for more than one hour 
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D. Pain prevents me from standing for more than 30 minutes 
E. Pain prevents me from standing for more than 10 minutes 
F. Pain prevents me from standing at all 
 
SECTION 7 – Sleeping 
A. Pain does not prevent me from sleeping well 
B. I can sleep well only by using tablets 
C. Even when I take tablets I have less than six hours of sleep 
D. Even when I take tablets I have less than four hours of sleep 
E. Even when I take tablets I have less than two hours of sleep 
F. Pain prevents me from sleeping at all. 
 
SECTION 8 – Sex Life 
A. My sex life is normal and causes no extra pain. 
B. My sex life is normal but causes some extra pain. 
C. My sex life is nearly normal but is very painful. 
D. My sex is severely restricted because of pain. 
E. My sex life is nearly absent because of pain. 
F. Pain prevents any sex life at all. 
 
SECTION 9 – Social Life 
A. My social life is normal and gives me no extra pain. 
B. My social life is normal but increases the degree of pain 
C. I can’t participate in more energetic activities like dancing or tennis 
D. Pain restricts my social life and I don’t go out as often. 
E. Pain restricts my social life at home. 
F. I have no social life because of pain. 
 
SECTION 10 – Travelling 
A. I can travel anywhere without pain. 
B. I can travel anywhere but it gives me extra pain. 
C. Pain is bad but I manage journeys over two hours. 
D. Pain restricts me to journeys of less than one hour. 
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E. Pain restricts me to short necessary journeys of less than 30 minutes. 
F. Pain prevents me from travelling. 
 
CASE REPORT FORM (CRF 8-4) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID……………………………………… 
 
PATIENT ASSESSMENT:    PREOP   6 weeks   6 months    12months    24 months  
  (circle one) 
10.8.ZURICH CLAUDICATION QUESTIONNAIRE 
 
Please Read: This questionnaire has been designed to give the doctor information as to how your back 
pain has affected your ability to manage in everyday life.  Please answer every section by circling the ONE 
CHOICE that most applies to you.  We realize you may consider that two of the statements in any one 
section relate to you, but please just circle the one choice which most closely describes your problem. 
 
PART l: - Symptom Severity Scale 
In the last month, how would you describe: 
 
Question 1.  The pain you have had on average including the pain in you back, buttocks and pain that goes 
down your legs? 
1.   None 
2.   Mild 
3.   Moderate 
4.   Severe 
5.   Very severe 
 
Question 2.  How often have you had back, buttock, or leg pain?  
1.   Less than once a week 
2.   At least once a week 
3.   Everyday, for at least a few minutes 
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4.   Everyday, for most of the day 
5.   Every minute of the day 
 
Question 3.  The pain in your back or buttocks? 
1.   None 
2.   Mild 
3.   Moderate 
4.   Severe 
5.   Very severe 
 
Question 4.  The pain in your legs or feet? 
1.   None 
2.   Mild 
3.   Moderate 
4.   Severe 
5.   Very severe 
 
Question 5.  Numbness or tingling in your legs or feet? 
 
1.   None 
2.   Mild 
3.   Moderate 
4.   Severe 
5.  Very severe  
 
Question 6.  Problems with your balance? 
1.   No, I have had no problems with balance 
2.   Yes, sometimes I feel my balance is off, or that I   
      am not sure footed 
3.   Yes, often I feel my balance is off, or that I am     
       not   sure footed 
 
 
Question 7. Weakness in your legs or feet? 
1. None 
2. Mild 
3. Moderate 
4. Severe 
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5. Very Severe 
 
 
PART 2: - Physical Function Scale 
In the last month, on a typical day; 
Question 8.  How far have you been able to walk?  
1.   Over 2 miles 
2.   Over 2 blocks, but les than 2 miles 
3.   Over 50 feet, but less than 2 blocks 
4.   Less than 50 feet  
 
Question 9. Have you taken walks outdoors or in the shopping centres? 
1.   Yes, comfortably 
2.   Yes, but sometimes with pain 
3.   Yes, but always with pain 
4.   No 
 
Questio 10. Have you been shopping for groceries or other items? 
1. Yes, comfortably 
2. Yes, but sometimes with pain 
3. Yes, but always with pain 
4. No 
 Question 11.  Have you walked around the different rooms in your house or apartment?  
1.   Yes, comfortably 
2.   Yes, but sometimes with pain 
3.   Yes, but always with pain 
4.   No 
 
Question 12.  Have you walked from your bedroom to the bathroom?  
1.   Yes, comfortably 
2.   Yes, but sometimes with pain 
3.   Yes, but always with pain 
4.   No 
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Part 3: - Satisfaction Scale 
How satisfied are you with: 
 
 
 
Question 13. The overall result of back operation 
1. Very satisfied 
2. Somewhat satisfied 
3. Somewhat dissatisfied 
4. Very dissatisfied 
 
Question 14.  Relief of pain following the operation?  
1.   Very satisfied 
2.   Somewhat satisfied 
3.   Somewhat dissatisfied 
4.   Very dissatisfied 
 
Question 15.  Your ability to walk following the operation 
 
1.   Very satisfied 
2.   Somewhat satisfied 
3.   Somewhat dissatisfied 
4.   Very dissatisfied 
 
Question 16.  Your ability to do housework, yard work, or job following the operation? 
1.   Very satisfied 
2.   Somewhat satisfied 
3.   Somewhat dissatisfied 
4.   Very dissatisfied 
 
Question 17.  Your strength in the thighs, legs and feet? 
1.   Very satisfied 
2.   Somewhat satisfied 
3.   Somewhat dissatisfied 
4.   Very dissatisfied 
 
Question 18.  Your balance or steadiness on your feet? 
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1.   Very satisfied 
2.   Somewhat satisfied 
3.   Somewhat dissatisfied 
4.   Very dissatisfied 
CASE REPORT FORM (CRF 8-2) 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID……………………………………… 
PATIENT ASSESSMENT:  Preop  Discharge  6 wks  6 mths  12mths    24mths  
  (circle one) 
10.9.EQ5D 
By placing a tick in one box in each group below, please indicate which statements best 
describe your own health state today 
 
Mobility 
I have no problems in walking about 
I have some problems in walking about 
I am confined to bed 
 
Self-Care 
I have no problems with self-care 
I have some problems washing or dressing myself 
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I am unable to wash or dress myself 
 
Usual activities (e.g. work, study, housework, family or 
Leisure activities) 
I have no problems with performing my usual activities 
I have some problems with performing usual activities 
I am unable to perform my usual activities 
 
Pain/Discomfort 
I have no pain or discomfort 
I have moderate pain or discomfort 
I have extreme pain or discomfort 
 
Anxiety/Depression 
I am not anxious or depressed 
I am moderately anxious or depressed 
I am extremely anxious or depressed 
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EQ5D VAS 
Best Imaginable Health State – We would like you to indicate on this scale how good or bad 
your own health is today, in your opinion. Please do this by drawing a line from the box below 
to whichever point on the scale indicates how good or bad your health state is today. 
                          
 
Best imaginable health 
state   100 
Worst  imaginable health 
state       0 
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COST EFFECTIVENESS OF LUMBAR LAMINECTOMY VS XSTOP 
 
CASE REPORT FORM (CRF 8-5) 
 
CENTRE: …………………………………………. 
PATIENT HOSPITAL NUMBER………………… 
PATIENT ID………………………………………       
 
PATIENT ASSESSMENT:    Preop     6 wks   6 mths   12mths    24 mths  
(circle one) 
10.10.SF-36 
INSTRUCTIONS: This survey asks your vies about your health.  This 
information will help keep track of how you feel and how well you are 
able to do your usual activities. 
Answer every question by marking the answer as indicated.  If you are 
unsure about how to answer a question, please give the best answer 
you can. 
1. In general, would you say your health is:                  (circle one) 
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      Excellent……………………………………………………………. 1 
Very good …………………………………………………………...2 
Good ………………………………………………………………...3 
Fair…………………………………………………………………..4 
Poor………………………………………………………………….5 
 
2.Compared to one year ago, how would you rate your health in general 
now? 
                                                                 
                                                                                                      (circle one) 
     Much better now than one year ago ………………………………1 
     Somewhat better now than one year ago………………………….2 
     About the same as one year ago……………………………………3 
     Somewhat worse now than one year ago………………………….4 
     Much worse now than one year ago……………………………….5 
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3.The following items are about activities you might do during a typical 
day.  Does your health now limit you in these activities? If so, how 
much? 
  
                                                                        (circle a number on each 
line) 
ACTIVITIES Yes, 
limited a 
lot 
Yes, 
limited a 
little 
No, not 
limited 
at all 
Vigorous activity, such as running, 
lifting heavy objects, participating in 
strenuous sports 
 
1 2 3 
Moderate activities, such as moving a 
 table, pushing a vacuum cleaner, bowling,  
or playing golf 
 
1 2 3 
Lifting or carrying groceries 1 2 3 
Climbing several flights of stairs 
 
1 2 3 
Climbing one flight of stairs 
 
1 2 3 
Bending, kneeling, or stooping 
 
1 2 3 
Walking more than a mile 
 
1 2 3 
Walking half a mile 
 
1 2 3 
Walking 100 yards 
 
1 2 3 
Bathing or dressing yourself 
 
1 2 3 
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4.During the past 4 weeks, have you had any of the following problems 
with your work or other regular daily activities as a result of your 
physical health? 
      (circle one number on each line)  
 YES NO 
a. Cut down on the amount of itme you spent on work or 
other activities 
1 2 
b. Accomplished less than you would like 1 2 
c. Were limited in the kind of work or other activities 1 2 
d. Had difficulty performing the work or other activities 
(for example, it took extra effort) 
1 2 
 
5.During the past 4 weeks have you had any of the following problems 
with your work or other regular daily activities as a result of any 
emotional problems (such as feeling depressed or anxious)? 
                                                                           (circle one number on each 
line) 
 YES NO 
a. Cut down the 
amount of time you 
spent on work or other 
activities 
1 2 
b. Accomplished less 
than you would like 
1 2 
c. Didn’t  do work or 
other activities as 
carefully as usual 
1 2 
 
 
6. During the past 4 weeks, to what extent has your physical health or 
emotional problems interfered with your normal social activities with 
family, friends, neighbours, or groups? 
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(circle one) 
Not at all……………………………………………………..1 
                                    
Slightly……………………………………………………….2 
                                    
Moderately…………………………………………………...3 
 
Quite a bit…………………………………………………….4 
                                    
Extremely…………………………………………………….5 
 
7. How much bodily pain have you had during the past 4 weeks? 
                                                                                                                      
(circle one) 
                                   
None………………………………………………………….1 
 
Very mild…………………………………………………….2 
                                    
Mild………………………………………………………….3 
                                    
Moderate…………………………………………………….4 
                                    
Severe………………………………………………………..5 
 
Very severe………………………………………………….6 
 
8. During the past 4 weeks, how much did pain interfere with your 
normal work (including both work outside the home and housework)? 
                                                                                                                   
(circle one) 
Not at all……………………………………………………1 
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A little bit…………………………………………………...2 
                                    
Moderately………………………………………………….3 
 
Quite a bit…………………………………………………..4 
                                     
Extremely………………………………………………….5
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9. These questions are about how you feel and how things have been 
with you during the past 4 weeks.  For each question, please give the 
one answer that comes closest to the way you have been feeling. How 
much of the time during the past 4 weeks – 
 
 (circle one) 
 All of 
the 
time 
Most of 
the 
time 
A good 
bit of 
time 
Some 
of the 
time 
A little 
of the 
time 
None of 
the 
time 
a. Did you 
feel full of 
life 
1 2 3 4 5 6 
b. Have you 
been a very 
nervous 
person 
1 2 3 4 5 6 
c. Have you 
felt so down 
that nothing 
could cheer 
you up 
1 2 3 4 5 6 
d. Have you 
felt calm and 
peaceful? 
1 2 3 4 5 6 
e. Did you 
have a lot of 
energy 
1 2 3 4 5 6 
f. Have you 
felt 
downhearted 
and low? 
1 2 3 4 5 6 
g. Did you 1 2 3 4 5 6 
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feel worn 
out? 
h. Have you 
been a 
happy 
person? 
1 2 3 4 5 6 
i. Did you 
feel tired? 
1 2 3 4 5 6 
 
 
10. During the past 4 weeks, how much of the time has your physical 
health or emotional problems interfered with your social activities (like 
visiting with friends, relatives, etc)? 
 
 (circle one) 
                   All of the time…………………………………………………….1 
                   Most of the time………………………………………………….2 
                   Some of the time…………………………………………………3 
                   A little of the time………………………………………………..4 
                   None of the time………………………………………………….5 
 
 
11. How TRUE or FALSE is each of the following statements for you? 
 
                                                                       (circle one number on each 
line) 
 Definitely 
True 
Mostly 
True 
Don’t 
Know 
Mostly 
False 
Definitely 
False 
a. I seem 
to get ill a 
little 
easier 
1 2 3 4 5 
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than other 
people 
b. I am as 
healthy as 
anubody I 
know 
1 2 3 4 5 
c. I expect 
my health 
to get 
worse 
1 2 3 4 5 
d. My 
health is 
excellent 
1 2 3 4 5 
 
 
 
 
 
  
                                                          
 
 
 
